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ABSTRACT 
Alzheimer’s disease (AD) is the most common neurodegenerative disease worldwide and is 
the sixth leading cause of death in the U.S. Current AD medications only temporarily relieve 
symptoms, and none can prevent, cure, or even slow AD. There is an urgent demand for effective 
drugs for AD prevention and treatment. C-Glycosylflavones, a class of phytochemicals, display 
diverse benefits to human health and recently noted for their neuroprotective effects. They are a 
novel and valuable source of anti-AD agents. Identification and validation of therapeutic targets 
of C-glycosylflavones for neuroprotection against AD are crucial to convey the mechanistic 
understanding of these agents in pharmaceutical applications. The principal objectives of the 
dissertation research aim to unravel the mechanistic basis of natural and synthetic C-
glycosylflavones for potential AD therapies. Different research strategies such as 
target/phenotype-based screening and chemical proteomics approaches were adopted and 
integrated into an innovative drug discovery paradigm for target identification and validation of 
C-glycosylflavones.  
Our efforts to search for natural anti-AD agents led to the discovery that a C-glycosylflavone 
called isoorientin from corn silks is neuroprotective. Isoorientin selectively inhibits glycogen 
synthase kinase-3β (GSK-3β), an enzyme most relevant to AD tauopathy. Molecular docking and 
enzyme kinetics indicated that isoorientin selectively inhibits GSK-3β via a substrate competition 
rather than the common ATP competition. Cellular studies demonstrated that isoorientin effectively 
attenuates tau hyperphosphorylation and amyloid neurotoxicity in human SH-SY5Y cells. By 
applying computer-aided drug design approach, novel analogues of C-glycosylflavones as GSK-
3β inhibitors were synthesized. The new analogues show significant improvements of potency and 
passive membrane permeability compared to isoorientin. In addition, they have distinct kinase 
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selectivity to GSK-3β and effectively block GSK-3β–mediated tau and amyloid neurotoxicities. 
Finally, by harnessing the chemical proteomics and bioinformatics technologies, we revealed that 
C-glycosylflavones are novel multitarget ligands for potential AD prevention.  
Collectively, the present dissertation elaborates a hypothesis-driven research on AD drug 
discovery. The new findings and knowledge gained through this study will broaden the 
understanding of mechanism of actions of C-glycosylflavones for potential AD therapies. 
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CHAPTER 1 
1. INTRODUCTION 
1.1. Neurological Pathologies of Alzheimer’s Disease 
Alzheimer’s disease (AD) is a progressive and irreversible neurodegenerative disease 
worldwide. The AD syndrome is attributed to the gradual loss of neurons, particularly in the 
hippocampus and neocortex where brain regions involved in memory, cognition, language, 
emotion, and motor skills.1 According to the latest statistics, AD is the sixth leading cause of death 
in the U.S. and one-third of seniors dies with AD. The direct cost of AD patients in the U.S. was 
approximately $259 billion in 2017, and it is estimated that such costs will rise to $1.1 trillion by 
2050.2 In Hawaii, AD affects 11% of people over the age of 65. Caring for AD patients places a 
huge burden on Hawaii families. While millions of people suffer from this fatal disease, the four 
drugs approved by the United States Food and Drug Administration (FDA) marginally improve 
cognition of AD patients. The consensus is that these medications only temporarily relieve 
symptoms, but none can prevent, halt, cure, or even slow AD.3 There is a critical and urgent 
demand for effective drugs for AD prevention and treatment.  
Although the exact etiology remains poorly understood, current advances in AD research 
implicate that a complexity of genetic, aging, and environmental factors appears to be causative. 
Many gene mutations associated with amyloid precursor protein (APP) are known to cause the 
early-onset, familial AD that follows a Mendelian inheritance pattern, but it only accounts for less 
than 5% of incident cases.4-5 Mutations in MAPT gene encoding tau protein also give rise to certain 
familial tauopathies such as frontotemporal dementia (FTD) closely relevant to AD.6-7 In contrast, 
over 95% of AD is characterized as late-onset or sporadic that follows non-Mendelian inheritance. 
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For example, individuals caring copies of the ε4 allele of apolipoprotein E (APOE4) significantly 
increase risk for sporadic AD.8-9 Besides genetics, environmental stress, traumatic brain injury, 
and aging-associated incidence are also potential risk factors for AD.10-11 
Mounting evidence indicates that AD is a form of neurodegeneration associated with 
abnormal protein production and aggregation, which is categorized as a proteopathy. In AD brains, 
the prevalent presence of senile plaques and neurofibrillary tangles (NFTs) accompanied by 
synaptic dysfunction and neuroinflammation are the molecular characteristics.1, 10 Senile plaques 
are extracellular deposits of β-amyloid (Aβ) peptide, which are a pathological hallmark of AD. In 
familial AD, mutations in APP or presenilin (PSEN1 and PSEN2) genes significantly promote 
APP processing by β/γ-secretases, leading to enhanced production of toxic Aβ peptides.4 
Accumulation of Aβ forms toxic aggregates impairing neuronal functions. Aβ aggregates interfere 
with the neurotransmitter receptors, disrupt the synaptic transmission, and eventually trigger 
neurotoxic events such as formation of reactive oxygen species (ROS), Ca2+ dysregulation, 
mitochondrial damage, neuroinflammation, and neuronal loss. These genetic and molecular 
observations are thus the basis of the “amyloid cascade hypothesis of AD”.5  
On the other hand, NFTs composing intracellular hyperphosphorylated tau proteins are 
another major hallmark in AD pathology. Tau protein, an important microtubule-associated protein 
mainly expressed in neurons, stabilizes the integrity and functionality of microtubules in the 
neuronal cytoskeleton and maintains healthy axonal transport.12 In adult human brains, there are 
six isoforms of tau generated by alternative mRNA splicing from a single MAPT gene on 
chromosome 17.13 These tau variants contain 0–2 inserts in the N-terminal regions and have three 
(3R) or four repeats (4R) in the C-terminal regions for microtubule binding.14 The interaction of 
tau with microtubule is primarily modulated by phosphorylation. Tau gene (MAPT) mutations and 
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aberrant phosphorylation of tau proteins have been found in many neurodegenerative diseases such 
as frontotemporal dementia and parkinsonism linked to chromosome-17 (FTDP-17), progressive 
supranuclear palsy (PSP), corticobasal degeneration (CBD), and globular glial tauopathy, showing 
that tauopathy plays a causative role in neurodegeneration and dementia.15-16 AD is considered as 
a secondary tauopathy that requires involvement of amyloidosis for the disease causation. In AD, 
all six tau isoforms (3R and 4R) are present in the disease filaments.17 Abnormal phosphorylation 
of tau proteins disrupts their binding to microtubules in neurons, leading to destabilization of 
microtubules and mislocalization of the abnormal tau to the soma and dendrites.18 Aggregation of 
hyperphosphorylated tau proteins results in the formation of neurotoxic paired helical filaments as 
well as NFTs. This aberrant signaling cascade is thought to contribute to neuronal death and 
declined cognition, giving rise to the “tau hypothesis of AD”.7, 19 
Both Aβ plagues and tau tangles are characteristic for their neurotoxicity, however, their 
mechanistic causality pertaining to which critical toxic species accounts for the clinical AD 
symptoms is still unclear.20-21 Nevertheless, recent evidence suggests that Aβ, particularly the 
soluble Aβ oligomers, is plausibly the pathogenic initiator of AD, while tau aggregation and 
spreading in the brain cortices correlate more closely to neuronal loss and cognitive decline in AD 
progression.22-23 Therapeutic strategies focusing on the Aβ and tau interventions are thought to be 
promising to impede the pathogenesis and progression of AD rather than ameliorate symptoms, 
which are attractive for potential AD treatments.3, 11, 24-26 However, the continued failures of anti-
Aβ approaches in AD clinical trials27-28 drive researchers to embrace more diverse and innovative 
drug pipelines for AD.25-26 
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1.2. Therapeutic Potentials of C-Glycosylflavones for Alzheimer’s 
Disease 
Flavones, a class of polyphenolic compounds widely occurring in plants, are major 
constituents in the human diet including crops, fruits, vegetables, as well as beverages of plant 
origin such as juice, tea, wine, and cocoa. They are important phytochemicals displaying diverse 
benefits to human health.29 Current studies in animals and humans have demonstrated that many 
herbal and dietary supplements with flavone-rich extracts can inhibit neurotoxicity, suppress 
neuroinflammation, and promote memory and cognition.30-32 In particular, certain types of 
flavones exert neuroprotective effects via targeting key AD-relevant proteins such as 
cholinesterases, GSK-3 and CDK5 kinases, and secretases, which are a novel and valuable source 
of anti-AD agents.33-35 Conventionally, the neuroprotective action of flavones is thought to be 
mediated by their anti-oxidative or free radical scavenging activities.36-37 These classical properties, 
however, could not fully explain the observed pharmacology of flavones on diverse molecular 
events in AD pathways. In fact, it has become evident that flavones more likely exert their 
neuroprotective actions via cell signaling that regulates neuronal apoptosis, survival, 
differentiation, and proliferation.33, 35 Flavones can interact with key intracellular receptors or 
enzymes (e.g., proteases, kinases, and phosphatases) that are involved in signaling cascades of AD 
responsible for either gene expression or biochemical response.33, 35  
Flavones in flora mostly exist in forms of O-glycosides and C-glycosides. While O-
glycosylflavones present as majority, C-glycosylflavones are found to be more stable than the O-
glycosyl counterpart, and appear to have better therapeutic properties on human health.38 Many C-
glycosylflavones of natural and synthetic origins are valuable for disease interventions.29, 38 For 
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instance, flavopiridol, a synthetic flavonoid inspired by natural C-glycosylflavones, has become 
an advanced cyclin-dependent kinase (CDK) inhibitor in Phase II clinical trials for cancers.39-40 
With respect to the chemical structure of C-glycosylflavones, the presence of a carbon-linked 
glycosidic bond makes these compounds more resistant to metabolic hydrolysis and degradation. 
It has been reported that some C-glycosyl flavonoids bind to sodium glucose co-transporters 
(SGLT1/2), which enables their distribution across intestinal barrier through transepithelial 
transport,41 and across blood brain barrier (BBB) via secondary active transport.42-43 
Pharmacokinetic and pharmacodynamic studies have shown that C-glycosylflavones normally 
retain higher concentrations and a longer mean residence time in the blood plasma after oral and 
intravenous administration.38 The unique features of C-glycosylflavones, in conjunction with 
neuroprotective activities, shed light on their therapeutic potential for the intervention of 
neurodegenerative diseases such as AD.32 However, systematic evaluations of C-glycosylflavones 
pertaining to their neuroprotective mechanisms against AD are scarcely reported. Identification 
and validation of therapeutic targets of C-glycosylflavones involving AD pathologies are crucial 
to convey a better understanding of the molecular mechanisms on the basis of flavone-protein 
interactions, as well as to assess their therapeutic values in nutraceutical and pharmaceutical 
applications. 
1.3. Current Approaches for Target Identification and Validation in 
Drug Discovery 
Drug discovery aims to search for bioactive molecules that selectively and specifically 
modulate the functions of target proteins with precise mechanism of actions. Target identification 
and validation studies play a pivotal role in drug discovery. Traditionally, phenotype-based 
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screenings are extensively used where compound candidates are directly exposed into the 
biologically relevant contexts, usually in cells or animals, to observe the perturbative effects on 
physiological or disease models of interest.44-45 This approach thus provides the opportunity of 
discovering bioactive and functional molecules without knowing the exact protein targets in 
advance. However, it requires follow-up studies to identify and validate single or multiple 
therapeutic targets involving in biological networks responsible for the observed phenotypes, 
which in many cases is complicated, laborious, and time-consuming. Given the revolutionary 
advances in molecular biology and bioassay technology, it is now possible to test compounds for 
bioactivity on purified proteins in various biochemical assays, particularly for high-throughput 
screening purposes.46-48 This target-based approach offers a rapid means to directly link the 
bioactive molecules with preselected protein targets relevant to the disease of interest. Subsequent 
functional investigations aim to validate whether the biochemical interactions between the 
compound and the protein targets could result in expected disease-altered phenotypes in cellular 
or animal models. Although this approach appears to be straightforward, the direct interaction with 
a single target may not reflect the actual phenotypic phenomena, as a bioactive molecule often 
modulates multiple targets simultaneously in a biological context. In general, combinations of 
phenotype- and target-based approaches are necessary to fully characterize and identify the precise 
therapeutic targets as well as to elucidate mechanism of actions of bioactive molecules. 
Chemical proteomics is an emerging research discipline and a powerful tool for target 
identification and validation of bioactive molecules. This approach benefits from the tremendous 
development in the mass spectrometry (MS) technology over the past decade.49-50 Bioactive 
molecules such as natural products are well-known for their ability to intervene cell signaling by 
multifunctional actions on different protein targets, resulting in either a pharmacological synergy 
 7 
 
 
or an undesired toxic effect. Chemical proteomics thus provides a direct, unbiased, and systematic 
method for global profiling of protein targets of a bioactive molecule.51-53 By incorporating 
bioinformatics, it offers comprehensive information with a proteome-wide coverage to elucidate 
the mechanism of actions of bioactive molecules, and to assess their impacts on biomolecular 
networks.54 Compared to traditional methods, this approach overcomes the bottlenecks of 
phenotype- or target-based screenings, which potentially facilitate the process of drug discovery 
with time and cost efficiency.  
Nowadays, many strategies of chemical proteomics have been applied in drug discovery 
programs of academia and industry. The most common chemical proteomics strategy harnesses 
the affinity chromatography coupled with mass spectrometry.55-56 While this affinity-based 
chemical proteomics approach has shown many successes for target identification and validation 
of drugs and natural products, its limitations are noted. This method normally demands for a 
relatively high amount of proteins and bioactive molecules, and thus a sustainable source of 
materials is the requisite. Secondly, it is critical to immobilize bioactive molecules without altering 
bioactivity. Regarding the chemical challenges, the lack of suitable functional groups amenable 
for chemical modification is a major obstacle. Additionally, in order to minimize the interference 
on both bioactive molecules and protein targets, the choice of sites on the molecule for 
modification and of the linker moiety for immobilization are critical, which requires a thoughtful 
and rational design based on structure-activity relationship (SAR) studies.57-60 In proteomics 
considerations, identification of binding proteins does not always correlate to the binding affinity 
of bioactive molecules (e.g., IC50 values), as MS analysis only gives protein ID and spectral counts 
with respect to their abundance in the protein mixture. Therefore, affinity parameters need to be 
determined in subsequent competition experiments. In recent years, new experimental design by 
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combining the affinity-based competition with quantitative proteomics, such as stable isotope 
labeling with amino acids in cell culture (SILAC)61 and isobaric tags for relative and absolute 
quantitation (iTRAQ),62 has given a practical solution addressing these technical issues. The 
affinity-based chemical proteomics have shown versatile applications in many research fields and 
has become a valuable tool implemented in drug discovery paradigm. 
1.4. Research Hypotheses and Objectives 
The principal objective of this research is to investigate natural and synthetic C-
glycosylflavones for potential AD therapies. The aforementioned methodologies, e.g., 
target/phenotype-based screenings and affinity-based chemical proteomics approaches, were 
adopted and integrated into a rational paradigm for target identification and validation of C-
glycosylflavones within neuroproteome. The new knowledge gained through this study will be a 
valuable contribution to the AD biomedical sciences. We expect the findings of this research will 
broaden the understanding of mechanism of actions of C-glycosylflavones for AD prevention and 
treatment, and eventually develop novel agents in aid of AD drug discovery. 
 
Objective-1. Discovery and validation of natural C-glycosylflavones as potential anti-AD agents 
Hypothesis: C-Glycosylflavones of corn silks are potential selective glycogen synthase kinase-3β 
(GSK-3β) inhibitors exerting neuroprotection against AD tauopathy. 
Key points lead to the hypothesis for Objective 1:  
Tau protein hyperphosphorylation is a major component of AD pathology. GSK-3β is a key 
kinase responsible for aberrant tau hyperphosphorylation in AD. Abnormal tau phosphorylation by 
GSK-3β undermines the healthy dynamics of tau protein with microtubules and plays a central 
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role in AD pathology. Selective inhibition of GSK-3β to attenuate tau hyperphosphorylation is a 
promising therapeutic strategy for AD. Corn silks (CS, Zea mays L.) of crop maize are a traditional 
medicine and recently noted for their neuroprotective benefits.63 C-Glycosylflavones are 
characteristic in CS.64 We hypothesize that C-glycosylflavones of CS are potential GSK-3β 
inhibitors exerting neuroprotection against AD tauopathy. 
 
Objective-2. Computer-aided drug design of novel C-glycosylflavones as anti-AD agents targeting 
GSK-3β 
Hypothesis: Potency and selectivity of C-glycosylflavones against GSK-3β can be improved via 
rational structural modifications. 
Key points lead to the hypothesis for Objective 2:  
Isoorientin, a 6-C-glycosylflavone from CS, alleviates tau hyperphosphorylation and amyloid 
neurotoxicity through GSK-3β inhibition. Isoorientin selectively inhibits GSK-3β via an ATP-
noncompetitive but substrate-competitive mechanism.65 In addition, it has been reported that 
isoorientin shows in vitro and in vivo effects reducing neuroinflammation, oxidative stress, and 
mitochondrial dysfunction.66-69 Subchronic toxicity study of CS-derived flavones in mice and rats 
suggests that isoorientin is a reasonably safe and tolerable agent.70-71 Isoorientin is a promising 
natural product drug lead for AD. It is moderately potent to GSK-3β with notable selectivity.65 We 
hypothesize that structural modifications of isoorientin by computer-aided drug design approach 
can offer novel GSK-3β inhibitors with improved potency as potential anti-AD agents. 
 
Objective-3. Elucidation of potential pleiotropic mechanisms of C-glycosylflavones in neurons by 
targeted chemical proteomics  
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Hypothesis: Isoorientin simultaneously interacts with GSK-3β and other therapeutic targets 
relevant to AD, which sheds light on its pleiotropic mechanisms and enhances its pharmaceutical 
values. 
Key points lead to the hypothesis for Objective 3:  
AD is a complex neurodegenerative disease involving multiple pathogenic mechanisms. An 
anti-AD agent modulating multiple targets and signaling pathways in a disease-relevant context is 
valuable in pharmaceutical applications. Flavones are well-known for their multifunctional actions 
on intervening diseases, which suggests the presence of multiple targets. The feature of pleiotropy 
can plausibly enhance therapeutic values of flavones by leveraging multiple beneficial activities 
and outweigh potential toxic effects.72 Isoorientin and its new analogues have a good safety margin 
and tolerability, and elicit unique neuroprotection via targeting GSK-3β.65, 73 We hypothesize that 
isoorientin also acts on other protein targets to gain a maximal anti-AD effect. Global and unbiased 
profiling of therapeutic targets by chemical proteomics approaches can provide a full picture of 
the pleiotropic mechanisms of isoorientin with appreciation of the biomolecular networking of the 
targets in AD pathways. 
 
 11 
 
 
CHAPTER 2 
2. C-GLYCOSYLFLAVONES AGAINST ALZHEIMER’S 
DISEASE 
2.1. Natural C-Glycosylflavones Alleviate Tau Phosphorylation and 
Amyloid Neurotoxicity through GSK-3β Inhibition † 
Many tau-protein kinases (TPKs) and microtubule affinity-regulating kinases (MARKs) 
mediate tau phosphorylation.74 Among them, glycogen synthase kinase-3β (GSK-3β) is one of the 
most relevant kinases for aberrant tau phosphorylation in AD. In AD brains, over 70% of GSK-3β 
phosphorylation sites flanking the microtubule-binding domain of tau protein are typically 
phosphorylated.75-77 Abnormal tau phosphorylation by GSK-3β undermines the healthy dynamics 
of tau protein with microtubules. Overactive GSK-3β plays a central role in AD pathology, causing 
neurodegeneration, inflammatory response, toxic Aβ production as well as synaptic deficit.76 
Therefore, development of GSK-3β inhibitors attenuating tau hyperphosphorylation is a promising 
therapeutic strategy for AD treatment.3, 11, 24, 78 
Corn silks (CS) of the food crop maize (Zea mays L.) have been an alternative medicine widely 
adopted by the Asia-Pacific cultures for the treatment of hyperglycemia, hyperlipidemia, cystitis, 
prostate disorder and urinary infection.63 Studies have shown that CS extracts are a 
phytotherapeutic agent with antibiotic, anti-oxidative, anti-inflammatory, anti-diabetic, and 
anticancer activities.79-82 Owing to the diverse bioactivities, CS metabolites are of interest to 
                                                             
† Reproduced in part with permission from Liang, Z.; Zhang, B.; Su, W. W.; Williams, P. G.; Li, Q. X. ACS Chem. 
Neurosci. 2016, 7, 912-923. Copyright © 2016 American Chemical Society. 
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natural product and agricultural chemists. Phytochemical and metabolomic studies revealed that 
CS is rich in flavonoids, polysaccharides, terpenoids, and steroids. Among them, flavones are 
particularly abundant and characteristic in maize crops.63-64 It has been proposed that the unique 
biological properties of CS such as antibiotic, anti-inflammatory and anticancer effects are mainly 
associated with these flavones. However, there are fewer studies of systematic evaluations of CS-
derived flavones for nutraceutical and pharmaceutical applications. 
As part of our efforts to look for AD phytopharmaceuticals, we utilized a kinase assay to 
screen GSK-3β and CDK5/p25 inhibitors. Both GSK-3β and CDK5/p25 have been implicated in 
tau hyperphosphorylation.75 Interestingly, an extract of CS selectively inhibited GSK-3β but not 
CDK5/p25. Successive bioassay-guided fractionation of this CS extract afforded two known 6-C-
glycosylflavones, isoorientin (1) and 3’-methoxymaysin (2). In addition to in silico studies, in vitro 
enzymatic assays demonstrated an ATP noncompetitive but substrate competitive inhibition by 1 
and 2 specific to GSK-3β. A whole-cell lysate assay further confirmed that 1 effectively inhibited 
tau hyperphosphorylation mediated by GSK-3β in vitro. 
Aβ induces tau hyperphosphorylation and neurotoxicity in human neuroblastoma SH-SY5Y 
cells, which is a common cell model for AD research.83-85 While this cellular system remains 
limited to represent in vivo neuropathology of AD, the inductive effects of exogenous Aβ on SH-
SY5Y cells make it possible to study therapeutic interventions involving AD-mimic pathways.84, 
86-87 By implementing this in vitro model, immunoblot and cell viability analyses indicated that 1 
and 2 are nontoxic agents, but inhibit cellular GSK-3β, and prevent tau hyperphosphorylation and 
neuronal cytotoxicity from amyloid insult in SH-SY5Y cells. 
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Figure 2.1. 6-C-Glycosylflavones from corn silks. 
The flavone rings are labeled as A, B, and C, and the positions of atom are labeled in Arabic 
numbers according to the IUPAC rules. 
 
2.1.1. Isolation and Identification of GSK-3β Inhibitory 
Compounds from Corn Silks 
We recently utilized an in vitro universal luminescence-based kinase assay to screen potential 
GSK-3β and CDK5/p25 inhibitors. In this assay, ADP generated from a kinase reaction is 
chemically converted to ATP, which then couples with luciferase, such that the intensity of signal 
from the luciferase reaction is proportional to kinase activity. Kinase inhibitors were isolated from 
CS extracts via the bioassay-guided fractionation (Figure 2.2). The resulting ethyl acetate (EtOAc) 
fraction (CS-EA) showed plausible inhibition of GSK-3β activity, giving a 42.7% inhibition at a 
concentration of 100 µg/mL (Table 2.1). In contrast, no significant inhibition against CDK5/p25 
was observed with this fraction at the same concentration (data not shown). LC-QTOF-MS 
profiling revealed that the EtOAc fraction contained a series of compounds with molecular weights 
between 480 and 600 amu along with UV maxima at 260 and 350 nm, suggesting the presence of 
glycosidic flavones.79 Further bioassay-guided fractionation and HPLC purification of this EtOAc 
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fraction led to the isolation of two 6-C-glycosylflavones, 1 and 2 in over 95% purity as determined 
by HPLC-UV at 205 nm. Chemical identity of 1 and 2 was determined by NMR spectroscopic 
comparison with reported data88-89 in conjunction with ESI-CID-MS/MS analyses.90 The ESI-
QTOF-CID-MS/MS analysis of 2 showed an ion at m/z 445.1136 corresponding to [Y1]+, 
confirming the presence of a rhamnose, while the observed ion [0,2B]+ at m/z 150.6861 indicated a 
methoxy group at the B-ring of 2 (see Appendix 1). 1 and 2 showed moderate GSK-3β inhibition 
with an IC50 value of 185 and 288 μM, respectively, whereas they were inactive against CDK5/p25 
(IC50 > 15 mM) (Figure 2.3A). 
Flavonoids have been reported as potential colloidal aggregators showing promiscuous 
inhibition of proteins.91 These promiscuous inhibitors aggregate with proteins nonspecifically and 
promote protein unfolding, which is a common cause of false positives in high-throughput 
screenings. To investigate if the GSK-3β inhibition of 1 was due to this undesired mechanism, 1 
was assayed against GSK-3β in a kinase buffer containing varying concentrations of Triton X-100 
to disrupt possible aggregation.92 Intriguingly, GSK-3β inhibition was insensitive to the addition 
of detergent as the resulting IC50 value of 1 did not significantly change (with 0.01% Triton, IC50, 
192 μM) (see Appendix 2). This observation was consistent with the inhibitory behavior of 
staurosporine, a well-known GSK-3β inhibitor without aggregation (with 0.01% Triton, IC50, 3 
nM). Conversely, luteolin, a flavone showing GSK-3β inhibition but promoting aggregation,91 
decreased the potency by 16-fold with the addition of 0.01% Triton (increased IC50 value from 2 
to 32 μM). Structurally, luteolin is the flavone core of 1 without C-glycone. The behavioral 
difference between luteolin and 1 in the promiscuous inhibition assay suggested that the C-
glycosyl group of 1 plays an essential role in GSK-3β inhibition. Since ruling out the possibility 
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of promiscuous inhibition, further biological evaluations proceeded with the stronger GSK-3β 
inhibitor 1. 
Table 2.1. Inhibitory activity of CS extracts against GSK-3β. 
Sample ID Inhibitory Activity % (± SEM %) a 
 100 µg/mL 
CS-EA 42.7 ± 1.0 
CS-EA-F 44.5 ± 2.3 
CS-EA-F-1 20.1 ± 1.3 
CS-EA-F-2 (Compound 1) 48.4 ± 2.2 
CS-EA-F-3 (Compound 2) 41.5 ± 1.4 
CS-EA-F-4 32.3 ± 3.0 
CS-EA-F-5 16.8 ± 1.3 
Staurosporine (reference) 100.9 ± 1.6 
a Data were means of quadruplicate of each of two independent experiments with ± SEM (n = 8). 
 
 
Figure 2.2. Schematic of GSK-3β assay guided fractionation of 1 and 2 from corn silks. 
The crude extract was subject to successive partitioning using n-hexane, ethyl acetate (EtOAc), n-
butanol and H2O to yield four primary fractions. The fractions with the most potent GSK-3β 
inhibition were further subject to flash column chromatography on a polyamide column using a 
step gradient of MeOH in H2O, affording eight fractions (A-H). Separation of fraction F (CS-EA-
F) by HPLC afforded five subfractions, whose GSK-3β inhibitory activities were concentrated in 
subfraction-2 (CS-EA-F-2) and subfraction-3 (CS-EA-F-3). HPLC purification led to the isolation 
of compound 1 and 2. *Fractions showed > 40% inhibition at 100 µg/mL in the GSK-3β kinase 
assay.  
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2.1.2. Isoorientin Selectively Inhibits GSK-3β in an ATP 
Noncompetitive Mechanism 
To further evaluate the kinase inhibitory selectivity, 1 was assayed on a broad panel of 22 
kinases relevant to AD, using the universal kinase assay system. As shown in Figure 2.3B, 1 
effectively inhibited GSK-3β (decreased 52.4% kinase activity, p < 0.0001) in vitro at a 
concentration of 224 μM compared to the control (100% kinase activity). It is interesting that 1 
did not significantly inhibit other 18 kinases (p > 0.05) except AKT1, PKC and CK2. Although 1 
also showed approximately 30% inhibition against AKT1, PKC and CK2, inhibitory selectivity of 
GSK-3β was the most distinct in this study. Aside from GSK-3β it has been reported that CDK5, 
ERK2, JNK, p38, PKA, AKT, PKC, CAMKII, DAPK, AMPK, and CK1/2 contribute positively to 
tau hyperphosphorylation in human.75 The selectivity of 1 to GSK-3β over the other AD relevant 
kinases suggested that 1 interacts with GSK-3β at an allosteric domain rather than the common 
conserved ATP-binding pocket. 
Enzyme kinetic experiments were then performed to elucidate the underlying mechanism of 
1 on GSK-3β inhibition. As illustrated in Figure 2.3C, when concentrations of the GSK-3β 
substrate GS2 (peptide YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE, derived from human muscle 
glycogen synthase) were held constant at 17 μM, velocities of ATP-ADP conversion at a given 
concentration of 1 were measured over a period of time. Michealis-Menten kinetic analysis 
indicated that 1 reduced GSK-3β activity (decreased Vmax) with an increase of concentration of 1 
but not compete with ATP at the active site of GSK-3β, for which it remained an unaltered 
Michaelis constant (Km, 76 μM). Moreover, a Dixon plot of enzyme kinetics showed a convergence 
of intersecting lines on horizontal axis that further corroborated the ATP noncompetitive 
mechanism of 1 with a Ki value of 210 μM (Figure 2.3D). 
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GSK-3β is a proline-directed serine/threonine kinase ubiquitously expressed in mammals. It 
plays a pivotal role in regulating various processes of cell signal transduction including glycogen 
metabolism, gene transcription, protein translation, cytoskeletal stabilization, cell development 
and apoptosis. In particular, GSK-3β is a key regulator mediating neural development in human.93 
The normal state of GSK-3β regulates the healthy functioning of neurons, whereas elevated 
activity of GSK-3β is implicated in AD pathology.75-76 Inhibiting levels of GSK-3β in an aberrant 
state is a promising therapeutic strategy for AD treatment. To date, the majority of inhibitors has 
targeted the highly conserved ATP-binding cavity on GSK-3β.3 Although GSK-3β inhibitors 
targeting this active site could achieve high potency, the limited selectivity of ATP competitive 
inhibitors raises concerns about the safety and tolerability of this class of molecules, which remains 
a major hurdle in AD drug development.11 Alternatively, seeking ATP noncompetitive inhibitors is 
a feasible approach to improve inhibitory selectivity, because these inhibitors tend to bind to 
uniquely folded domains within GSK-3β instead of simply blocking ATP entrance.94 In addition, 
since GSK-3β regulates essential cell signaling events, moderate-to-weak inhibition of aberrant 
GSK-3β activity may actually normalize GSK-3β functions.95 The efficacy of many ATP 
noncompetitive GSK-3β inhibitors of synthetic and natural origins has been demonstrated in a 
variety of cellular and animal models. Two of them, Tideglusib (a TDZD compound) and lithium 
ion, have advanced to Phase II clinical trials, which offers a promising prospect.95 In the present 
study, because maize is a food crop, it is conceivable that 1 along with its CS-derived C-glycosidic 
flavones, acting as ATP noncompetitive inhibitors of GSK-3β, are safe agents worthy of advanced 
biological studies. 
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Figure 2.3. Isoorientin (1) selectively inhibits GSK-3β via an ATP noncompetitive 
mechanism. 
Data were means of quadruplicate of each of two independent experiments with ± SEM (n = 8). 
The data were analyzed by one-way ANOVA with Tukey’s multiple comparison test. *p < 0.05, 
**p < 0.01, ***p < 0.001, ****p < 0.0001 relative to control. ISO, isoorientin. (A) 1 inhibited GSK-
3β activity with an IC50 value of 185 ± 25 μM. The IC50 value of 1 to CDK5/p25 was > 15 mM. 
Results were presented as the percentage of the kinase activity relative to control (5% DMSO 
vehicle). Inhibition curves were analyzed by four-parameter regression. (B) Effect of 1 on the 
activities of 22 protein kinases. Protein kinases were assayed in the presence of 224 μM 1 or control 
(5% DMSO vehicle). (C) GSK-3β inhibitory kinetics in vitro, when GSK-3β substrate GS2 was 
kept constant at 17 μM. GSK-3β activity was determined by increasing concentrations of 1 in the 
presence of varying ATP concentrations. The lines represented the result of a non-linear regression 
analysis of the entire data set using a best-fit kinetic model for enzyme inhibition. The analysis 
showed a noncompetitive inhibition of ATP with a Ki of 210 ± 22 μM, and a Km of 76 ± 9 μM. (D) 
Dixon plots of GSK-3β activity in the presence of varying concentrations of ATP versus 1. The 
lines were linear regression plotting of 1/V against concentration of 1 at a given concentration of 
ATP. Intersecting at the same point on the X axis indicated a noncompetitive inhibition with 
respect to ATP.  
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2.1.3. Isoorientin Exerts Inhibition of GSK-3β in a Substrate 
Competitive Mode 
Owing to the aforementioned drawbacks of ATP competitive inhibitors of GSK-3β, new ATP 
noncompetitive inhibitors with increased selectivity are of high interest in the development of AD 
pharmaceuticals targeting tauopathy. Comprehensive mapping and identification of the binding 
sites of GSK-3β by computational simulations has allowed for a better elaboration and evaluation 
of allosteric kinase inhibitors.94 For example, some complex small-molecules, such as manzamine 
A96 and peptide L803,95 have been validated as ATP noncompetitive inhibitors with the assistance 
of molecular modeling.  
The interaction of 1 with GSK-3β was therefore examined by computational simulation using 
the X-ray crystallographic structures of GSK-3β (PDB code 1PYX and 1Q3D). Protein and ligand 
structures were prepared as described prior to docking. Using these parameters, the ligand 
staurosporine, a known ATP competitive inhibitor, was successfully re-docked into the active 
ATP-binding site of GSK-3β, with a RMSD of 0.93 Å compared to its original crystal structure97 
(Figure 2.4A and B). Simulation under the same condition revealed that 1 resides within the 
substrate-binding site of GSK-3β, an orthosteric cavity immediately near to the ATP-binding 
pocket (Figure 2.4C). The C-glycone of 1 makes polar interactions with GSK-3β residues Leu88, 
Gln89, Asp90, Lys94 and Arg96 within the substrate-binding pocket to form hydrogen bonds. The 
aromatic flavone core of 1 shows hydrophobic interactions with residues Phe67 and Val87, and 
the 7-hydroxyl oxygen atom at the A-ring of the flavone core shows a hydrogen bond with residue 
Asn95. In conjunction, interactions of the 3’-hydroxyl oxygen atom at the catechol B-ring of the 
flavone core with the two Mg2+ ions in the magnesium-binding site of GSK-3β potentially stabilize 
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these binding interactions. The role of Mg2+ cofactors is known to be essential for the GSK-3β 
kinase reaction as they assist the key steps in ATP phosphoryl transfer. Competitive replacement 
of magnesium by lithium significantly inhibits GSK-3β activity.98 In the present study, interactions 
of 1 with Mg2+ may weaken the binding affinity of ATP with GSK-3β. Furthermore, residues 
Phe67, Gln89 and Asn95 within the substrate-binding site of GSK-3β are particularly crucial for 
substrate recognition as mutating any of these amino acids causes the loss of kinase activity.99 The 
docking results indicated that interactions of 1 with these key residues in the substrate-binding site 
of GSK-3β may partially explain its inhibitory action and selectivity (IC50, 185 μM). In comparison, 
2 (IC50, 288 μM) shows less favorable interactions with Phe67, Gln89 and Asn95, probably due to 
steric hindrance from the larger C-glycone (Figure 2.4D). Structural features of both flavone and 
glycone in 1 favor specific interactions with the substrate-binding pocket of GSK-3β, whereas 
luteolin without C-glycone showed nonspecific inhibition of GSK-3β (see Appendix 2). The C-
glycosidic moiety putatively acts as a key structural element in 1 for GSK-3β specific inhibition 
and selectivity.  
To validate the molecular docking results, we conducted kinetic experiments of GSK-3β when 
ATP concentrations were fixed at 25 μM. At a given concentration of 1, rates of ATP conversion 
were plotted versus different concentrations of substrate GS2. In this case, Michealis-Menten 
kinetics and corresponding Dixon plot clearly showed a competitive inhibition mode between GS2 
and 1 with a Ki value of 125 μM (Figure 2.4E and F), indicating that 1 interacts with the substrate-
binding site of GSK-3β as predicted from the docking postulation. Taken together, the 
enzymological experiments in silico and in vitro supported an ATP noncompetitive inhibition 
mechanism by which 1 inhibits GSK-3β via interactions within the substrate-binding pocket.  
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Figure 2.4. Isoorientin (1) is a substrate competitive inhibitor of GSK-3β. 
Predicted docking structures of ATP (A), staurosporine (B), 1 (C) and 2 (D) with GSK-3β (PDB 
code 1PYX). Surface representation of the ATP-binding site of GSK-3β is shown in orange, the 
substrate-binding site of GSK-3β is shown in green. Within substrate-binding site, surface features 
are shown with acidic residues in red, basic residues in blue, hydrophobic residues in green. 
Magnesium ions are shown as bright green spheres. The dotted lines represent interactions with 
magnesium ions and hydrogen bonds with side chain residues of GSK-3β. (E) GSK-3β inhibitory 
kinetics in vitro, when ATP was kept constant at 25 μM. GSK-3β activity was determined by 
increasing concentrations of 1 in the presence of varying concentrations of kinase substrate GS2. 
The lines represented the result of a non-linear regression analysis of the entire data set using a 
best-fit kinetic model for enzyme inhibition. Data were means of quadruplicate of each of two 
independent experiments with ± SEM (n = 8). The analysis showed a competitive inhibition of 
GS2 with a Ki of 125 ± 13 μM, and a Vmax of 0.66 ± 0.02 μM/min. (F) Dixon plots of GSK-3β 
activity in the presence of varying concentrations of GS2 versus 1. The lines were linear regression 
plotting of 1/V against concentration of 1 at a given concentration of GS2. Intersecting point above 
the X axis indicated a competitive inhibition with respect to substrate GS2. ISO, isoorientin. 
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2.1.4. Isoorientin Inhibits GSK-3β-Mediated Tau 
Hyperphosphorylation in a Whole-Cell Lysate Kinase Assay 
Given our hypothesis that 1, being an ATP noncompetitive inhibitor of GSK-3β, can alleviate 
tau hyperphosphorylation, we investigated the potential of 1 against GSK-3β-mediated tau 
phosphorylation. To determine whether the intervention of 1 on tau phosphorylation is ascribed to 
a direct GSK-3β inhibition in an ex vivo matrix, we designed a simple in vitro GSK-3β assay to 
take advantage of a whole-cell lysate of the neuroblastoma SH-SY5Y cells. In this assay, an aliquot 
of lysate was fortified with exogenous GSK-3β (wt/wt 0.25%), and incubated with 1 (112 μM) or 
LiCl (10 mM) for 2 h, followed by western blotting probed with anti-tau pS199/pS202 and pS396 
antibodies. Tau-5 and GSK-3β antibodies were also applied to assess the respective total protein 
levels. It has been reported that phosphorylation sites pS199/pS202 and pS396 on tau are GSK-3β 
specific.74 Abnormal tau phosphorylation at these sites impairs microtubule stabilization and 
neurite outgrowth, which is closely linked to AD.74, 100 Western blot results substantiated that 
overactive GSK-3β by introducing exogenous GSK-3β significantly increased tau phosphorylation 
at sites pS199/pS202 and pS396 approximately three fold (p < 0.0001) in comparison to their basal 
phosphorylation levels (lysate spiked with heat-inactivated GSK-3β) (Figure 2.5). Conversely, 
treatment of 1 or LiCl showed an apparent attenuation on tau phosphorylation for those specific 
sites mediated by GSK-3β (p < 0.01). Noticeably, the anti-tau phosphorylation potency of 1 at 112 
μM was comparable to that of LiCl at 10 mM, which the latter is a weak but specific GSK-3β 
inhibitor (IC50, 2 mM) currently in clinical trials for AD. The encouraging data from the whole-
cell lysate kinase assay provided plausible evidence of GSK-3β inhibition and its subsequent effect 
on GSK-3β-mediated tau hyperphosphorylation upon treatment with 1. 
 23 
 
 
 
 
Figure 2.5. Isoorientin (1) attenuates GSK-3β mediated tau phosphorylation in a SH-SY5Y 
whole-cell lysate kinase assay. 
(A) Cell lysate aliquots were spiked with 0.25% (wt/wt) GSK-3β, and incubated with 112 μM 1, 
10 mM LiCl or 5% DMSO vehicle in a kinase buffer at 37 ˚C for 2 h. Immunoblot analysis was 
performed with antibodies against Tau-5, Tau pS199/pS202, pS396 and GSK-3β. β-Actin level 
was used as a protein loading control. (B) Densitometric analysis of western blotting for tau protein 
levels. Optical densities were normalized to β-actin and fold changes were calculated relative to 
the control with ± SEM (n = 3). The data were analyzed by one-way ANOVA with Tukey’s 
multiple comparison test. ####p < 0.0001 relative to inactive GSK-3β spiked control; **p < 0.01, 
***p < 0.001, ****p < 0.0001 relative to the active GSK-3β spiked control. ISO, isoorientin. 
2.1.5. Isoorientin Attenuates Aβ-Induced Tau 
Hyperphosphorylation in SH-SY5Y Cells 
Although in vitro enzymological studies demonstrated the potential of 1 for GSK-3β inhibition 
and anti-tau phosphorylation, additional validations for those effects within a cellular level remain 
necessary. Growing evidence indicated that Aβ activates GSK-3β via PI3K/AKT/GSK-3β 
signaling in AD, thereby causing downstream tau hyperphosphorylation in neurons.76, 101 We 
examined the alleviative effects of 1 on tau hyperphosphorylation in a cell model relevant to Aβ 
pathology, in which the cells were treated with Aβ42. Human neuroblastoma SH-SY5Y cells were 
used in this research as on differentiation they possess the functionality and molecular features 
resembling to human neurons.84-85 Cellular phosphorylation levels were assessed with antibodies 
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against pS199/pS202 and pS396 on tau protein, while the extent of an inactive form of GSK-3β 
(phosphorylated GSK-3β at Ser9) with antibody GSK-3β pS9. Those abnormal phosphorylations 
have been found in AD.74, 76 Tau-5 and GSK-3β antibodies were used to evaluate the respective 
total protein expressions.  
Figure 2.6 shows that treatment of SH-SY5Y cells with 10 μM Aβ42 for 72 h increased tau 
phosphorylation at sites pS199/pS202 and pS396 approximately 3.5 and 2.3-fold, respectively, 
relative to untreated cells. In contrast, pretreatment of 1 at varying concentrations (28, 112 and 448 
μM) to SH-SY5Y cells for 1 h followed by co-incubation with 10 μM Aβ42 for 72 h significantly 
decreased tau phosphorylation levels at all phosphorylation sites in a dose-dependent manner (p < 
0.01) (Figure 2.6B). Significant alleviative effects of 1 on tau phosphorylation were achieved even 
at lower doses (e.g., 28 μM).  
No significant change was observed in levels of both GSK-3β pS9 and total GSK-3β in the 
cells upon treatments (either Aβ42 treatment alone or co-incubation of 1 with Aβ42) compared to 
untreated cells (p > 0.05) (Figure 2.6A and C). A downregulating effect of Aβ, in particular the 
Aβ25-35 fragment, on an inactive form of GSK-3β has been postulated to account for GSK-3β 
activation in certain cell models.102-103 The results of the present study, however, showed no 
apparent changes on GSK-3β pS9 levels upon treatments, suggesting complexity in GSK-3β 
activation. While the exact mechanism between Aβ42 stimuli and GSK-3β activation in SH-SY5Y 
cells is still unclear, the consequential effect of 1 on anti-tau phosphorylation is putatively from a 
direct inhibition of GSK-3β in the cells (Figure 2.6). 
GSK-3β inhibition and anti-tau phosphorylation of 1 were further experimentally supported 
by co-treatment of 1 with GSK-3β specific inhibitors in Aβ42 treated SH-SY5Y cells. LiCl (IC50, 2 
mM) and TDZD-8 (IC50, 2 μM) are GSK-3β specific inhibitors and have shown a promise for AD 
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treatment.95 We therefore used them as references to compare effects of 1 on anti-tau 
hyperphosphorylation in the cells. As depicted in Figure 2.7A, brief pretreatment of 1 (112 μM), 
LiCl (10 mM) or TDZD-8 (10 μM) to SH-SY5Y cells for 1 h followed by co-incubation with 10 
μM Aβ42 for 72 h displayed an expected decrease of tau phosphorylation at sites pS199/pS202 and 
pS396 (p < 0.001). Notably, when co-treatment of 1 (112 μM) with LiCl (10 mM) to SH-SY5Y 
cells for 1 h followed by co-incubation with 10 μM Aβ42 for 72 h, an effect against tau 
phosphorylation for sites pS199/pS202 and pS396 was enhanced in comparison with either 1 or 
LiCl individual treatment (Figure 2.7B). Co-treatment of 1 with LiCl could result in a synergistic 
effect on anti-tau phosphorylation due to their distinct mechanisms of GSK-3β inhibition – 
substrate competition by 1 and Mg2+ displacement by Li+. On the other hand, TDZD-8 (10 μM) 
co-treated with 1 (112 μM) did not change the level of anti-tau phosphorylation in comparison 
with TDZD-8 alone (p > 0.05). This phenomenon can be plausibly explained by the fact that 
TDZDs are ATP noncompetitive and irreversible inhibitors of GSK-3β.104 While X-ray 
crystallographic structures of GSK-3β with TDZDs were not available, computational simulation 
suggested that TDZDs appear to interact within the substrate-binding site of GSK-3β.105 It is 
possible that the more potent and irreversible inhibitor TDZD-8 (IC50, 2 μM) overperformed 1 
during co-treatment (Figure 2.7A and B). Upon those treatments, little changes in the levels of 
GSK-3β pS9 and total GSK-3β were observed by western blot analyses (p > 0.05) (Figure 2.7C). 
Nonetheless, the similarity of pharmacological phenomena between 1 and the known GSK-3β 
specific inhibitors, in conjunction with the findings in the whole-cell lysate kinase assay, indeed 
conferred that 1 is an effective GSK-3β inhibitor attenuating aberrant tau phosphorylation in the 
human cells. 
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Figure 2.6. Isoorientin (1) attenuates Aβ42 induced tau phosphorylation in SH-SY5Y cells. 
(A) Cells were pretreated with varying concentrations of 1 or 0.2% DMSO vehicle for 1 h followed 
by 10 μM Aβ42 treatment and incubated for 72 h. Immunoblot analysis was performed with 
antibodies against Tau-5, Tau pS199/pS202, Tau pS396, GSK-3β, and GSK-3β pS9. β-Actin level 
was used as a protein loading control. (B) Densitometric analysis of western blotting for tau protein 
levels. (C) Densitometric analysis of western blotting for GSK-3β levels. Optical densities were 
normalized to β-actin and fold changes were calculated relative to the control with ± SEM (n = 3). 
The data were analyzed by one-way ANOVA with Tukey’s multiple comparison test. ###p < 0.001, 
####p < 0.0001 relative to control; **p < 0.01, ***p < 0.001, ****p < 0.0001 relative to the 10 μM 
Aβ42 treatment. ISO, isoorientin. 
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Figure 2.7. Isoorientin (1) attenuates Aβ42 induced tau phosphorylation by inhibiting GSK-
3β in SH-SY5Y cells. 
(A) Cells were pretreated with individual inhibitor (112 μM for 1; 10 mM for LiCl; 10 μM for 
TDZD-8) or a combination (1/LiCl or 1/TDZD-8) for 1 h followed by 10 μM Aβ42 treatment and 
incubated for 72 h. Immunoblot analysis was performed with antibodies against Tau-5, Tau 
pS199/pS202, Tau pS396, GSK-3β, and GSK-3β pS9. β-Actin level was used as a protein loading 
control. (B) Densitometric analysis of western blotting for tau protein levels. (C) Densitometric 
analysis of western blotting for GSK-3β levels. Optical densities were normalized to β-actin and 
fold changes were calculated relative to the control with ± SEM (n = 3). The data were analyzed 
by one-way ANOVA with Tukey’s multiple comparison test. ####p < 0.0001 relative to control; 
***p < 0.001, ****p < 0.0001 relative to the 10 μM Aβ42 treatment. ISO, isoorientin. 
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2.1.6. Isoorientin Exerts Neuroprotection against Aβ-Induced 
Cytotoxicity in SH-SY5Y Cells 
We investigated whether 1 exerts neuroprotective effects against Aβ-induced cytotoxicity in 
differentiated human SH-SY5Y cells. Oligomers of Aβ42 can activate GSK-3β, resulting in tau 
hyperphosphorylation and microtubule disassembly within axons of neuron.100 This neurotoxic 
effect of Aβ42 could consequently lead to the axonal and dendritic impairment followed by neuron 
cell death.106-108 Such toxic effects were substantiated by a dramatic cell viability reduction after 
the addition of Aβ42 oligomers in SH-SY5Y cells (Figure 2.8A). Since Aβ42 at 10 μM inhibited 
about 50% cell number in vitro based on cell viability assay, this dose was used in the subsequent 
experiments. Pretreatment of SH-SY5Y cells with 1 (112 μM) for 1 h followed by co-incubation 
with 10 μM Aβ42 for 72 h resulted in a neuroprotection against cell viability loss, whose effect was 
similar to the known GSK-3β inhibitors LiCl and TDZD-8 (Figure 2.8B). Interestingly, co-
treatment of 1 (112 μM) with LiCl (10 mM) showed a synergistic neuroprotection, whereas co-
treatment with TDZD-8 (10 μM) did not (Figure 2.8B). Quantitative dose-response measurement 
of cell viability demonstrated effective inhibitions of 1 to neurotoxic induction by 10 μM Aβ42 
with an EC50 value of 47 μM (Figure 2.8C and D). Remarkably, no cytotoxicity of 1 to SH-SY5Y 
cells was noted up to a dose of 896 μM (Figure 2.8E). Instead, the data showed that 1 slightly 
stimulated cell proliferation. This result suggested that 1 exhibited a good safety margin and 
tolerability profile. In addition, microscopic observations illustrated apparent neuronal 
morphological changes of SH-SY5Y cells upon 10 μM Aβ42 treatment, particularly the substantial 
retraction of neurites (Figure 2.9A and B). In contrast, treatment of 1 effectively prevented the 
differentiated SH-SY5Y cells from Aβ42 intoxication as a large number of healthy cells with 
extended neurites were observed (Figure 2.9C and D). These observations together with the cell 
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viability analysis suggested that 1 exhibits effective anti-Aβ neurotoxicity through protecting cell 
differentiation and neurite extension, whose functions are highly regulated by tau proteins in 
neuron. 
To further verify that C-glycosylflavones in the CS extracts are contributive to 
neuroprotection, we assayed CS fractions on anti-Aβ neurotoxicity. Those fractions active in the 
GSK-3β assay indeed displayed proportional effects in defense of Aβ-induced cytotoxicity in SH-
SY5Y cells (see Appendix 3). Interestingly, 2, the less potent GSK-3β inhibitor, exerted 
neuroprotection but with a weaker potency compared to 1 (EC50, 154 μM). 
 
 
 
Figure 2.8. Isoorientin (1) alleviates 10 μM Aβ42 induced neurotoxicity in differentiated SH-
SY5Y cells. 
Cell viability was determined using the MTS Cell Proliferation Assay. Colorimetric intensity of 
nontreated control cells in the MTS assay was normalized as 100% cell viability and that of solvent 
blank without cell culture was normalized as 0% cell viability. Data were means of triplicate of 
each of two independent experiments with ± SEM (n = 6). The data were analyzed by one-way 
ANOVA with Tukey’s multiple comparison test. ####p < 0.0001 relative to vehicle control; *p < 
0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 relative to the 10 μM Aβ42 treatment. ISO, isoorientin. 
(A) Aβ42 induced neurotoxicity in differentiated SH-SY5Y cells. Cells were treated with varying 
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concentrations of Aβ42 or 0.2% DMSO vehicle and incubated for 72 h. (B) Comparison of 
neuroprotection of 1, LiCl and TDZD-8 in SH-SY5Y cells. Cells were pretreated with 1 (112 μM), 
LiCl (10 mM), TDZD-8 (10 μM) or a combination (1/LiCl or 1/TDZD-8) for 1 h followed by 10 
μM Aβ42 treatment and incubated for 72 h. (C) Cells were pretreated with varying concentrations 
of 1 or 0.2% DMSO vehicle for 1 h followed by 10 μM Aβ42 treatment and incubated for 72 h. (D) 
1 inhibited neurotoxicity induced by 10 μM Aβ42 with an EC50 value of 47 ± 22 μM. Results were 
presented as the percentage of the neuroprotective activity relative to control (100%) and 10 μM 
Aβ42 treatment (0%). Neuroprotection curve was analyzed by four-parameter regression. (E) 
Cytotoxicity assessment of 1 in SH-SY5Y cells. Cells were treated with varying concentrations of 
1 or 0.2% DMSO vehicle and incubated for 72 h.  
 
 
 
Figure 2.9. Morphological changes of SH-SY5Y cells after treatment for 72 h. 
(A) 0.2% DMSO treatment as vehicle control. Differentiated cells with extended neurites. (B) 10 
μM Aβ42 treatment. Impaired and nondifferentiated cells with retracted neurites. (C) Pretreatment 
of 28 μM 1 followed by 10 μM Aβ42 treatment. Partial differentiated cells with extended neurites. 
(D) Pretreatment of 448 μM 1 followed by 10 μM Aβ42 treatment. Protected differentiated cells 
with extended neurites. Micrographs represent the average morphologic characteristics of cell 
cultures under a given condition of 4-6 experimental replicates. Scale bar = 100 μm. ISO, 
isoorientin. 
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2.1.7. Discussion 
6-C-glycosylflavones are a major class of flavones produced in CS via the maysin biosynthetic 
pathway.109 These endogenous flavones are well known for their unique activities against corn 
earworms.79, 109 While these C-glycosylflavones have originally evolved in maize plant for 
chemical defense purposes, it has been postulated that this class of metabolites can exert biological 
effects on therapeutic targets such as AD-relevant kinases in human on the basis of their chemical 
characteristics.35, 110 With respect to the chemical structure of C-glycosylflavones, the presence of 
carbon-linked glycosidic bond makes these compounds more resistant to metabolic hydrolysis, 
which is distinct from the O-glycosylflavones prevalent in flora. Interestingly, studies reported that 
CS-derived flavones show neuroprotective activities by inhibiting cholinesterases111 and reactive 
oxygen species112 in different enzyme-based or cell-based models. It is also reported that 1 exerts 
anticancer activity by intervening the PI3K/AKT signaling in human HepG2 cells,66, 113 which the 
pathway is highly associated with neuronal survival relevant to AD.101 CS-derived flavones 
including 1 may potentiate a synergistic effect by leveraging multi-activities to gain a maximal 
neuroprotective profile to tackle AD. Among those activities, anti-tau hyperphosphorylation 
through GSK-3β inhibition by 1 is a key contributor, as supported by the results of the present 
study. 
Flavones are known for their multi-functional actions.35, 110 It has become evident that 
flavones exerting their neuroprotection are probably due to the interaction with key cellular 
receptors or enzymes that regulate neuronal apoptosis, survival, differentiation and proliferation.35, 
114 AD is a complex neurodegeneration involving Aβ neurotoxicity, tau hyperphosphorylation, 
Ca2+ dysregulation, oxidative stress production, neuroinflammation, and synaptic dysfunction.1 An 
anti-AD agent modulating multiple targets and signaling pathways in a disease-relevant context 
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can offer valuable properties in pharmaceutical applications. In the present study, because Aβ42 
triggers neurotoxicity through complex pathways in SH-SY5Y cells, the pleiotropic concept54, 72 
may explain the slight discrepancy that 1 is more potent in the cellular assay (EC50, 47 ± 22 μM) 
than in the GSK-3β assay (substrate-competitive inhibition Ki, 125 ± 13 μM). While 1 showed 
selective inhibition of GSK-3β among 22 AD-relevant kinases tested, its potential action on multi-
targets may be favorable in AD therapies. C-glycosylflavones warrant further investigation as AD 
phytopharmaceuticals. 
As of today, four drugs have been approved by the US FDA for AD treatment, while one has 
been approved by the Chinese FDA. All of them only alleviate short-term cognitive symptoms.3 
There is a critical demand for new agents with greater efficacy and safety to slow, halt, prevent 
and ideally reverse AD. The present study emphasized a tau-targeted therapeutic strategy to 
remedy AD. We screened phytochemicals for potential inhibition of AD-relevant kinases. A 
tandem approach of bioassay-guided fractionation and LC-MS analysis of CS extracts afforded 
two 6-C-glycosylflavones (1 and 2) as GSK-3β inhibitors. Isoorientin (1) showed moderate 
potency but apparent selectivity in the kinase assay profile system. In vitro enzymatic and cellular 
evaluations as well as in silico molecular modeling revealed a putative mechanism of action by 
which 1 involves in blocking GSK-3β via a noncompetitive inhibition for ATP to attenuate tau 
hyperphosphorylation. The results demonstrated the first time that CS-derived C-glycosylflavones 
are ATP noncompetitive inhibitors of GSK-3β. 1 also exerts effective neuroprotection against Aβ-
induced cytotoxicity in the human SH-SY5Y cell model, which is plausibly involved in the tau-
dependent pathway. 1 can be a potential lead candidate with a good safety margin for AD 
prevention and treatment. Nevertheless, SAR-based development remains necessary to achieve a 
better efficacy, bioavailability, and blood-brain barrier permeability of C-glycosyl flavonoids. 
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Experiments using site-directed mutagenesis of the key residues in GSK-3β would help further 
validate the specific interactions of 1 in the substrate-binding site. It is worthwhile to note that 1 
also significantly inhibits AKT1, PKC and CK2 by approximately 30%, the potential multi-target 
and/or off-target effects should not be neglected. Addressing the kinase selectivity issue is an 
important aspect in the future SAR-based lead optimization. Further assessments of 1 and its 
analogues in animal models must be conducted in order to validate their in vivo effectiveness for 
toxic tau clearance as well as the cognitive benefits. 
 
 
* Methods and experimental procedures are listed in Chapter 3 of the dissertation.  
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2.2. Computer-Aided Drug Discovery of Novel C-Glycosylflavones as 
Anti-Alzheimer’s Agents Targeting GSK-3β † 
Traditional GSK-3β inhibitors target the highly conserved ATP site. However, the limited 
selectivity of those inhibitors raises safety concerns owing to off-target effects and, therefore, 
remains a major challenge in GSK-3β based drug development.78 Despite substantial efforts in 
developing GSK-3β inhibitors in the past decades, to date only lithium carbonate and tideglusib (a 
TDZD compound) have been studied in clinical trials for AD.24 Lithium carbonate shows a weak 
inhibition (IC50, 2 mM),78 while tideglusib (IC50, 100 nM) is an irreversible and time-dependent 
inhibitor of GSK-3β.104, 115 In recent years, strategies have been employed to search for selective 
and reversible GSK-3β inhibitors, particularly those are not ATP-site directed. It is known that the 
substrate domain of GSK-3β is less conserved with a unique folding different from other kinases.78, 
116 Inhibitors targeting this site are thought to be more specific and selective than the ATP-
competitive inhibitors.78, 116 Yet few substrate-competitive inhibitors of GSK-3β have been 
reported.96, 117-119 New, potent, selective and reversible inhibitors targeting the substrate site on 
GSK-3β are potential disease-modifying therapies for AD. 
We have undertaken a different approach to discover potential substrate-competitive 
inhibitors of GSK-3β from natural sources. Natural products are valuable starting points for drug 
discovery as they have been naturally selected and optimized under evolutionary pressure and 
obtained privileged structures for protein binding.120 C-Glycosylflavones and their aglycones 
(Figure 2.10) omnipresent in plants are important phytochemicals noted for anti-oxidation, anti-
                                                             
† Reproduced in part with permission from Liang, Z.; Li, Q. X. ACS Chem. Neurosci. 2018, DOI: 
10.1021/acschemneuro.8b00010. Copyright © 2018 American Chemical Society. 
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inflammation, anti-cancer, anti-cardiovascular diseases, and cognitive enhancement.35, 38, 121 We 
recently screened corn silks for GSK-3β inhibitors and isolated a 6-C-glycosylflavone, isoorientin 
(1) (see Section 2.1).65 Compound 1 alleviates tau hyperphosphorylation and amyloid 
neurotoxicity through selective and reversible GSK-3β inhibition,65 by which the mechanism of 
action is substrate competition rather than the common ATP competition (see Section 2.1).65 In 
addition, a recent study showed that 1 and related natural flavones attenuate Aβ burden and 
neuroinflammation in an APPswe/PSEN1dE9 mouse model of AD.69 1 from maize crop65 is 
conceivably safe as supported by in vivo subchronic toxicity studies of corn silk-derived flavones 
in mice and rats.70-71 1 is a promising medicinal natural product with a novel mode of action for 
reducing AD burdens.65, 69, 71 However, the lack of druggable potency (IC50, 185 µM), commonly 
suffered by bioactive natural products, makes it challenging in pharmaceutical applications. 
Potency improvement, through structure-activity relationship (SAR)-based optimization, 
pharmacological and pharmacokinetic evaluations, as well as testing administration routes in vivo 
are therefore necessary to develop analogues of 1 with therapeutic potential. 
In our recent paper, preliminary examination of the predicted 3D structure of the GSK-3β-1 
complex revealed that the substrate pocket of GSK-3β favors specific interactions with both the 
C-glycone and flavone moieties in 1.65 In particular, a cleft composed of Phe67, Val87, Leu88, 
and Phe93 on GSK-3β is critical for substrate recognition (Figure 2.4).94 This concave cleft could 
accommodate a hydrophobic moiety favoring ligand binding, which is in the vicinity of the 
primary hydroxyl group on C-glycone of 1. This raises our hypothesis that introduction of a 
hydrophobic functional group at this primary alcohol enhances affinity and selectivity of 1 to GSK-
3β. In addition, methylation of the phenolic hydroxyls can improve bioavailability, metabolic 
stability, and potency of flavones.122 
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In the present study, a new series of 1 analogues containing a 6-C-glycosylflavone scaffold 
were semi-synthesized to target the substrate site on GSK-3β. Potency, selectivity, passive 
membrane permeability, anti-tau hyperphosphorylation, and anti-Aβ neurotoxicity of the new 
inhibitors were evaluated with molecular and cellular studies, SAR analysis, and molecular 
modeling.  
 
 
Figure 2.10. Natural C-glycosyl and aglycosyl flavones 1, 3 and 4. 
The flavone rings are labeled as A, B, and C, and the positions of atom are labeled in Arabic 
numbers according to the IUPAC rules. 
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2.2.1. Chemical Design and Synthesis 
 
 
Figure 2.11. Chemical modifications beginning with isoorientin. 
a Reagents and conditions: (a) TMSCHN2, toluene, methanol, rt, 80%; (b) [TEMPO]+[BF4]−, 
DCM, pyridine, rt, 95%; (c) R-NH2, HCTU, DIPEA, DMF, DCM, rt, 80-90%. 
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Based on the strategy noted in Section 2.1 that addition of a hydrophobic moiety around the 
primary hydroxyl on the C-glycone to increase ligand-binding affinity and methylation of phenolic 
hydroxyls to increase bioavailability and metabolic stability, a series of new analogues of 1 were 
designed and synthesized (Table 2.2). The semi-synthesis of 6-C-glycosylflavones from 1 was 
carried out according to the route outlined in Figure 2.11. The four phenolic hydroxyls on the 
flavone core of 1 were first selectively methylated by TMSCHN2 in a methanolic toluene solution 
according to a previously described method.123 The resulting tetra-methylated product (5) then 
underwent an oxoammonium salt-mediated oxidation. We optimized an oxidation protocol124 
using a [TEMPO]+[BF4]− salt in a pyridine base solution at room temperature, which 
chemoselectively transformed the primary alcohol to a carboxylic acid without affecting the 
secondary hydroxyls on the C-glycone. This method successfully afforded the desired product (6) 
in over 95% yield which was confirmed by ESI-TOF-MS and NMR analyses. The carboxylic acid 
derivative 6 was then subjected to methyl esterification to afford 7. It is known that an ester bond 
is susceptible to metabolic hydrolysis. Our chemical design thus focused on amide analogues with 
better physiochemical stability. A small library of hydrophobic amides (8-31) was generated by 
coupling 6 with a series of organic amines via HCTU catalysis. Aliphatic, alicyclic, aromatic and 
fluorinated amines were selected for the solution-phase amidation (Table 1). The resulting 
hydrophobic amides were evaluated on their SAR, cytotoxicity, anti-AD activity, and passive 
membrane permeability. All final products were characterized by NMR and HRMS, and were over 
95% purity determined by HPLC-UV at 210, 254, and 340 nm. 
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Table 2.2. Chemical structures of natural and semi-synthetic C-glycosylflavones. 
O
O
O
O
O
O
O
OH
OH
HO
X2
R1
R1
R1
R1
X1
R2
1, 5-31
1
2
3
45
6
7
8
1'
2'
3'
4'
5'
6'
H
 
cmpd Functional group 
no. R1 X1 X2 R2 
1 H H2 O H 
5 CH3 H2 O H 
6 CH3 O O H 
7 CH3 O O CH3 
8 CH3 O NH 
 
9 CH3 O NH 
 
10 CH3 O NH 
 
11 CH3 O NH 
 
12 CH3 O NH 
 
13 CH3 O NH 
 
14 CH3 O NH 
 
15 CH3 O NH 
 
16 CH3 O NH 
 
17 CH3 O NH 
 
 40 
 
 
18 CH3 O NH 
 
19 CH3 O NH 
 
20 CH3 O NH 
 
21 CH3 O NH 
 
22 CH3 O NH 
N  
23 CH3 O NH 
N
S
 
24 CH3 O NH 
F  
25 CH3 O NH F
 
26 CH3 O NH 
F  
27 CH3 O NH CF3  
28 CH3 O NH F  
29 CH3 O NH 
CF3  
30 CH3 O NH CF3(S)
 
31 CH3 O NH CF3(R)
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2.2.2. Structure Activity Relationship and Ligand-Lipophilic 
Efficiency of C-Glycosylflavones to GSK-3β 
The semi-synthetic 6-C-glycosylflavones (5-31) were assayed on GSK-3β inhibition in 
comparison to three natural flavones with structural similarities (one 6-C-glycosylflavone 
isoorientin 1, one 8-C-glycosylflavone orientin 3, and a flavone aglycone luteolin 4). Among the 
three flavones (1, 3 and 4, Figure 2.10), 4 showed the highest potency against GSK-3β (IC50, 3.1 
μM in Table 2.3), but it is nonspecific and promiscuous as noted in the literature and our previous 
studies.65, 125 1 with C-glycosides at 6-position showed a moderate potency against GSK-3β with 
an IC50 value of 185 (Table 2.3). In contrast, 3 with an 8-C-glycoside was inactive (IC50, > 5 mM). 
The results demonstrated that the presence and position of C-glycone on the flavone core are 
critical for GSK-3β inhibition, which agrees with our previous observation.65  
The tetramethylated alcohol (5) and tetramethylated carboxylic acid (6) slightly decreased the 
potency (IC50, 237 and 239 μM, respectively) in comparison with 1, indicating a trivial 
contribution of the phenolic hydroxyl groups to GSK-3β inhibition. However, a methyl ester (7) 
(IC50, 135 μM) increased the potency by 1.37-fold as compared to 1 (IC50, 185 μM), suggesting 
hydrophobic groups at the primary hydroxyl position preferred for GSK-3β inhibition. 
Remarkably, transforming the primary alcohol to corresponding hydrophobic amides (8-31) 
(Table 2) significantly increased the potency against GSK-3β as most analogues displayed IC50 
values less than 50 μM and ten of them (9, 13, 16, 17, 20, 21, 27, 29, 30 and 31) were less than 20 
μM. As shown in Figure 2.12A, the aliphatic (e.g., 9 and 13) and alicyclic amides (e.g., 16 and 17) 
exhibited a higher affinity to GSK-3β than the aromatic amides (e.g., 20-23). Small (14 and 15) or 
large (18 and 19) alicyclic rings showed a less affinity than the cyclopentyl (16) or cyclohexyl (17) 
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analogues, plausibly due to the size of the hydrophobic concave cleft in the substrate site on GSK-
3β. A branched isopropyl group (9, 30, and 31) showed a higher affinity than a linear propyl group 
(8, 28, and 29). Monofluorination of phenyl (24), benzyl (25), ethyl (26) or propyl (28) groups did 
not improve affinity as compared to nonfluorinated counterparts (e.g., 8, 20, and 21). It is 
interesting that a trifluoromethyl (CF3) group has a significant effect on potency. Compounds 27, 
29, 30 and 31 containing a CF3 moiety consistently improved binding affinity to GSK-3β in 
comparison with no fluorine or monofluorinated counterparts (e.g., 8, 9, 26 and 28) (Figure 2.12A). 
In particular, 30 (IC50, 0.59 μM) with a (S)-CF3 group increased the potency against GSK-3β by 
310-fold in comparison with 1, and is about 4-fold more potent than its epimer 31 with a (R)-CF3 
group (IC50, 2.3 μM). All new analogues were not promiscuous or pan-assay interference 
compounds to GSK-3β as determined with a detergent-based assay.65, 92 
Ligand-lipophilic efficiency (LiPE) is a parameter commonly used in drug design to assess 
the quality of compound candidates. Lipophilicity is the most important druglike physiochemical 
property that highly correlates to absorption, distribution, metabolism, excretion and toxicity 
(ADMET) profiles and ultimately to the pharmacological response for oral drugs.126-127 High 
potency (large pIC50) is a desirable feature in drug candidates, as it reduces the risk of off-target 
and nonspecific pharmacology. Correlation between lipophilicity (CLogP) and potency (pIC50) 
provides a valuable parameter to estimate druglikeness.128 Many of the semi-synthetic analogues 
clustered in an upper-right range of the LiPEs between 2 and 4, indicating that both lipophilicity 
(CLogP) and GSK-3β inhibitory potency (pIC50) have been increased relative to 1 (Figure 2.12B). 
Particularly, 30 has the highest LiPE value (> 4) among the analogues, suggesting a unique 
contribution of the CF3 moiety of 30 to improving potency and lipophilicity. 
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Table 2.3. Comparison of natural and semi-synthetic C-glycosylflavones on GSK-3β 
inhibition and CLogP. 
cmpd GSK-3β inhibition CLogP b  cmpd GSK-3β inhibition CLogP b 
no. IC50 (μM) a   no. IC50 (μM) a  
1 184.9 ± 1.4 0.21  17 9.0 ± 1.3 2.55 
3 5153 ± 31 0.21  18 26.0 ± 1.2 3.16 
4 3.1 ± 1.3 2.31  19 33.5 ± 0.8 3.17 
5 239.2 ± 1.2 1.28  20 19.7 ± 1.1 2.21 
6 237.3 ± 1.4 0.80  21 15.8 ± 1.2 2.34 
7 135.0 ± 1.3 1.21  22 35.6 ± 1.3 1.54 
8 29.2 ± 1.1 1.57  23 35.1 ± 1.0 1.45 
9 5.4 ± 0.1 1.35  24 56.2 ± 1.2 2.61 
10 33.3 ± 1.1 2.10  25 21.7 ± 1.2 2.48 
11 31.1 ± 1.2 1.97  26 34.8 ± 1.0 0.77 
12 28.0 ± 1.1 2.63  27 19.3 ± 0.8 1.31 
13 9.4 ± 0.9 3.16  28 49.5 ± 1.2 1.00 
14 25.8 ± 1.1 1.10  29 17.2 ± 0.9 1.29 
15 61.9 ± 1.2 1.43  30 0.59 ± 0.04 1.62 
16 13.1 ± 1.1 1.99  31 2.3 ± 0.5 1.62 
a IC50 values were the mean of quadruplicate of each of two independent experiments. bCLogP 
values were calculated by a fragment-based method.129 cmpd, compound. 
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Figure 2.12. Analyses of GSK-3β inhibitory activities for compounds 1-31. 
(A) Scatter plot of pIC50 (-LogIC50) for GSK-3β inhibitors 1, 8-31. The parent compound 
isoorientin 1 is shown in red, aliphatic amide analogues are shown in cyan, alicyclic amide 
analogues are shown in blue, aromatic amide analogues are shown in yellow, and fluorinated 
amide analogues are shown in purple. (B) Plot of CLogP versus pIC50 for GSK-3β inhibitors 1-
31. Diagonal lines represent areas of the same LiPEs to estimate druglikeness. LiPE = pIC50 – 
CLogP. Solid circle, natural flavones; Open circle, semi-synthetic flavones. cmpd, compound. (C) 
A summary of the important structural changes from ISO to new analogues. R represents 
hydrophobic functional groups. 
 
2.2.3. Evaluations of New C-Glycosylflavones on Anti-Tau 
Hyperphosphorylation Mediated by GSK-3β 
Compounds 9, 17, 21, and 30 were selected for further evaluation on their effect against GSK-
3β mediated tau hyperphosphorylation relative to 1, as they are the most potent GSK-3β inhibitors 
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within each of the aliphatic, alicyclic, aromatic and fluorinated amide analogues, respectively. We 
recently established an in vitro GSK-3β assay using a whole-cell lysate of human SH-SY5Y 
neuroblastomas and demonstrated that the pS396 site on tau protein is GSK-3β specific.65 This 
method provides a rapid means to assess intact ligand-kinase interaction in an ex vivo protein 
matrix of a lysate and circumvent compound degradation in a cell system. Direct GSK-3β 
inhibition by isoorientin 1 led to its consequent effect against GSK-3β–mediated tau 
hyperphosphorylation on the pS396 site in the SH-SY5Y lysate.65 In analogy, an aliquot of lysate 
was fortified with GSK-3β (wt/wt 0.25%), and incubated with 9, 17, 21, or 30 at different 
concentrations (2, 10, and 50 μM) for 2 h followed by an enzyme-linked immunosorbent assay 
(ELISA) with an anti-tau pS396 antibody. TDZD-8 (10 μM) and 1 (100 μM) were used as 
reference controls. Quantitative ELISA measurements substantiated that introducing exogenous 
GSK-3β significantly increased phosphorylation by approximately 2.5-fold (p < 0.0001) at the site 
pS396 on tau proteins as compared to their basal levels (lysate fortified with heat-inactivated GSK-
3β) (Figure 2.13). In contrast, treatment of 9, 17, 21, or 30 effectively attenuated tau 
hyperphosphorylation in a dose-dependent manner (p < 0.0001). All four analogues showed vast 
improvements of anti-tau hyperphosphorylation in comparison to the natural product 1. Compound 
30 at 10 μM exerted an anti-tau effect comparable to TDZD-8 (a known potent GSK-3β inhibitor, 
IC50 = 2 μM) at the same concentration (p < 0.05). These results demonstrated that the new 6-C-
glycosylflavone analogues indeed alleviate tau hyperphosphorylation, of which 30 is the most 
promising candidate suitable for further in vivo pharmacological assessments. 
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Figure 2.13. Compounds 9, 17, 21 and 30 attenuate GSK-3β-mediated tau phosphorylation 
in a SH-SY5Y whole-cell lysate kinase assay. 
Cell lysate aliquots were fortified with 0.25% (wt/wt) GSK-3β, and incubated with 2–50 μM of 9, 
17, 21, 30, or 5% DMSO vehicle in a kinase buffer at 37 °C for 2 h. 10 μM TDZD-8 and 100 μM 
isoorientin (1) were used as reference controls. ELISA analysis was performed with specific 
antibody against Tau pS396 to quantify tau phosphorylation levels. Fold changes were calculated 
relative to the control with ± SEM (n = 4). Data were analyzed by one-way ANOVA with Tukey’s 
multiple comparison test. ####p < 0.0001 relative to inactive GSK-3β fortified control; ****p < 
0.0001 relative to the active GSK-3β fortified control; •p < 0.05, ••p < 0.01 and ••••p < 0.0001 
relative to the TDZD-8 reference control. 
 
2.2.4. GSK-3β Kinetic Studies on the Inhibition Mode of Compound 
30 
To determine the GSK-3β inhibitory mechanism, the most potent analogue 30 (Figure 2.14A) 
was assayed to competitively replace ATP or the GSK-3β substrate GS2 (a peptide derived from 
human muscle glycogen synthase). Under a constant concentration of the substrate GS2 (17 μM), 
ATP concentrations varied from 2 to 50 μM and 30 concentrations varied from 0 to 5 μM. The 
Lineweaver‒Burk plots show a convergence of intersecting lines on the x-axis, indicating an 
unaltered Michaelis‒Menten constant (Km) but a reduced GSK-3β activity (increased 1/Vmax) when 
the concentration of 30 increased (Figure 2.14B(a)). This suggested no competition between ATP 
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and 30. In the second set of experiments under a constant concentration of ATP (10 μM), substrate 
GS2 concentrations varied from 8 to 66 μM and 30 concentrations varied from 0 to 5 μM. The 
Lineweaver‒Burk plots show that all lines intersected at the same point on the y-axis, suggesting 
an unchanged 1/Vmax but an increase of Km when the concentration of 30 increased (Figure 
2.14B(b)). The data demonstrated that 30 competed with the substrate GS2. The enzyme inhibitory 
behaviors of 30 are similar to that of the parent compound 165 and therefore confirm that the new 
analogues are indeed substrate-competitive, ATP-noncompetitive inhibitors of GSK-3β.  
 
2.2.5. Kinase Selectivity Profile of Compound 30 
It is prudent to evaluate kinase selectivity in the early phases of drug discovery. Compound 
30 was screened against a panel of 41 human protein kinases for selectivity relevant to AD and 
other CNS disorders.77 30 at 5 μM showed an overall good selectivity as it effectively inhibited 
GSK-3β by decreasing 92.3% kinase activity (p < 0.0001) in comparison to the control (100% 
kinase activity), Besides, 30 also inhibited by approximately 40% kinase activities for CDK1, 
PDK1, and Aurora B, whereas it showed only smaller inhibition against 37 out of 41 kinases in 
the test panel (Figure 2.14C). Notably, between the two GSK-3 isoforms (GSK-3α and GSK-3β), 
30 at 5 μM displayed a 12.3-fold selectivity to GSK-3β (92.3% inhibition) versus GSK-3α (7.5% 
inhibition). 
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Figure 2.14. Compound 30 selectively inhibits GSK-3β via a substrate-competitive 
mechanism. 
Data were the mean of quadruplicate of each of two independent experiments with ± SEM (n = 8). 
The data were analyzed by one-way ANOVA with Tukey’s multiple comparison test. *p < 0.05, 
**p < 0.01, ***p < 0.001, ****p < 0.0001 relative to the control. (A) Structure of 30 and inhibition 
curves of 30 with an IC50 of 0.59 μM and 1 with an IC50 of 184.9 μM. The results were presented 
as the percentage of the kinase activity relative to control (5% DMSO vehicle). Inhibition curves 
were analyzed by four-parameter regression. (B) Lineweaver‒Burk plots of GSK-3β kinetic data 
at increasing concentrations of 30 from 0 to 5 μM. (a) The lines are linear regression plotting of 
1/V against 1/ATP at a given concentration of 30. ATP concentrations varied from 2 to 50 μM, 
while the concentration of the GSK-3β substrate GS2 was kept constant at 17 μM. Intersecting at 
the same point on the x-axis indicates noncompetitive inhibition with respect to ATP. (b) The lines 
are linear regression plotting of 1/V against 1/GS2 at a given concentration of 30. Substrate GS2 
concentrations varied from 8 to 66 μM, while the ATP concentration was kept constant at 10 μM. 
Intersecting at the same point on the y-axis indicates competitive inhibition with respect to the 
substrate GS2. (C) Inhibitory effects of 30 on the activities of 41 kinases. Kinases were assayed in 
the presence of 5 μM 30 or control (5% DMSO vehicle). Dotted lines represent 10% and 50% 
inhibition thresholds. 
 49 
 
 
2.2.6. Evaluation of Compound 30 on Cytotoxicity and Anti-
Amyloid Neurotoxicity 
To investigate whether semi-synthetic 6-C-glycosylflavone analogues exert neuroprotection 
against Aβ-induced neurotoxicity, 30 was assayed in a cellular model where Aβ42 oligomers were 
administrated in human SH-SY5Y neuroblastomas.65, 85 Compound 30 displayed a good 
tolerability profile similar to 1 as no observable cytotoxicity up to a dose of 1 mM (Figure 2.15A).65 
On the other hand, treatment of 10 μM Aβ42 oligomers decreased cell viability to 40% compared 
with the controls (Figure 2.15B). However, such Aβ42 neurotoxicity was greatly relieved, as 
pretreatment of SH-SY5Y cells with 30 at concentrations from 1.25 to 20 μM for 1 h followed by 
coincubation with 10 μM Aβ42 for 72 h recovered cell viability from 40% to 100% in a dose-
dependent manner. The neuroprotective potency of 30 (EC50, 8.7 μM) (Figure 2.15C) was a 5.4-
fold increase in comparison to its parent compound 1 (EC50, 47 μM).65 
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Figure 2.15. Compound 30 alleviates 10 μM Aβ42 induced neurotoxicity in differentiated SH-
SY5Y cells. 
Cell viability was determined using the MTS Cell Proliferation Assay. Colorimetric intensity of 
nontreated control cells in the MTS assay was normalized as 100% cell viability and that of solvent 
blank without cell culture was normalized as 0% cell viability. Data were means of triplicate of 
each of two independent experiments with ± SEM (n = 6). The data were analyzed by one-way 
ANOVA with Tukey’s multiple comparison test. ####p < 0.0001 relative to vehicle control; ****p 
< 0.0001 relative to the 10 μM Aβ42 treatment. (A) Cytotoxicity assessment of 30 in SH-SY5Y 
cells. Cells were treated with varying concentrations of 30 or 0.2% DMSO vehicle and incubated 
for 72 h. (B) Cells were pretreated with varying concentrations of 30 or 0.2% DMSO vehicle for 
1 h followed by 10 μM Aβ42 treatment and incubated for 72 h. 10 μM TDZD-8 was used as a 
reference control. (C) 30 inhibited neurotoxicity induced by 10 μM Aβ42 with an EC50 value of 8.7 
μM. Results were presented as the percentage of the neuroprotective activity relative to control 
(100%) and 10 μM Aβ42 treatment (0%). Neuroprotection curve was analyzed by four-parameter 
regression. (D) Morphological changes of SH-SY5Y cells after treatment for 72 h. (a) 0.2% DMSO 
treatment as vehicle control. Differentiated cells with extended neurites. (b) 10 μM Aβ42 treatment. 
Dying and impaired cells with retracted neurites. (c) Pretreatment of 10 μM 30 followed by 10 μM 
Aβ42 treatment. Protected differentiated cells with extended neurites. Micrographs represent the 
average morphologic characteristics of cell cultures under a given condition of 4-6 experimental 
replicates. Scale bar = 100 μm. 
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Morphological observations also illustrated that pretreatment by 30 at 10 μM effectively 
protected the SH-SY5Y cells from Aβ42 toxicity, as the neuronal cells were healthy and well 
differentiated with extended neurites (Figure 2.15D). Although a similar neuroprotective activity 
was observed to 1, 30 exhibited approximately 20-fold improvement of effectiveness in 
comparison to its parent compound (EC90: 30 in 10 μM versus 1 in 200 μM).65 In good agreement 
with our previous findings, 30 and the other 6-C-glycosylflavone analogues exerted anti-Aβ 
neurotoxicity through protecting neurite outgrowth and neuronal differentiation, whose functions 
are constitutively regulated by GSK-3β and tau protein within axonal microtubules.26 
 
2.2.7. Evaluations of New C-Glycosylflavones on Passive Membrane 
Permeability 
Oral administration is noninvasive and is preferred for chronical diseases such as AD and 
other CNS disorders. It is advantageous to discover passive membrane permeable AD drugs 
targeting GSK-3β upon oral administration. The parallel artificial membrane permeability assay 
(PAMPA) is used to assess passive and transcellular permeability, which is well correlated with in 
vivo oral absorption rates for drugs that cross the gastrointestinal barrier.130 In the PAMPA model, 
the amount of target compounds diffused from a donor compartment to an acceptor compartment 
through a trilayer phospholipid precoated membrane was measured to assess oral-absorption 
potential of drug candidates. In the present study, 1, 4, 9, 17, 21, and 30 were evaluated with the 
PAMPA assay. Theophylline and atenolol known for their low permeability were used as negative 
controls. Desipramine known for its high permeability was used as a positive control. The 
measured effective permeability coefficients (Pe) were compared with the literature data.130 
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Table 2.4. PAMPA permeability and CLogP values of compounds tested. 
cmpd PAMPA Permeability CLogP 
no. Pe (× 10-6 cm/s) a R (%) b Permeability 
classification c 
 
Isoorientin (1) 0.51 ± 0.01 48 low 0.21 
Luteolin (4) 1.42 ± 0.07 43 medium 2.31 
9 1.55 ± 0.06 46 high 1.35 
17 1.77 ± 0.07 20 high 2.55 
21 1.35 ± 0.08 30 medium 2.34 
30 2.23 ± 0.21 30 high 1.62 
Theophylline 0.04 ± 0.01 n/a low -0.03 
Atenolol d 0.29 ± 0.09 40 low -0.11 
Desipramine d 13.43 ± 0.91 96 high 4.47 
a Pe values were the mean of PAMPA measurements (n = 3-4) with ± SD. b Percent recovery (R%) 
measures mass retention of compounds trapped inside the PAMPA membrane. c PAMPA 
permeability classification: high (Pe > 1.5 × 10-6 cm/s), medium (1.0 × 10-6 cm/s ≤ Pe ≤ 1.5 × 10-6 
cm/s), low (Pe < 1.0 × 10-6 cm/s). d The measured Pe values are comparable to the data in ref.130 
 
The new analogues 9, 17, 21, and 30 demonstrated a significant increase of permeability upon 
5 h of incubation in comparison with their parent compound 1 (Table 2.4). Methylation of phenolic 
hydroxyls and transformation of the primary hydroxyl to hydrophobic amides on the C-glycone of 
1 increased the PAMPA permeability (Pe) ranging from 2.6 to 4.4-fold relative to 1. Such Pe 
changes agreed well with the CLogP changes (Table 2.4). The best PAMPA permeability of 30 is 
probably attributed to the CF3 group. Multiple hydroxyl groups in C-glycone and flavone moieties 
make 1 poorly permeable, which is consistent with the literature reports.131 For comparison, 
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luteolin (4), an aglycone flavone, had a medium PAMPA permeability similar to 9, 17, and 21, 
indicating the liability of the polar C-glycone of 1 in respect to passive diffusion. Regardless, it is 
indispensable to assess pharmacokinetics of the new kinase inhibitors for their in vivo 
bioavailability which involves the complexity of active and facilitated transports in addition to 
passive diffusion. 
 
2.2.8. Key Molecular Interactions between New C-Glycosylflavones 
and the Substrate Site of GSK-3β 
To elucidate the molecular mechanisms by which the new 6-C-glycosylflavones increase the 
binding affinity and selectivity to GSK-3β relative to 1, compounds 5-31 were docked into GSK-
3β enzyme. The AutoDock Vina program was used in the present study because it has shown good 
accuracies for binding pose prediction and scoring function.132-134 This docking tool has been 
widely used in drug design and applied in many cases of GSK-3β inhibitor discovery.94, 118, 135-136 
Two X-ray crystallographic structures of GSK-3β (PDB codes 1PYX97 and 1H8F137) were 
chosen to take into account for potential induced fit effects upon ligand binding. The GSK-3β in 
1PYX contains two Mg2+ ions and a ligand ANP, a non-hydrolyzed ATP derivative, at the ATP 
site. Upon binding of Mg2+ ions and an ATP-mimic ligand, it is postulated that GSK-3β undergoes 
subtle conformational changes in both the ATP and substrate sites for an optimal kinase reaction, 
a phenomenon known as induced fit effects.138-139 The GSK-3β structure in 1PYX hence adopts a 
conformation that resembles the native enzyme ready for substrate recognition. Docking 5-31 into 
the substrate site of GSK-3β using 1PYX would give more reliable binding poses. On the other 
hand, the GSK-3β in 1H8F is by far the only available X-ray crystallographic structure containing 
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the ligand HEPES in the substrate site. HEPES in 1H8F may cause induced fit changes of GSK-
3β conformation, particularly for the substrate site. Given the new 6-C-glycosylflavones are 
substrate competitive, we used 1PYX and 1H8F in molecular docking. The docking method was 
validated by re-docking and cross-docking experiments using both ATP-competitive and 
substrate-competitive inhibitors (see Appendix 10). 
The synthetic 6-C-glycosylflavones (5-31) and their parent 1 were thus docked into 1PYX 
and 1H8F with the AutoDock Vina program. Docking scores of 1PYX show a better linear fit to 
the experimental pIC50 values (R2 = 0.7844) than that of 1H8F (R2 = 0.6999) (see Appendix 11), 
suggesting more accurate predictions of binding poses using 1PYX than 1H8F. The 1PYX docking 
data set was therefore used in the remainder of the study to analyze the molecular interactions 
responsible for the improved potency and selectivity to GSK-3β.  
The docking results of 1PYX showed that the C-glycone moiety of 5-31 forms hydrogen 
bonds with GSK-3β residues Gln89, Asn95, Arg96 and Glu97 within the substrate pocket, which 
is similar to 1 (see Appendix 12). Moreover, the newly introduced hydrophobic groups indeed 
exhibit a favorable ligand pose to the concave surface comprised of Phe67, Val87, Leu88 and 
Phe93 on GSK-3β. The most potent compounds 30 and 31 (IC50, 0.59 and 2.3 μM, respectively) 
contain a CF3 moiety, which may form orthogonal multipolar interactions for protein binding.140-
141 To visualize such molecular interactions, we conducted flexible-residue docking134, 142 to refine 
binding poses of 9, 30, and 31 in 1PYX. To prepare GSK-3β structure, side chains of Ser66, Phe67, 
Leu88, Gln89, Asp90, Phe93, Asn95 and Lys183 within the substrate site were treated as flexible. 
The docking results of 30 suggested formation of orthogonal multipolar interactions. The (S)-CF3 
in 30 shows a favorable geometry within typical F···C distances to Leu88 (backbone amide 
carbonyl carbon, 3.3 Å), Gln89 (backbone amide carbonyl carbon, 3.6 Å) and Asp90 (side chain 
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carbonyl carbon, 3.3 and 3.8 Å) (Figure 2.16C). It also forms a polar interaction with the backbone 
NH of Asp90 (F···H distance, 2.6 Å). In contrast, the (R)-CF3 group of 31 is absent from these 
interactions probably owing to the orientation and steric hindrance by switching CH3 and CF3 
positions at the stereocenter (Figures 2.16B to C). Therefore, only hydrophobic interactions with 
Phe67, Val87 and Leu88 of GSK-3β exist in 31 (improper configuration of CF3 for orthogonal 
multipolar interactions) as well as 9 (lack of CF3) (Figures 2.16A to B).  
Interestingly, the docking results showed that the catechol B-ring of the flavone core in 9, 30 
and 31 appears to have a π-cation interaction with Lys183.143-145 The distance between the catechol 
B-ring center and ε‒NH3+ cation of Lys183 is 4.1 Å at an angle of 71.5° (Figure 2.16C and 
Appendix 13). In conjunction, the side chain ε‒NH3+ of Lys183 forms weak hydrogen bonds with 
two methoxy oxygen atoms of catechol B-ring (distances of 3.1 and 3.2 Å). The orthogonal 
multipolar and π-cation interactions potentially enhance the binding affinity to GSK-3β. 
Nonetheless, additional validations with site-directed mutagenesis and X-ray co-crystallography 
remain necessary to confirm the molecular docking predictions. 
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Figure 2.16. Predicted docking poses of 9 (A), 31 (B) and 30 (C) within the substrate site of 
GSK-3β (PDB code 1PYX).  
Dotted lines represent interactions via hydrogen bonding, π-cation interaction or orthogonal 
multipolar interactions with key amino acid residues of GSK-3β. Key molecular interaction 
distances are highlighted. 
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2.2.9. Potential Causes for the Isoform-Selectivity of Compound 30 
between GSK-3α and GSK-3β 
Isoform-selectivity of 30 to GSK-3β over GSK-3α (Figure 2.14C) was assessed with 
comparative molecular modeling. Yet no X-ray crystallographic structures of GSK-3α are 
available in PDB, a homology model of GSK-3α was built with the SWISS-MODEL server146 (see 
Appendix 14). A full human GSK-3α amino acid sequence (UniProt code: P49840) was searched 
against protein databases in BLAST and HHblits and overall 4470 templates were found. A GSK-
3β template (PDB code 1PYX) resulted in a top ranking with an overall sequence identity of 
82.97%, thereby selected for homology modeling of GSK-3α. A sequence alignment between the 
two GSK-3 isoforms indicated that GSK-3α has extra amino acid portions flanking the N- and C-
termini of GSK-3β (see Appendix 15). Within the matched sequence portion, most amino acid 
differences occur in the N- and C-terminal regions. In contrast, both the ATP and substrate domains 
of GSK-3α/β isoforms are conserved as high as 92.37% identical, in which only few amino acid 
residues are different in these regions. The superposition and comparison of GSK-3β structure 
(PDB code 1PYX) with the GSK-3α homology model (Figure 2.17A) implied that those subtle 
differences of amino acid residues in the kinase catalytic domain (both ATP and substrate pockets) 
may affect substrate recognition as well as ligand binding. Intriguingly, docking experiment using 
the GSK-3α homology model showed that 30 resides a similar location in the substrate site in 
comparison to GSK-3β docking data (Figures 2.17B to C). However, the resulting binding pose of 
30 in GSK-3α favors neither a π-cation interaction of catechol B-ring nor the orthogonal multipolar 
interactions of the (S)-CF3 group. It is conceivable that the isoform-specificity of 30 to GSK-3β 
might be in part due to the lack of these critical molecular interactions in GSK-3α. Instead, the (S)-
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trifluoroisopropyl group of 30 simply exerts hydrophobic affinity with the homologous residues 
Phe130, Val150, and Leu151 in the substrate site of GSK-3α (Figure 2.17C). 
 
 
 
 
Figure 2.17. Molecular models of GSK-3β and GSK-3α and the docking complexes with 
compound 30. 
(A) Superposition of GSK-3β structure (PDB code 1PYX) and GSK-3α homology model (UniProt 
code P49840). The ATP and substrate sites are highlighted in circles, and the N- and C-termini are 
depicted. The ATP and substrate sites of GSK-3α/β isoforms are highly conserved and most of 
amino acid differences occur in the N- and C-terminal regions. (B) Predicted docking pose of 30 
into the substrate site of GSK-3β structure. (C) Predicted docking pose of 30 into the substrate site 
of GSK-3α homology model. GSK-3 isoforms are shown as gray cartoons. In both isoforms, 
selected conserved residues are displayed as green sticks. In GSK-3β, nonconserved residues are 
displayed as blue sticks. In GSK-3α, nonconserved residues are displayed as magenta sticks. The 
dotted lines represent key molecular interactions.  
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2.2.10. Discussion 
GSK-3β plays a central role in signaling pathways of AD. Accumulating evidence has 
demonstrated that GSK-3β is activated abnormally by Aβ and in turn hyperphosphorylates tau 
proteins in neurons. This eventually triggers the tauopathic cascade in AD progression.1, 26, 76 
Development of selective GSK-3β inhibitors as a disease-modifying therapy for AD, therefore, is 
highly attractive. In recent years, discovery of selective inhibitors targeting the substrate site of 
GSK-3β has emerged as a rational and feasible strategy in AD drug design.78 Unlike the ATP-site 
directed GSK-3β inhibitors that frequently bind to many off-target kinases, inhibitors targeting the 
substrate site on GSK-3β plausibly overcome this limitation. GSK-3β phosphorylates its specific 
substrates for biological processes such as glucose homeostasis, immune response, neurogenesis, 
cell proliferation and apoptosis, and circadian rhythm, which has a plethora of normal functions 
for human health.147 However, GSK-3β is aberrantly overactive in AD. Subtle modulation of GSK-
3β activity at a normal level rather than complete shut-off to prevent disruption of its normal 
cellular functions will be highly advantageous in AD therapy.76 Targeting the substrate site to 
intervene the GSK-3β-substrate recognition would be a feasible means to find selective 
inhibitors.116 Until now, substrate-competitive inhibitors of GSK-3β are limited in the structural 
classes of marine alkaloid manzamines,96 labdane diterpenoid andrographolide,118 peptidomimetic 
inhibitors,119 and synthetic compound ITDZ series.117 These inhibitors were in the low micromolar 
to sub-micromolar range of potency, but exhibited a good selectivity to GSK-3β under in vitro or 
in vivo evaluations. Such findings substantiate the rationale of developing substrate-competitive 
inhibitors of GSK-3β for AD by which the agents can attain an utmost therapeutic advantage ‒ a 
high selectivity to avoid potential side effects.  
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Herein, we reported a new structural class of substrate-competitive inhibitors with significant 
selectivity for GSK-3β, inspired by isoorientin (1), containing a 6-C-glycosylflavone scaffold. It 
is a valuable addition to the known substrate-competitive inhibitors and offers new lead 
compounds for AD. The inhibitors are new chemical probes allowing to elucidate the underling 
mechanisms of GSK-3β inhibition and selectivity.  
The SAR analysis, in vitro enzymatic kinetics, and in silico docking studies indicate that both 
the presence and position of C-glycone on the flavone core are essential features binding to the 
substrate site on GSK-3β. A flavone core (4) alone is promiscuous and tends to slide into the ATP 
site and thus lose the required selectivity (see Appendix 10). The presence of a C-glycone at 8-
position (3, IC50, > 5 mM) rather than 6-position (1, IC50, 185 μM) results in an unfavorable 
binding pose to the substrate site plausibly due to the loss of key hydrogen bonds with Gln89, 
Asp90, Asn95, and Arg96 (see Appendix 12). Such unique SAR features inspire us to semi-
synthesize a series of novel analogues of 1 that selectively inhibit GSK-3β at the substrate site. 
Data suggest that the new lipophilic amide analogues (8-31) increase the potency against GSK-3β 
for 3‒310 fold (Table 2.3) and passive membrane permeability for 2.6‒4.4 fold relative to 1 (Table 
2.4). Systematic modifications of the carbon-chain length and ring size and bioisosteric 
replacement in the R2-group on the C-glycone of 1 (Table 2.2) confer a dramatic GSK-3β potency 
improvement. The structural modifications contribute hydrophobic affinities with Phe67, Val87 
and Leu88 in the substrate site of GSK-3β (see Appendix 12), which is concurrently supported by 
the LiPE analysis (LiPE highlights potency changes to the net of lipophilicity). Compounds 9, 30, 
and 31 containing an isopropyl moiety have IC50 values of 5.4, 0.59, and 2.3 μM, respectively, 
which are most potent among the analogues. It suggests that they adopt a suitable carbon-chain 
length and topological size within the hydrophobic cleft of the substrate site. LiPE analysis also 
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indicates that 9, 30, and 31 are quality ligands (LiPE values ≥ 4). In addition, the new analogues 
alleviate tau hyperphosphorylation and Aβ neurotoxicity through GSK-3β inhibition in the human 
SH-SY5Y neuronal model (Figures 2.13 and 2.15).  
With respect to the GSK-3β selectivity of 30, π-cation interaction and orthogonal multipolar 
interactions appear to play a critical role. In protein structures, the aromatic side chain of Phe or 
Tyr usually involves a favorable π-cation interaction with the cationic side chain of Lys or Arg.143 
In analogy, if a small aromatic ligand binds to a protein, potential π-cation interactions would be 
an important contribution to the binding affinity. Such phenomena have been exemplified in our 
previous study144 as well as other investigations.136, 148-149 Flavonoids seem to be the case ‒ 
interactions between the aromatic A/B-rings with the cationic Lys or Arg residues.135, 150 In the 
docking experiments, we found that the catechol B-ring of the flavone core in 30 forms a π-cation 
interaction with Lys183 of GSK-3β (distance, 4.1 Å; angle, 71.5°). To a certain extent, this might 
stabilize the binding conformation and orientation within the substrate site.  
It is known that halogen atoms have distinct chemical properties contributing to the molecular 
recognition. Introduction of halogens such as F, Cl, Br, and I is a common tactic in drug design.151 
Fluorinated compounds commonly form orthogonal multipolar interactions with the backbone and 
side chain carbonyl carbons (Asp/Glu/Asn/Gln) or the guanidinium carbon (Arg) of amino acid 
residues in protein structures.140-141 It is estimated that substitution of CH3 for CF3 may improve 
5- to 10-fold ligand binding affinity.141, 152 In the present study, 27 (IC50, 19.3 μM) and 29 (IC50, 
17.2 μM) containing a 2,2,2-trifluoroethyl and 3,3,3-trifluoropropyl, respectively, show an 
improved potency relative to their analogue 8 (IC50, 29.2 μM) without a CF3 group. In addition, 
30 and 31 containing a 1,1,1-trifluoroisopropyl are more potent than their analogue 9 without a 
CF3 group. Docking experiments suggest that the isopropyl (S)-CF3 group of 30 interacts with the 
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backbone and side chain carbonyls of Leu88, Gln89, and Asp90 (Figure 2.16C) within typical 
interaction distances (F···C, 3.0‒3.7 Å).141 Such orthogonal multipolar interactions might in part 
give rise to an increased potency of 30 (IC50, 0.59 μM) against GSK-3β approximately 9-fold and 
4-fold compared to 9 (IC50, 5.4 μM) and 31 (IC50, 2.3 μM), respectively. Conversely, 31 with a 
(R)-CF3 group may be lack of these critical molecular interactions (Figures 2.16B to C) and thus 
has weaker binding affinity than 30. The differential and stereospecific binding of the CF3 group 
between 30 and 31 plausibly explains the high inhibitory selectivity to GSK-3β (Figures 2.12 and 
2.14). 
Interestingly, 30 exhibits isoform-selectivity to GSK-3β over GSK-3α, which deserves 
discussion. In humans, GSK-3α (51 kDa) and GSK-3β (47 kDa) are derived from different genes 
and have distinct functions.147 Both isoforms share an overall sequence identity of 83%, especially 
at the ATP catalytic domain with 93% identity.153 However, they differ substantially in the N- and 
C-terminal lobes that are thought to cause protein conformational dynamics and differential 
cellular localization.147, 153 Subtle amino acid differences in the substrate site between two isoforms 
putatively affect substrate recognition and preference as noted in the literature.154-155 Wang et al. 
reported that GSK-3β phosphorylates a substrate (phosphatase inhibitor-2) 10-time faster than 
GSK-3α,154 indicating the differential substrate recognition of GSK-3 isoforms. Soutar et al. 
demonstrated that the specific sites T231, T235, and S396 on tau proteins are solely 
phosphorylated by GSK-3β but not GSK-3α,155 giving an evidence of substrate specificity between 
two isoforms. Those studies pose a possibility to discover isoform-selective inhibitors via targeting 
the substrate site of GSK-3β. Compound 30 attains GSK-3β isoform-selectivity probably because 
of both the π-cation interaction with Lys183 and the orthogonal multipolar interactions with 
Leu88, Gln89, and Asp90 in GSK-3β on the basis of the comparative docking of GSK-3α/β 
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(Figures 2.16C and 2.17). In contrast, 30 appears being absent from those key molecular 
interactions within the substrate site of GSK-3α (Figure 2.17C). In addition, the highly 
nonconserved regions in GSK-3α, such as the N- and C-terminal domains (Figure 2.17A), can 
modulate enzyme conformations and thereby may affect the binding of 30. Notwithstanding, the 
molecular mechanism suggested by computational modeling requires further verification by 
conclusive experimental evidence such as site-directed mutagenesis and X-ray co-crystallography.  
In summary, we described a new class of substrate-competitive inhibitors of GSK-3β focusing 
on modifications of the primary hydroxyl group in the C-glycone of isoorientin (1). The results 
demonstrated that the 6-C-glycone moiety of the new inhibitors defines the specific binding at the 
substrate site rather than the ATP site on GSK-3β. The data also help explore topological 
requirements in the substrate site of GSK-3β and highlight the critical SAR. Those inhibitors 
effectively attenuate tau hyperphosphorylation and amyloid neurotoxicity in molecular and 
cellular models by which the mechanism is involved in GSK-3β inhibition via an ATP 
noncompetitive but substrate competitive manner. The inhibitors not only significantly increased 
the potency, kinase selectivity, and isoform-selectivity, but also improved passive membrane 
permeability in comparison with the natural product counterparts. Among them, 30 (IC50, 0.59 
μM) showed a potency improvement by 310-fold and a promising profile in various biological 
assessments, which warrants further exploration. SAR analyses and in silico mechanistic 
investigations suggested that the hydrophobic, π-cation and orthogonal multipolar interactions of 
30 with the substrate site lead to selective inhibition against GSK-3β, but neither GSK-3α nor a 
broad panel of kinases tested. Nevertheless, additional SAR knowledge and physiochemical 
property optimization of the GSK-3β inhibitors based on the 6-C-glycosylflavone scaffold are 
essential to the CNS drug discovery campaign. It is important to conduct experiments on how the 
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new inhibitors show ATP noncompetitive and how their binding to the substrate site induces the 
GSK-3β conformational changes affecting ATP affinity in kinase reaction. Such data will help 
further development of this class of inhibitors in the future. Pharmacokinetics and in vivo animal 
studies of the new GSK-3β inhibitors will help understand drug delivery, target engagement and 
efficacy, which would suggest the therapeutic potential of these agents for AD and other GSK-3β 
relevant neuropsychiatric and neurodegenerative diseases. 
 
 
* Methods and experimental procedures are listed in Chapter 3 of the dissertation.  
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2.3. Targeted Chemical Proteomics Analysis of C-Glycosylflavone 
Reveals Its Pleiotropic Actions in Perturbation of Alzheimer’s 
Signaling 
AD is a complex neurodegenerative disease involving multiple pathogenic mechanisms such 
as Aβ cascade, tau hyperphosphorylation, synaptic dysfunction, neuroinflammation, Ca2+ 
dysregulation, oxidative stress, mitochondria damage, and lysosome/autophagy dysfunction.1, 5, 26 
Current evidence suggests that the AD pathogenic mechanisms are not mutually exclusive but 
more likely “cross-talk” with each other.22 The traditional concept of pharmacology that “one drug, 
one target, one disease” may not be suitable to the complex and chronical diseases such as AD.72, 
156 An anti-AD agent modulating multiple targets and signaling pathways in a disease-relevant 
context is valuable in pharmaceutical applications.156-159 Investigation of its potential pleiotropic 
action makes possible to understand how an anti-AD agent exerts neuroprotective effects to be the 
outcome of molecular and cellular networks involving multiscale mechanism of actions.54, 72, 160 
Flavones are well-known for their multifunctional actions for disease intervention.35, 38, 110 It 
has become evident that flavones exerting their neuroprotection are due to interactions with 
multiple cellular receptors or enzymes that regulate neuronal apoptosis, survival, differentiation, 
and proliferation.29, 35 The multi-targeted feature of flavones can plausibly enhance therapeutic 
values by leveraging multiple beneficial activities and outweigh potential toxic effects.72, 157 We 
previously demonstrated that the natural C-glycosylflavone isoorientin (1) and its new synthetic 
analogues showed a good safety margin and tolerability, and elicited unique neuroprotective 
activities in neurons.65, 73 However, an obvious discrepancy between cellular (EC50, 47 μM) and 
enzymatic (GSK-3β IC50, 185 μM) potencies for 1 was also noted.65 We hypothesize that the C-
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glycosylflavones also act on other protein targets in additional to GSK-3β and gain a maximal anti-
AD effect. This motivated us to pursue continued investigation. 
Chemical proteomics is an emerging research discipline and a powerful tool for target 
identification of bioactive molecules.49-50 Global and unbiased profiling of therapeutic targets by 
chemical proteomics can provide a full picture of the pleiotropic mechanisms of the C-
glycosylflavone with appreciation of biomolecular networks of the targets in AD pathways.51-53, 
161 In the present study, we applied a targeted chemical proteomics strategy by harnessing the 
affinity chromatography coupled with the iTRAQ-based quantitative proteomics approach.55, 162 A 
schematic of workflow is described in Figure 2.18. Briefly, the 6-C-glycosylflavone as a chemical 
probe was immobilized to matrices (e.g., sepharose resins) and incubated with cell lysates that 
were derived from an AD-mimic neuronal model. The binding affinity allowed for ligand-protein 
complexes to be separated from the unbound or nonspecific binding proteins after stringent 
washing. Captured proteins were then eluted and subjected to tryptic digestion. The digested 
peptides were labeled with isobaric tags for relative and absolute quantitation (iTRAQ),62 and 
analyzed by biological mass spectrometry. The resulting MS data were searched against protein 
databases (e.g., SwissProt and NCBI) for protein identification and quantification. The 
protein/function networks were analyzed by bioinformatics tools (e.g., Cytoscape, STRING, and 
Ingenuity Pathway Analysis), which would reveal potential mechanisms of the C-glycosylflavones 
on neuroprotection. 
Human SH-SY5Y neuroblastoma cells are a common in vitro cell model. These cells can be 
differentiated with morphological and biochemical features resembling to human mature 
neurons.85, 163-164 The differentiated SH-SY5Y cells express high levels of mature tau isoforms with 
proper neuronal distribution.85, 165-166 Furthermore, it has been reported that SH-SY5Y cells express 
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the AD-relevant proteins APP and Aβ.167 Therefore, this cell model has been widely adopted as a 
reproducible, easily accessible, and affordable alternative to the primary neurons for neuroscience, 
especially in the AD research field.  
Chronic Aβ exposure (sub-micromolar to nanomolar levels) in neuronal cells triggers AD-
mimic pathologies such as tau hyperphosphorylation, Ca2+ homeostatic dysregulation, activation 
of MAPK/ERK-linked toxicity pathway, mitochondrial dysfunction, and the ultimately loss of 
neuronal integrity.84, 107-108 Herein, we adopted human neuroblastoma SH-SY5Y cells treated with 
Aβ as a cell model.65, 73 While this cellular system remains limited to represent actual 
neuropathology of AD in humans, the inductive stress of prolonged Aβ exposure in SH-SY5Y cells 
would lead to pathological changes within molecular and cellular levels relevant to AD83-84 as well 
as make it possible to study therapeutic interventions involving AD-mimic pathways.84, 86-87, 168-169 
In the present targeted chemical proteomics study, we used the cell lysates from the chronic Aβ-
treated SH-SY5Y cells as the neuroproteome.  
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Figure 2.18. Workflow for affinity-based quantitative chemical proteomics analysis. 
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2.3.1. Design and Synthesis of C-Glycosylflavone Probe (CGF-
Probe) 
 
 
Figure 2.19. Design of the CGF-probe. 
(A) Structure of the free ligand 13 and its GSK-3β inhibition curve with an IC50 of 9.6 μM. Results 
were presented as the percentage of the kinase activity relative to control (5% DMSO vehicle). 
Data were the mean of quadruplicate of each of two independent experiments with ± SEM (n = 8). 
Inhibition curves were analyzed by four-parameter regression. (B) A design affinity probe (CGF-
probe) containing the ligand, spacer, and matrix portions, where the chemical structure composed 
of the ligand and spacer is the same as the free ligand 13. 
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Figure 2.20. Construction of the CGF-probe beginning with isoorientin. 
a Reagents and conditions: (a) TMSCHN2, toluene, methanol, rt, 80%; (b) [TEMPO]+[BF4]−, 
DCM, pyridine, rt, 95%; (c) Resin-NH2, excess EDCI, aqueous, pH 5.0, 4 °C, 90%. 
 
 
With an aim at the unbiased profiling of potential target proteins of C-glycosylflavones to 
assess their pleiotropic actions, the affinity-based chemical proteomics provides the opportunity 
to better understand on-target and off-target engagement of the ligand in the lysate of SH-SY5Y 
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cells. In Section 2.2, we have developed a series of selective GSK-3β inhibitors containing the C-
glycosylflavone scaffold.73 SAR studies demonstrated that compound 13, an analogue of 
isoorientin 1, with a hexyl amide group on the C-glycone inhibited GSK-3β with an IC50 value of 
9.6 μM (Figure 2.19A). The moderate potency (IC50 < 10 μM) and reasonable selectivity of 13 on 
GSK-3β would allow for the target sampling in the cell lysate in an unbiased manner rather than 
only capturing GSK-3β (i.e., using compound 30, which is highly optimized for targeting GSK-
3β).  
The design of an affinity probe must ensure that the ligand to be immobilized retains 
appropriate functional activity and binding specificity.59-60 The probe must have a spacer 
(commonly 6–15 atom length, flexible chain) linking the ligand to the resin matrix to ensure the 
binding accessibility and specificity to target proteins.59-60 Therefore, we designed a CGF-probe 
by coupling the ligand to the EAH Sepharose-4B resin, which contains a covalent linkage of 1,6-
diaminohexane to sepharose as the spacer (Figure 2.19B). The CGF-probe was synthesized 
according to the route outlined in Figure 2.20. The key step was involved in an amide coupling of 
the compound 6 with EAH Sepharose-4B resins via EDCI catalysis. The ligand immobilization on 
resins was in 90% yield as determined by HPLC and readily visualized by the characteristic yellow 
color of C-glycosylflavones in comparison to the original resins (Figure 2.21). 
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Figure 2.21. Comparison of EAH-4B resins before and after CGF immobilization. 
 
2.3.2. Functional Validation of the CGF-Probe 
To confirm that CGF-probe retains the same binding specificity to GSK-3β as the free ligand, 
an affinity pulldown assay was conducted in parallel using both CGF-tag and no-tag resins. A 
mixture of standard proteins (i.e., GSK-3β, bovine thyroglobulin, IgA, IgG, ovalbumin, and 
myoglobin) with different molecular weights and functions was subjected to affinity 
chromatography followed by 10% SDS-PAGE. As shown in Figure 2.22, the CFG-probe 
specifically bound to GSK-3β within the protein mixture, which was observed in SDS-gel staining 
and confirmed by MS analysis (in-gel digestion of the respective band). In contrast, the resins 
without CGF-tag showed no protein binding at all. The results thus validated the functional activity 
of the synthetic CGF-probe. 
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Figure 2.22. Functional validation of the CGF-probe for GSK-3β binding specificity. 
SDS-PAGE analysis on the protein mixture in the affinity pulldown assays with CGF-tag or no-
tag resins. The protein mixture containing bovine thyroglobulin, IgA, IgG, GSK-3β, ovalbumin, 
and myoglobin. M, protein marker. H-chain, antibody heavy chain. L-chain, antibody light chain. 
 
 
 
2.3.3. Identification of Specific Targets of C-Glycosylflavone by 
Affinity-Based Quantitative Chemical Proteomics in a 
Neuronal Model 
Affinity-based quantitative chemical proteomics was performed to profile and identify target 
proteins in a neuronal cell model. SH-SY5Y cells was treated with 1 μM Aβ42 for 72 h. The 
resulting cells were harvested and lysed. To cope with the experimental variations, the cell lysate 
was split into eight aliquots for four sets of experiments in duplicate. Each of two aliquots were 
subjected to the affinity pulldown assay in varied conditions. The resulting eluates were subjected 
 74 
 
 
to in-solution tryptic digestion followed by iTRAQ-8plex labeling. In particular, the iTRAQ labels 
113-114 were used on the control samples whose proteins were from the affinity chromatography 
with no-tag resins; labels 115-116 were used on the samples whose proteins were from the affinity 
chromatography with CGF-tag resins; labels 117-118 were used on the samples whose proteins 
were from the low-dose competitive affinity chromatography (50 μM free ligand 13) with CGF-
tag resins; and labels 119-121 were used on the samples whose proteins were from the high-dose 
competitive affinity chromatography (100 μM free ligand 13) with CGF-tag resins. After labeling, 
samples were pooled together and analyzed by nanoLC-ESI-QTOF-MS/MS to identify and 
quantify target proteins. 
For specific target proteins bound to the CGF-probe, the iTRAQ reporter ions 115-116 showed 
significantly higher signal intensities than 113-114 (reporter ions for those proteins pulled down 
with no-tag resins) in MS spectra. In addition, the three-set experiments using the CGF-probe 
showed a MS signal pattern of decreasing intensities of the reporter ions due to the free ligand 
competition in affinity chromatography (i.e., ion intensities 115-116 > 117-118 > 119-121). 
Conversely, for nonspecific binding proteins, the iTRAQ reporter ions of all four-set experiments 
showed similar intensities in MS spectra. 
In preliminary experiments, a total of 24 proteins were identified by the MASCOT protein 
search (Table 2.5). iTRAQ ratios (115-116 versus 113-114) of each identified protein were 
subjected to statistical analysis and only proteins identified with a significance value of p < 0.05 
and 1% false discovery rate (FDR) were considered reliable hits. To differentiate specific binding 
proteins from nonspecific ones, a stringent iTRAQ ratio of 2.5-fold cutoff was established to avoid 
false positives according to the described procedure.62 Collectively, six proteins (histone H2A type 
1-B/E, histone H1.2, histone H2A.V, calmodulin-1, galectin-3-binding protein, and heterogeneous 
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nuclear ribonucleoprotein A1-like 2) were identified as specific target proteins of the CGF-probe, 
and their reporter ion intensities showed a dose-dependent manner in the free ligand competition 
(Table 2.5).Three proteins (histone H2A type 2-A, nucleolar and coiled-body phosphoprotein 1, 
and mitochondrial 60 kDa heat shock protein) were identified as nonspecific binding proteins. The 
remaining 15 proteins were not quantified by iTRAQ. The fold changes of iTRAQ ratios of the 
identified binding proteins are shown in Figure 2.23. 
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Table 2.5. Summary of protein identification and iTRAQ-based quantification.  
Rank a Mascot 
score 
UniProtKB 
Accession # 
Protein MW 
(kDa) 
Peptides b SC c 
(%)  
iTRAQ 
ratio d 
1 234.5 H2A1B_HUMAN Histone H2A type 1-B/E OS=Homo 
sapiens GN=HIST1H2AB PE=1 
SV=2 
14.1 2 22.3 4.46 
2 210.4 H12_HUMAN Histone H1.2 OS=Homo sapiens 
GN=HIST1H1C PE=1 SV=2 
21.4 2 8.9 6.37 
3 191.8 H2A2A_HUMAN Histone H2A type 2-A OS=Homo 
sapiens GN=HIST2H2AA3 PE=1 
SV=3 
14.1 1 22.3 0.97 
4 154.9 CALM1_HUMAN Calmodulin-1 OS=Homo sapiens 
GN=CALM1 PE=1 SV=2 
16.8 1 24.8 4.64 
5 130.6 NOLC1_HUMAN Nucleolar and coiled-body 
phosphoprotein 1 OS=Homo sapiens 
GN=NOLC1 PE=1 SV=2 
73.6 1 2.1 0.73 
6 127.1 LG3BP_HUMAN Galectin-3-binding protein 
OS=Homo sapiens GN=LGALS3BP 
PE=1 SV=1 
65.3 1 3.4 5.36 
7 82.1 ACTB_HUMAN Actin, cytoplasmic 1 OS=Homo 
sapiens GN=ACTB PE=1 SV=1 
41.7 1 7.7 n/a 
8 60.6 H15_HUMAN Histone H1.5 OS=Homo sapiens 
GN=HIST1H1B PE=1 SV=3 
22.6 3 10.6 n/a 
9 52.9 1433G_HUMAN 14-3-3 protein gamma OS=Homo 
sapiens GN=YWHAG PE=1 SV=2 
28.3 2 11.7 n/a 
10 48.2 PDS5A_HUMAN Sister chromatid cohesion protein 
PDS5 homolog A OS=Homo sapiens 
GN=PDS5A PE=1 SV=1 
150.7 1 2.5 n/a 
11 44.7 1433E_HUMAN 14-3-3 protein epsilon OS=Homo 
sapiens GN=YWHAE PE=1 SV=1 
29.2 3 11.4 n/a 
12 43.8 MARE1_HUMAN Microtubule-associated protein 
RP/EB family member 1 OS=Homo 
sapiens GN=MAPRE1 PE=1 SV=3 
30.0 2 11.9 n/a 
13 34.9 TTBK1_HUMAN Tau-tubulin kinase 1 OS=Homo 
sapiens GN=TTBK1 PE=1 SV=2 
142.6 1 0.9 n/a 
14 33.4 RA1L2_HUMAN Heterogeneous nuclear 
ribonucleoprotein A1-like 2 
OS=Homo sapiens 
GN=HNRNPA1L2 PE=2 SV=2 
34.2 1 3.1 4.08 
15 29.5 GRP75_HUMAN Stress-70 protein, mitochondrial 
OS=Homo sapiens GN=HSPA9 PE=1 
SV=2 
73.6 1 6.9 n/a 
16 23.5 SNRPA_HUMAN U1 small nuclear ribonucleoprotein A 
OS=Homo sapiens GN=SNRPA 
PE=1 SV=3 
31.3 2 11.0 n/a 
17 20.8 CH60_HUMAN 60 kDa heat shock protein, 
mitochondrial OS=Homo sapiens 
GN=HSPD1 PE=1 SV=2 
61.0 1 3.7 0.87 
18 20.6 H2AV_HUMAN Histone H2A.V OS=Homo sapiens 
GN=H2AFV PE=1 SV=3 
13.5 1 22.7 4.34 
19 18.8 TNR16_HUMAN Tumor necrosis factor receptor 
superfamily member 16 OS=Homo 
sapiens GN=NGFR PE=1 SV=1 
45.2 1 1.6 n/a 
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20 18.6 SOSB1_HUMAN SOSS complex subunit B1 
OS=Homo sapiens GN=NABP2 
PE=1 SV=1 
22.3 1 6.2 n/a 
21 18.2 1433T_HUMAN 14-3-3 protein theta OS=Homo 
sapiens GN=YWHAQ PE=1 SV=1 
27.7 1 4.9 n/a 
22 16.5 RU2A_HUMAN U2 small nuclear ribonucleoprotein 
A' OS=Homo sapiens GN=SNRPA1 
PE=1 SV=2 
28.4 1 5.5 n/a 
23 16.3 RAB34_HUMAN Ras-related protein Rab-34 
OS=Homo sapiens GN=RAB34 
PE=1 SV=1 
29 1 3.9 n/a 
24 13.5 H2B1B_HUMAN Histone H2B type 1-B OS=Homo 
sapiens GN=HIST1H2BB PE=1 
SV=2 
13.9 1 11.9 n/a 
a Ranking based on the Mascot score. b Number of identified peptides. c Sequence coverage.  
d Median of iTRAQ ratios of reporter ions (115-116)/(113-114), representing ratios of proteins 
from CGF-tag pulldown versus proteins from no-tag pulldown. 
 
 
 
Figure 2.23. Heatmap of iTRAQ ratios of the identified target proteins in the affinity 
pulldown assays. 
A stringent iTRAQ ratio of 2.5-fold cutoff was set to differentiate between the specific and 
nonspecific binding proteins. Competitive affinity assays (0, 50, and 100 μM free ligand 13) 
indicate a decreased binding capacity of the CGF-probe. FL, free ligand. 
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To further validate the identified specific binding proteins by iTRAQ analysis, the lysate 
eluates from each of affinity pulldown were analyzed by 12% SDS-PAGE. The resulting stained 
SDS-gel (Figure 2.24) showed that the CGF-tag resins enriched many proteins with molecular 
weights ranging from 15 to 50 kDa in comparison with the no-tag resins. Moreover, the 
competitive affinity assays with the free ligand 13 (0, 50, and 100 μM) decreased target proteins 
in a dose-dependent manner. Two selected protein bands as depicted were cut and proceeded with 
in-gel digestion followed by LC-MS protein analysis. They were confirmed as histone H1.2 and 
histone H2A type 1-B/E, which are the two highest scored proteins identified in the iTRAQ-based 
proteomic analysis (Table 2.5). 
Additional experiments aiming at target/pathway validation using different molecular biology 
techniques such as immunoblotting, biochemical assay, microarray, ChIP, qPCR, RNA-seq, or 
CRISPR-Cas9 genome editing to manipulate the SH-SY5Y cells will help elucidate the 
neuroprotective mechanisms. Nevertheless, the proteomics data by now demonstrated that the 6-
C-glycosylflavones specifically bind to other target proteins in addition to GSK-3β in the neuronal 
model. 
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Figure 2.24. Validation of the target proteins deduced from iTRAQ-based proteomics. 
SDS-PAGE analysis on the proteins from the SH-SY5Y cell lysate in the affinity pulldown using 
CGF-tag or no-tag resins. The stained SDS-gel showed that the CGF-tag resins enriched many 
proteins (i.e., range from 15 to 50 kDa) in comparison with the no-tag resins. Affinity competition 
with the free ligand 13 (0, 50, and 100 μM) showed decreasing target proteins in a dose-dependent 
manner. Two selected protein bands as depicted were cut and proceeded with in-gel digestion 
followed by LC-MS protein analysis, which were confirmed as histone H1.2 and histone H2A type 
1-B/E. M, protein marker. FL, free ligand. PTMs, post-translational modifications. 
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2.3.4. Biomolecular Networks Analysis of Target Proteins Reveals 
Potential Pleiotropic Actions of C-Glycosylflavone 
Molecular networking of the identified proteins was visualized and analyzed with Cytoscape 
3.6170 and STRING 10.5171. To establish comprehensive molecular networks with rational nodes 
(i.e., proteins) and edges (i.e., protein-protein associations), a total of 26 proteins identified by 
iTRAQ chemical proteomics (24 proteins) and by our previous kinase studies (GSK-3β and tau 
protein) were subjected to bioinformatic analyses. Interestingly, the functional protein networking 
(Figure 2.25) indicated that most of the identified proteins are biologically connected and show 
active associations as supported by the literature and curated databases (edge confidence score > 
0.400). The resulting protein-protein interaction (PPI) enrichment p-value is 0.000486. In 
particular, three protein clusters including core and linker histones, actin/GSK-3β/tau/calmodulin, 
and 14-3-3 proteins/MARE1/PDS5A/TNR16 are interconnected. Two small subset clusters 
including nuclear ribonucleoproteins (RA1L2/RU2A/SNPRA) and mitochondrial chaperone 
proteins (CH60/GPR75) are isolated. The proteins SOSB1, LG3BP, TTBK1, NOLC1, and RAB34 
show a low confidence of PPI (edge confidence score ≤ 0.150).  
Gene ontology (GO) annotation on cellular components (Figure 2.26) revealed that C-
glycosylflavones may perturb 36% of identified proteins involved with nucleus, 22% involved 
with cytoplasm, 14% involved with chromosome, 10% involved with cytoskeleton, 7% involved 
with cell membrane, 5% involved with mitochondrion, and 2% involved with phagosome, Golgi, 
or extracellular matrix. 
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Figure 2.25. Biomolecular networks of the identified proteins bound to C-glycosylflavones. 
The networks were constructed by Cytoscape and STRING programs. The edge thickness 
represents the statistical data confidence deduced by the literature and curated databases. Colored 
circles represent protein nodes. 
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Figure 2.26. Cellular component annotation of the identified proteins bound to C-
glycosylflavones. 
 
 
GO annotation on biological process with statistical assessment (FDR threshold, -log(p-
value) > 1.3) (Figure 2.27) indicated that nervous system development (e.g., substantia 
nigra/midbrain development, CNS development, and regulation of axonogenesis), apoptosis (both 
intrinsic and extrinsic pathways), chromatin modulation (e.g., histones and nucleosome assembly, 
chromatin assembly, and DNA packaging) are of highest probability affected by C-
glycosylflavones. Small GTPase signaling, microtubule dynamics, intracellular transport, and 
organelle organization are intervened as well.  
Regarding the KEGG pathway enrichments (Figure 2.28), bioinformatic analysis indicated 
that the Hippo signaling, cell cycle, and neurotrophin signaling are highly affected (-log(p-value) > 
3.0). The PI3K/Akt signaling that governs cell survival (FDR, -log(p-value) > 2.5), the 
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spliceosomal signaling (FDR, -log(p-value) > 1.8), Alzheimer’s pathway (FDR, -log(p-value) > 
1.5), and Rap1 signaling (FDR, -log(p-value) > 1.3) are also significantly affected. 
Interestingly, GO annotation on the molecular function suggested that most of the identified 
proteins are associated with enzyme/ligase binding, DNA/RNA binding, and small-molecule 
binding (Figure 2.29A). Particularly, 19 out of 26 identified proteins show statistically high 
probabilities of binding with organic cyclic or heterocyclic compounds (Figure 2.29B). Such a 
prediction is in good agreement with our iTRAQ-based chemical proteomics and the previous 
GSK-3β inhibition studies that the CGF-probe containing heterocyclic glycone and flavone 
moieties showed specific binding to histones (i.e., H2A1B, H12, and H2AV), RA1L2, and GSK-
3β. 
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Figure 2.27. Biological process of the identified proteins bound to C-glycosylflavones. 
The biological process was analyzed by gene ontology (GO) enrichment. FDR threshold, -log(p-
value) > 1.3, equivalent p < 0.05. 
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Figure 2.28. KEGG pathways of the identified proteins bound to C-glycosylflavones. 
The pathways were analyzed by STRING. FDR threshold, -log(p-value) > 1.3, equivalent p < 0.05. 
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Figure 2.29. Molecular function of the identified proteins bound to C-glycosylflavones. 
(A) The molecular function was analyzed by gene ontology (GO) enrichment. FDR threshold, -
log(p-value) > 1.3, equivalent p < 0.05. (B) Biomolecular networks of the identified proteins. 
Bicolored circles represent proteins predicted with high binding affinity to organic cyclic or 
heterocyclic small-molecule compounds. 
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2.3.5. Discussion 
In the present pilot study, an affinity-based quantitative chemical proteomics followed by 
comprehensive bioinformatic analyses revealed that the 6-C-glycosylflavones are indeed multi-
target directed ligands. Such pleiotropic actions may either exert multi-faceted benefits for AD or 
raise problems of potential toxicity and side effects.72, 156 Besides GSK-3β inhibition, these 
compounds specifically bind to histones, calmodulin-1 (CALM1), galectin-3-binding protein 
(LG3BP), and heterogeneous nuclear ribonucleoprotein A1-like 2 (RA1L2) in SH-SY5Y cells as 
supported by the iTRAQ quantitative proteomics study.  
Histone modulations and the corresponding PTMs have been recognized as a key factor in 
epigenetic regulation of gene expression in AD and other neurodegenerative disorders.172-173 In AD 
condition, small-molecule ligands bound to histones may exert intervention of epigenetic 
mechanisms in neurons such as DNA methylation and histone acetylation, which may recover 
neuroplasticity and cell viability.173-174 Drugs targeting epigenetic changes may reverse AD in 
genetic level, offering another strategy for the treatment of neurodegenerative disorders.173-174 
Calmodulin-1 (CALM1) is a multifunctional calcium-binding protein universal in human cells. 
CALM1 specific binds to Ca2+ ions involving in calcium signaling pathway by modifying various 
target proteins such as kinases or phosphatases.175 CALM1 also plays an important role in 
mediating synaptic activity in neurons. Ca2+ dysfunction has been implicated in amyloid cascade 
and AD pathogenesis.107, 176-177 The present data suggested that C-glycosylflavones bind to 
CALM1 and may intervene aberrant Ca2+ signaling in AD. Nonetheless, because calmodulins are 
essential regulators for the Ca2+ homeostasis in all human cells, modulating calmodulin activity by 
C-glycosylflavones, while not necessarily causing cellular toxicity directly, may also affect normal 
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signaling pathways. Investigation on how C-glycosylflavones intervene Ca2+ signaling in cells and 
how to avoid potential toxicity is mandatory. 
Galectin-3-binding protein (LG3BP) modulates cell adhesion and cell-matrix interactions. 
LG3BP has been implicated in immune response associated with natural killer (NK) and 
lymphokine-activated killer (LAK) cell cytotoxicity, which may stimulate immune defense against 
viruses and tumor cells.178 LG3BP interacts with galectin-3 mediating apoptosis. A recent study of 
AD showed that internalization of tau aggregates damages endosomal membrane, which was 
detected by galectin-3-binding assay.179 We hypothesize that tau pathology in AD may disrupt 
LG3BP functions in neurons that promotes neurodegeneration (i.e., apoptosis), and the C-
glycosylflavone may intervene this pathological pathway of AD. 
Heterogeneous nuclear ribonucleoprotein A1-like 2 (RA1L2) is involved in the processing 
and transport of mRNA and modulate RNA splicing. Dysfunctions and mutations of RA1L2 have 
been implicated in neurodegeneration such as amyotrophic lateral sclerosis (ALS) and multisystem 
proteinopathy (MSP).180 It has been reported that RA1L2 plays a role in regulation of RNA splicing 
of β-amyloid precursor protein in AD neurons.181-182 Our finding suggested C-glycosylflavones 
specifically bind to RA1L2 and may intervene aberrant RNA metabolism in AD.  
In summary, the preliminary data suggest pleiotropic actions of C-glycosylflavones. 
Nevertheless, all hypotheses deduced from the proteomics study require further rigorous 
investigations and more scientific efforts are necessary to advance this line of research. In 
particular, it should be prudent to investigate potential toxicity of the C-glycosylflavones due to 
their binding to histones, CALM1, LG3BP, or RA1L2, as all these proteins are essential to the 
normal cellular functions. It is important to perform a parallel proteomics experiment using SH-
SY5Y cell without Aβ treatment. A comparison of the chemical proteomics data between untreated 
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and Aβ-treated cultures would link specific changes with Aβ-induced cellular toxicity to the 
systems pharmacology/toxicology upon treatment of C-glycosylflavones. In addition, it is also 
advantageous to use primary neurons (i.e., cells isolated from the brain of model animals with 
Aβ/tau pathology) with better physiological and biochemical relevance instead of the SH-SY5Y 
cell model. 
 
 
 
* Methods and experimental procedures are listed in Chapter 3 of the dissertation.  
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2.4. Conclusions and Future Directions 
In this dissertation, I have elaborated a hypothesis-driven research on AD drug discovery. I 
have conducted rigorous and systematic investigations on C-glycosylflavones against tau and 
amyloid pathologies, which is involved with multidisciplinary strategies of natural products 
chemistry, biochemistry, medicinal chemistry, chemical biology, molecular biology, and 
neuroscience.  
Using target-based screening, the natural 6-C-glycosylflavone isoorientin from corn silks was 
identified as a substrate-competitive, ATP-noncompetitive inhibitor of GSK-3β. Subsequent 
phenotype-based screening substantiated its promising activities against tau hyperphosphorylation 
and Aβ neurotoxicity in the SH-SY5Y neuronal cell model for neuroprotection.65 In addition to 
our findings, isoorientin has been reported for in vitro inhibitory activities against cholinesterases 
and BACE1.183-184 Moreover, a recent study showed that the 6-C-glycosylflavone maysin, an 
analogue of isoorientin, attenuates Aβ burden and neuroinflammation in an APPswe/PSEN1dE9 
mouse model.69 Other pharmacological effects of isoorientin for human health have been revealed 
in the past years. Isoorientin shows selective antiproliferation and induces apoptosis on human 
hepatoblastoma cells (HepG2) but not on normal liver cells such as the rat liver cells (BRL-3A) 
and the human liver cell line (HL-7702).66, 113, 185-188 The anticancer mechanisms are attributed to 
anti-oxidation, mitochondrial perturbation, and intervention of the ROS-related p53, PI3K/Akt, 
JNK, and p38 signaling pathways.66, 113, 185-188 Isoorientin also inhibits human pancreatic and breast 
cancer cells.189-190 Moreover, it has been reported that isoorientin inhibits lipopolysaccharide-
induced inflammation via down-regulation of MAPK/NF-κB signaling pathway in BV-2 
microglia.67, 191 Isoorientin suppresses secretion of inflammatory cytokines in human keratinocytes 
(HaCaT).192 Recently, anti-obesitic and anti-diabetic effects of isoorientin have been reported. It 
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regulates lipid metabolism by improving mitochondrial function and activates the insulin signaling 
pathway in 3T3-L1 adipocytes in vitro193-194 as well as prevents hyperlipidemia and liver injury in 
high-fructose-fed mice.68 Regarding the toxicological profiles, isoorientin from food crop maize 
is conceivably safe and tolerable as supported by in vivo subchronic toxicity studies of corn silk-
derived flavones in mice and rats70-71 as well as the aforementioned animal studies for diabetes.68 
Taken together, the accumulating evidence indicates that isoorientin is a promising natural product 
drug lead with medicinal prospects, and our study contributes new knowledge of this agent for 
potential AD therapy. 
Aiming at improving therapeutic potential, computer-aided drug design and SAR-based 
optimization have led to discovery of a series of new synthetic GSK-3β inhibitors, inspired by the 
6-C-glycosylflavones, with high kinase selectivity, passive membrane permeability, and anti-AD 
activities in various biological evaluations.73, 145 While the results are encouraging, limitations need 
be noted that most investigations solely rely on techniques such as in vitro enzymatic assays, cell-
based assays, and in silico computational modeling. Additional experiments using site-directed 
mutagenesis of GSK-3β to generate mutants for kinase inhibitor study and eventually conducting 
X-ray co-crystallography of inhibitor–GSK-3β complex will offer more conclusive evidence to 
support the proposed molecular mechanisms and provide guidance for further lead optimization. 
In addition, it will be useful to investigate the pharmacological effect by co-dosing other known 
GSK-3β inhibitors with a given C-glycosylflavone-based inhibitor in SH-SY5Y cells, which could 
provide other aspects for functional validation. It would be also worth testing these agents for 
potential neuroregeneration. As for cell models in the future research, manipulating the SH-SY5Y 
cells with the CRISPR-Cas9 genome editing technique to generate GSK-3β null/mutant cells can 
be used as new tools for kinase inhibitor studies. Pharmacological studies of the new GSK-3β 
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inhibitors in primary neurons, glial cells or ex vivo brain slices derived from mouse models of 
Aβ/tau pathology should be considered. Ultimately, in vivo pharmacokinetics, pharmacodynamics, 
and animal studies are necessary to understand the neuroprotective efficacy of these agents for 
potential AD prevention.  
In a pilot study using the affinity-based chemical proteomics approach, additional protein 
targets have been identified. We demonstrated that the 6-C-glycosylflavones are novel multitarget 
neuroprotective agents. A proposal of pleiotropic actions by which these agents exert anti-AD 
activities is briefly summarized in Figure 2.30. The 6-C-glycosylflavones intervene tauopathy and 
amyloid toxicity via GSK-3β inhibition. They bind to calmodulin-1 to interfere Ca2+ homeostasis 
in synaptic transmission. They also bind to histones that would exert epigenetic perturbation in 
response to the neurodegenerative stress. Binding to LG3BP in conjunction with associated 
proteins in apoptotic signaling pathways would prevent from neuroinflammation and neuronal 
death. And interacting with RA1L2 would affect RNA splicing and metabolism in response to AD 
stresses. Such pleiotropic actions of the 6-C-glycosylflavones a least in part support the increasing 
knowledge in the literature that isoorientin shows diverse benefits in human health. Nonetheless, 
like an old saying tells that “any medication is a double-edged sword.” The 6-C-glycosylflavones 
bind to any of these protein targets may also affect their normal functions in cells. Future work 
should aim at target/pathway validation using different molecular biology techniques such as 
immunoblotting, biochemical assay, microarray, qPCR, etc. RNA-seq and ChIP-qPCR analyses 
will determine if the therapeutic intervention of 6-C-glycosylflavones is affecting gene expression 
or epigenetics in downstream pathways and identify any relationship between them. The 
metabolomic and biochemical analyses will determine the relationship between specific molecular 
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pathways and systems pharmacology/toxicology. Bioinformatic analysis will determine if any 
affected molecular pathways associated with AD pathology. 
Collectively, the new knowledge gained through this study confers the therapeutic potential 
of 6-C-glycosylflavones for AD prevention, which is a valuable contribution to the AD biomedical 
sciences as well as AD drug discovery. Notwithstanding, further investigations through rigorous 
scientific efforts are still mandatory in the future. 
 
 
Figure 2.30. A proposed pleiotropic tree of the C-glycosylflavones for Alzheimer’s disease. 
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CHAPTER 3 
3. EXPERIMENTAL PROCEDURES 
3.1. Chemicals and Reagents 
All solvents and reagents were from commercial sources and were used without further 
purification. Natural flavones (isoorientin, orientin, and luteolin), staurosporine, TDZD-8, lithium 
chloride, theophylline, atenolol, desipramine, TMSCHN2, [TEMPO]+[BF4]−, HCTU, retinoic acid, 
organic amines, Triton X-100, BCIP/NBT reagents, and protease inhibitor cocktail were from 
Sigma-Aldrich (Saint Louis, MO, USA). β-Amyloid peptide 1-42 (Aβ42) was from AnaSpec 
(Fremont, CA, USA). Trypsin/Lys-C mix, Kinase Selectivity Profiling Assay Kit, ADP-Glo 
Kinase Assay Kit, and CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay Kit were 
from Promega (Madison, WI, USA). Precoated PAMPA plate system was from Corning 
(Tewksbury, MA, USA). iTRAQ Reagent-8plex kit was from SCIEX (Foster City, CA, USA). 
Antibodies Tau-5, Tau pS199/pS202, Tau pS396, GSK-3β, GSK-3β pS9, human Tau pS396 
ELISA Kit, and Cell Extraction Buffer were from Invitrogen (Camarillo, CA, USA). β-Actin 
antibody was from GenScript (Piscataway, NJ, USA). Alkaline phosphatase-conjugated secondary 
antibodies were from Southern Biotech (Birmingham, AL, USA). EAH Sepharose 4B resins were 
from GE Healthcare (Chicago, IL, USA). 
3.2. General Procedures for Instrumental Analysis 
High-resolution mass spectrometric data were obtained on a Bruker maXis Impact nanoLC-
QTOF-MS spectrometer in ESI positive mode. Accurate masses of all analytes were obtained from 
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the pseudo-molecule [M+H]+ and were within 5 ppm mass error. 1H, 13C and 2D NMR data were 
recorded with a Varian Unity Inova 500 MHz spectrometer. NMR spectra were referenced to the 
appropriate residual solvent signal (δH 2.50, δC 39.5 for DMSO-d6) with chemical shifts reported 
in δ units (ppm). Resonance multiplicities are denoted s, d, t, q, m, and br for singlet, doublet, 
triplet, quartet, multiplet, and broad, respectively.  
All reactions were monitored by LC-MS (Bruker nanoLC-QTOF-MS). Compounds in crude 
reaction mixtures were separated by flash column chromatography on HyperSep C18 (40–63 μm), 
and purified by semi-preparative reverse phase Agilent HPLC with a diode array detector (Waters 
XSELECT CSH Phenyl-Hexyl column, 150 × 10 mm, 5 μm, a linear gradient over 30 min from 
10 to 50% aqueous acetonitrile containing 0.1% formic acid, flow rate 2.5 mL/min). 
The purity of each compound was determined by analytical reverse phase Agilent HPLC with 
a diode array detector (Waters XSELECT CSH Fluoro-Phenyl column, 150 × 4.6 mm, 3.5 μm, 
isocratic elution with 35% aqueous acetonitrile containing 0.1% formic acid, detection at 210, 254, 
and 340 nm, flow rate of 0.8 mL/min). All the tested compounds were over 95% purity by HPLC-
UV at 210 nm.  
Luminescent measurement was performed on an Agilent Cary Eclipse fluorescence 
spectrophotometer. Optical absorbance was measured on a Multiskan GO Microplate 
spectrophotometer. Microscopic images were observed under a Nikon Diaphot inverted tissue 
culture microscope with Optronics MicroFire microscope camera. 
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3.3. Collection of Corn Silks 
Fresh corn silks (CS, Zea mays L.) were collected from the Waimanalo Research Station, 
University of Hawaii at Manoa, USA. Upon collection, fresh CS sample was immediately 
lyophilized and stored at -20 °C until extraction. 
3.4. Extraction and Isolation of Natural 6-C-Glycosylflavones 
A modified protocol of the bioassay-guided fractionation was used.195 A 90 g portion of 
lyophilized CS sample was exhaustively extracted with 1000 mL (×5) of CH2Cl2:MeOH (v/v 2:1) 
to yield 45 g of crude extract. This crude extract was subject to successive solvent partitioning 
using a modified Kupchan method with n-hexane, ethyl acetate (EtOAc), n-butanol and H2O to 
yield four fractions of 3.7, 0.9, 4.8 and 34.7 g, respectively. The EtOAc fraction (0.9 g) was further 
subject to flash column chromatography on a DPA-6S polyamide column (50 g) using a step 
gradient of 25 (×2), 50 (×2), 75 (×2) and 100% (×2) MeOH in H2O, affording eight fractions (A-
H) of 230.5, 80.0, 40.2, 50.8, 30.5, 70.6, 70.1 and 90.5 mg. GSK-3β assay data indicated that the 
kinase inhibitory activity was concentrated in fraction F (70.6 mg). Separation of fraction F on a 
reversed-phase HPLC [CSH Fluoro-Phenyl, 150 × 4.6 mm, a linear gradient over 40 min from 10 
to 50% acetonitrile in H2O solvents, flow rate 0.7 mL/min, PDA detection] afforded five 
subfractions, whose GSK-3β inhibitory activities were concentrated in subfraction-2 (CS-EA-F-2; 
3.1 mg) and subfraction-3 (CS-EA-F-3; 5.4 mg). Further purification of these two subfractions 
under the same conditions led to the isolation of 1 (tR 17.5 min, 2.5 mg, 0.006% yield) and 2 (tR 
23.1 min, 1.2 mg, 0.003% yield) in over 95% purity as determined by HPLC-UV at 205 nm. The 
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identity of 1 and 2 was confirmed by ESI-QTOF-CID-MS/MS analysis and comparison with 
reported NMR spectroscopic data. 
3.5. General Procedure for Semi-Synthesis of 6-C-Glycosylflavone 
Analogues 
Preparation of Compound 5. The chemoselective methylation proceeded as described.123 To 
a stirred solution of 1 (45 mg, 0.1 mmol) in a mixture of toluene (6 mL) and methanol (4 mL) was 
added TMSCHN2 (2 M in hexane, 0.5 mL, 1 mmol). The reaction solution was stirred at room 
temperature for 8 h and the solvent was evaporated. The residue was purified by RP-HPLC (Waters 
XSELECT CSH Fluoro-Phenyl column, 150 × 4.6 mm, 3.5 μm, isocratic elution with 35% aqueous 
acetonitrile containing 0.1% formic acid, detection at 210, 254, and 340 nm, flow rate of 0.8 
mL/min) to afford 5. 
Preparation of Compound 6. To a stirred solution of 5 (45 mg, 0.09 mmol) in a mixture of 
dichloromethane (6 mL) and pyridine (3 mL) was added [TEMPO]+[BF4]− (oxoammonium salt, 
60 mg, 0.2 mmol). The reaction mixture was stirred at room temperature for 5 h. The reaction was 
quenched by adding drops of methanol and then evaporated to dryness. The residue was 
reconstituted in 5% MeOH/H2O and then eluted on a HyperSep C18 column using the same 
solvents to remove the red-orange nitroxide. Elution was continued with 90% MeOH/H2O and the 
eluate was collected as the crude product, which was further purified by RP-HPLC (Waters 
XSELECT CSH Fluoro-Phenyl column, 150 × 4.6 mm, 3.5 μm, isocratic elution with 35% aqueous 
acetonitrile containing 0.1% formic acid, detection at 210, 254, and 340 nm, flow rate of 0.8 
mL/min) to afford 6. 
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Preparation of Compound 7. To a stirred solution of 6 (1 mg, 2 μmol) in a mixture of toluene 
(1.5 mL) and methanol (1 mL) was added TMSCHN2 (2 M in hexane, 2 μL, 4 μmol). The reaction 
solution was stirred at room temperature for 1 h and the solvent was evaporated. The residue was 
purified by RP-HPLC (Waters XSELECT CSH Fluoro-Phenyl column, 150 × 4.6 mm, 3.5 μm, 
isocratic elution with 35% aqueous acetonitrile containing 0.1% formic acid, detection at 210, 254, 
and 340 nm, flow rate of 0.8 mL/min) to afford 7. 
Preparation of Compounds 8-31. To a stirred solution of 6 (5 mg, 9.7 μmol) in a mixture of 
dimethylformamide (1 mL) and DIPEA (0.5 mL) was added HCTU (10 mg, 24 μmol) and then 
stirred for 10 min at room temperature. To this solution was added corresponding organic amines 
(each 50 μmol) and stirred at room temperature for 5 h.  
The reaction was quenched by adding 1 N HCl followed by evaporation of solvents to dryness. 
The residue was purified by RP-HPLC (Waters XSELECT CSH Fluoro-Phenyl column, 150 × 4.6 
mm, 3.5 μm, isocratic elution with 35% aqueous acetonitrile containing 0.1% formic acid, 
detection at 210, 254, and 340 nm, flow rate of 0.8 mL/min) to afford the final products. 
3.6. Physical Data of Compound Characterization 
3.6.1. Natural 6-C-Glycosylflavones from Corn Silk 
Isoorientin (1): light yellow solid; HRESI-TOFMS m/z [M+H]+ 449.1085 (calcd for 
C21H21O11+, 449.1078, -1.4 ppm error). 
3’-Methoxymaysin (2): light yellow solid; HRESI-TOFMS m/z [M+H]+ 591.1711 (calcd for 
C28H31O14+, 591.1708, -0.5 ppm error). 
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3.6.2. Semi-Synthetic 6-C-Glycosylflavones 
2-(3,4-Dimethoxyphenyl)-5,7-dimethoxy-6-((2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-
(hydroxymethyl)tetrahydro-2H-pyran-2-yl)-4H-chromen-4-one (5). Light yellow solid (80% 
yield). 1H NMR (DMSO-d6) δ 7.65 (dd, J = 8.6, 2.2 Hz, 1H), 7.54 (d, J = 2.2 Hz, 1H), 7.12 (d, J 
= 8.6 Hz, 1H), 7.09 (br s, 1H), 6.72 (br s, 1H), 4.65 (br d, J = 9.7 Hz, 1H), 4.05 (dd, J = 12.7, 9.2 
Hz, 1H), 3.89 (s, 3H), 3.86 (s, 3H), 3.81 (s, 3H), 3.77 (s, 3H), 3.72 (dd, J = 12.6, 12.5 Hz, 1H), 
3.34 – 3.28 (m, 1H), 3.27 – 3.12 (m, 3H). 13C NMR (DMSO-d6) δ 175.5, 163.4, 160.2, 158.9, 
158.5, 151.8, 149.1, 123.2, 119.7, 111.9, 111.3, 109.4, 107.1, 107.0, 97.0, 82.0, 79.2, 73.1, 71.3, 
70.9, 62.6, 62.0, 61.8, 56.4, 55.8. HRESI-TOFMS m/z [M+H]+ 505.1710 (calcd for C25H29O11+, 
505.1704, -1.1 ppm error). HPLC purity: 97.1% (210 nm). 
(2S,3S,4R,5R,6S)-6-(2-(3,4-Dimethoxyphenyl)-5,7-dimethoxy-4-oxo-4H-chromen-6-yl)-
3,4,5-trihydroxytetrahydro-2H-pyran-2-carboxylic acid (6). Light yellow solid (95% yield). 
1H NMR (DMSO-d6) δ 7.65 (dd, J = 8.5, 2.0 Hz, 1H), 7.54 (d, J = 2.0 Hz, 1H), 7.12 (d, J = 8.5 
Hz, 1H), 7.09 (br s, 1H), 6.76 (d, J = 6.6 Hz, 1H), 4.60 (d, J = 10.1 Hz, 1H), 4.02 (m, 1H), 3.89 
(s, 3H), 3.85 (s, 3H), 3.82 (s, 3H), 3.75 (s, 3H), 3.30 – 3.16 (m, 3H). 13C NMR (DMSO-d6) δ 
175.5, 173.0, 162.2, 160.4, 158.9, 158.5, 151.9, 149.2, 123.2, 119.7, 111.9, 111.4, 109.4, 107.1, 
107.0, 97.1, 79.0, 78.5, 74.1, 72.5, 71.3, 63.5, 62.6, 56.6, 56.1. HRESI-TOFMS m/z [M+H]+ 
519.1502 (calcd for C25H27O12+, 519.1497, -0.9 ppm error). HPLC purity: 97.8% (210 nm). 
Methyl (2S,3S,4R,5R,6S)-6-(2-(3,4-dimethoxyphenyl)-5,7-dimethoxy-4-oxo-4H-
chromen-6-yl)-3,4,5-trihydroxytetrahydro-2H-pyran-2-carboxylate (7). Light yellow solid 
(87% yield). 1H NMR (DMSO-d6) δ 7.69 (dd, J = 8.5, 2.1 Hz, 1H), 7.56 (d, J = 2.1 Hz, 1H), 7.15 
(br s, 1H), 7.12 (d, J = 8.5 Hz, 1H), 6.80 (d, J = 5.5 Hz, 1H), 4.57 (d, J = 9.6 Hz, 1H), 4.00 (m, 
1H), 3.89 (s, 3H), 3.85 (s, 3H), 3.80 (s, 3H), 3.73 (s, 3H), 3.63 (s, 3H), 3.29 – 3.13 (m, 3H). 13C 
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NMR (DMSO-d6) δ 175.6, 172.9, 162.1, 160.1, 159.0, 158.4, 151.8, 149.1, 123.2, 119.7, 111.9, 
111.4, 109.4, 107.1, 107.0, 97.0, 79.0, 78.5, 74.1, 72.5, 71.3, 63.4, 62.6, 56.6, 56.0, 51.8. HRESI-
TOFMS m/z [M+H]+ 533.1656 (calcd for C26H29O12+, 533.1654, -0.5 ppm error). HPLC purity: 
97.1% (210 nm). 
(2S,3S,4R,5R,6S)-6-(2-(3,4-Dimethoxyphenyl)-5,7-dimethoxy-4-oxo-4H-chromen-6-yl)-
3,4,5-trihydroxy-N-propyltetrahydro-2H-pyran-2-carboxamide (8). Light yellow solid (90% 
yield). 1H NMR (DMSO-d6) δ 7.67 (d, J = 8.7 Hz, 1H), 7.53 (d, J = 2.2 Hz, 1H), 7.13 (s, 1H), 
7.12 (d, J = 8.7 Hz, 1H), 6.76 (d, J = 5.9 Hz, 1H), 4.67 (br d, J = 10.1 Hz, 1H), 4.06 (q, J = 10.3 
Hz, 1H), 3.87 (s, 3H), 3.83 (s, 3H), 3.77 (s, 3H), 3.71 (s, 3H), 3.60 (m, 1H), 3.50 (m, 1H), 3.23 
(m, 1H), 2.99 (m, 2H), 1.36 (m, 2H), 0.78 (td, J = 7.4, 2.2 Hz, 3H). 13C NMR (DMSO-d6) δ 
175.7, 168.7, 163.4, 160.5, 160.2, 158.4, 151.6, 149.3, 123.1, 120.4, 112.2, 111.9, 109.6, 107.2, 
107.0, 96.8, 80.6, 79.0, 74.4, 71.6, 69.6, 63.9, 63.1, 56.7, 56.1, 40.8, 22.6, 11.5. HRESI-TOFMS 
m/z [M+H]+ 560.2135 (calcd for C28H34NO11+, 560.2126, -1.6 ppm error). HPLC purity: 98.6% 
(210 nm).  
(2S,3S,4R,5R,6S)-6-(2-(3,4-Dimethoxyphenyl)-5,7-dimethoxy-4-oxo-4H-chromen-6-yl)-
3,4,5-trihydroxy-N-isopropyltetrahydro-2H-pyran-2-carboxamide (9). Light yellow solid 
(90% yield). 1H NMR (DMSO-d6) δ 7.67 (d, J = 8.1 Hz, 1H), 7.55 (d, J = 2.2 Hz, 1H), 7.14 (br s, 
1H), 7.12 (d, J = 9.7 Hz, 1H), 6.77 (d, J = 5.1 Hz, 1H), 4.67 (d, J = 9.7 Hz, 1H), 4.05 (m, 1H), 
3.92 (s, 3H), 3.89 (s, 3H), 3.85 (s, 3H), 3.83 (m, 1H), 3.81 (s, 3H), 3.59 (m, 1H), 3.57 (m, 1H), 
3.23 (m, 1H), 1.04 (d, J = 6.4 Hz, 3H), 1.01 (d, J = 6.8 Hz, 3H). 13C NMR (DMSO-d6) δ 175.5, 
168.7, 163.3, 161.7, 160.1, 158.7, 152.1, 149.2, 123.1, 119.5, 111.9, 111.3, 109.4, 107.1, 107.0, 
97.0, 79.8, 78.5, 73.8, 71.4, 70.3, 63.4, 62.5, 56.6, 55.8, 40.3, 22.2, 22.2. HRESI-TOFMS m/z 
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[M+H]+ 560.2117 (calcd for C28H34NO11+, 560.2126, 1.7 ppm error). HPLC purity: 97.2% (210 
nm). 
(2S,3S,4R,5R,6S)-6-(2-(3,4-Dimethoxyphenyl)-5,7-dimethoxy-4-oxo-4H-chromen-6-yl)-
3,4,5-trihydroxy-N-butyltetrahydro-2H-pyran-2-carboxamide (10). Light yellow solid (90% 
yield). 1H NMR (DMSO-d6) δ 7.68 (d, J = 8.6 Hz, 1H), 7.55 (d, J = 2.2 Hz, 1H), 7.14 (s, 1H), 
7.12 (d, J = 8.6 Hz, 1H), 6.81 (d, J = 6.7 Hz, 1H), 4.67 (br d, J = 10.2 Hz, 1H), 4.06 (m, 1H), 
3.89 (s, 3H), 3.85 (s, 3H), 3.80 (s, 3H), 3.74 (s, 3H), 3.58 (m, 1H), 3.50 (m, 1H), 3.23 (m, 1H), 
3.02 (m, 2H), 1.34 (m, 2H), 1.23 (m, 2H), 0.83 (m, 3H). 13C NMR (DMSO-d6) δ 175.9, 168.8, 
163.2, 160.3, 160.2, 158.3, 151.8, 149.1, 123.3, 119.7, 111.7, 111.5, 109.2, 107.2, 106.9, 96.5, 
80.1, 78.8, 74.0, 71.5, 70.3, 63.8, 62.9, 56.7, 56.1, 38.2, 31.2, 19.6, 13.8. HRESI-TOFMS m/z 
[M+H]+ 574.2289 (calcd for C29H36NO11+, 574.2283, -1.1 ppm error). HPLC purity: 97.4% (210 
nm). 
(2S,3S,4R,5R,6S)-6-(2-(3,4-Dimethoxyphenyl)-5,7-dimethoxy-4-oxo-4H-chromen-6-yl)-
3,4,5-trihydroxy-N-isobutyltetrahydro-2H-pyran-2-carboxamide (11). Light yellow solid 
(88% yield). 1H NMR (DMSO-d6) δ 7.62 (d, J = 8.8 Hz, 1H), 7.49 (d, J = 1.9 Hz, 1H), 7.14 (s, 
1H), 7.11 (d, J = 8.6 Hz, 1H), 6.81 (d, J = 6.9 Hz, 1H), 4.68 (br d, J = 10.2 Hz, 1H), 4.07 (m, 
1H), 3.89 (s, 3H), 3.84 (s, 3H), 3.80 (s, 3H), 3.75 (s, 3H), 3.62 (m, 1H), 3.49 (m, 1H), 3.24 (m, 
1H), 2.87 (t, J = 6.4 Hz, 2H), 1.66 (m, 1H), 0.79 (d, J = 6.7 Hz, 6H). 13C NMR (DMSO-d6) δ 
176.2, 167.3, 163.5, 160.6, 160.7, 158.8, 153.1, 149.5, 123.7, 120.7, 113.0, 112.7, 112.4, 108.3, 
107.4, 97.7, 81.0, 79.9, 75.2, 72.8, 71.5, 64.6, 64.1, 57.8, 56.9, 47.2, 29.4, 21.3, 21.3. HRESI-
TOFMS m/z [M+H]+ 574.2292 (calcd for C29H36NO11+, 574.2283, -1.6 ppm error). HPLC purity: 
99.1% (210 nm). 
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(2S,3S,4R,5R,6S)-6-(2-(3,4-Dimethoxyphenyl)-5,7-dimethoxy-4-oxo-4H-chromen-6-yl)-
3,4,5-trihydroxy-N-pentyltetrahydro-2H-pyran-2-carboxamide (12). Light yellow solid (89% 
yield). 1H NMR (500 MHz, DMSO-d6) δ 7.68 (d, J = 8.6 Hz, 1H), 7.55 (d, J = 2.1 Hz, 1H), 7.14 
(s, 1H), 7.12 (d, J = 8.6 Hz, 1H), 6.81 (d, J = 6.3 Hz, 1H), 4.67 (br d, J = 10.2 Hz, 1H), 4.06 (m, 
1H), 3.89 (s, 3H), 3.85 (s, 3H), 3.80 (s, 3H), 3.74 (s, 3H), 3.58 (m, 1H), 3.50 (m, 1H), 3.22 (m, 
1H), 3.03 (m, 2H), 1.35 (m, 2H), 1.23 (m, 2H), 1.20 (m, 2H), 0.83 (m, 3H). 13C NMR (DMSO-
d6) δ 175.9, 168.9, 163.2, 160.5, 160.3, 158.5, 151.9, 149.2, 123.4, 119.7, 111.8, 111.6, 109.3, 
107.0, 106.8, 96.4, 80.1, 78.8, 73.5, 71.6, 70.4, 63.5, 62.7, 56.1, 55.9, 38.4, 28.7, 28.6, 21.9, 14.0. 
HRESI-TOFMS m/z [M+H]+ 588.2456 (calcd for C30H38NO11+, 588.2439, -2.8 ppm error). 
HPLC purity: 98.2% (210 nm). 
(2S,3S,4R,5R,6S)-6-(2-(3,4-Dimethoxyphenyl)-5,7-dimethoxy-4-oxo-4H-chromen-6-yl)-
3,4,5-trihydroxy-N-hexyltetrahydro-2H-pyran-2-carboxamide (13). Light yellow solid (90% 
yield). 1H NMR (DMSO-d6) δ 7.68 (d, J = 8.6 Hz, 1H), 7.55 (d, J = 2.3 Hz, 1H), 7.14 (s, 1H), 
7.12 (d, J = 8.6 Hz, 1H), 6.81 (d, J = 5.9 Hz, 1H), 4.66 (br d, J = 10.5 Hz, 1H), 4.06 (q, J = 8.6 
Hz, 1H), 3.89 (s, 3H), 3.84 (s, 3H), 3.80 (s, 3H), 3.74 (s, 3H), 3.60 (m, 1H), 3.50 (m, 1H), 3.23 
(m, 1H), 3.01 (m, 2H), 1.40 – 1.15 (m, 8H), 0.82 (m, 3H). 13C NMR (DMSO-d6) δ 175.6, 168.8, 
163.4, 160.3, 160.2, 158.6, 151.8, 149.1, 123.1, 119.6, 112.1, 111.8, 109.3, 107.1, 107.0, 97.1, 
79.9, 78.7, 74.5, 71.5, 69.4, 63.5, 62.7, 56.6, 56.0, 38.5, 31.0, 28.9, 26.1, 22.1, 13.9. HRESI-
TOFMS m/z [M+H]+ 602.2572 (calcd for C31H40NO11+, 602.2596, 3.9 ppm error). HPLC purity: 
98.5% (210 nm). 
(2S,3S,4R,5R,6S)-N-Cyclopropyl-6-(2-(3,4-dimethoxyphenyl)-5,7-dimethoxy-4-oxo-4H-
chromen-6-yl)-3,4,5-trihydroxytetrahydro-2H-pyran-2-carboxamide (14). Light yellow solid 
(82% yield). 1H NMR (DMSO-d6) δ 7.67 (dt, J = 8.3, 2.2 Hz, 1H), 7.54 (d, J = 2.2 Hz, 1H), 7.16 
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(s, 1H), 7.12 (d, J = 8.3 Hz, 1H), 6.78 (d, J = 5.7 Hz, 1H), 4.64 (br d, J = 9.7 Hz, 1H), 4.06 (q, J 
= 8.9 Hz, 1H), 3.88 (s, 3H), 3.84 (s, 3H), 3.79 (s, 3H), 3.73 (s, 3H), 3.51 (m, 1H), 3.50 (m, 1H), 
3.19 (m, 1H), 2.62 (m, 1H), 0.79 (m, 2H), 0.58 (m, 2H). 13C NMR (DMSO-d6) δ 175.3, 167.6, 
163.4, 161.5, 160.3, 159.6, 152.5, 149.3, 123.4, 119.8, 111.8, 111.5, 109.4, 107.7, 107.0, 97.0, 
80.2, 78.9, 74.1, 71.3, 70.3, 63.5, 62.8, 56.1, 55.8, 23.1, 10.8, 10.8. HRESI-TOFMS m/z [M+H]+ 
558.1967 (calcd for C28H32NO11+, 558.1970, 0.5 ppm error). HPLC purity: 98.2% (210 nm). 
(2S,3S,4R,5R,6S)-N-Cyclobutyl-6-(2-(3,4-dimethoxyphenyl)-5,7-dimethoxy-4-oxo-4H-
chromen-6-yl)-3,4,5-trihydroxytetrahydro-2H-pyran-2-carboxamide (15). Light yellow solid 
(85% yield). 1H NMR (DMSO-d6) δ 7.67 (dt, J = 8.6, 2.1 Hz, 1H), 7.54 (d, J = 2.1 Hz, 1H), 7.16 
(s, 1H), 7.12 (d, J = 8.6 Hz, 1H), 6.77 (d, J = 7.2 Hz, 1H), 4.66 (br d, J = 9.7 Hz, 1H), 4.16 (q, J 
= 7.8 Hz, 1H), 4.05 (td, J = 9.3, 5.7 Hz, 1H), 3.88 (s, 3H), 3.84 (s, 3H), 3.78 (s, 3H), 3.74 (s, 3H), 
3.54 (m, 1H), 3.51 (m, 1H), 3.21 (m, 1H), 2.09 (m, 2H), 1.86 (m, 2H), 1.58 (m, 2H). 13C NMR 
(DMSO-d6) δ 175.5, 167.4, 163.1, 161.4, 160.5, 159.3, 152.2, 149.1, 123.2, 119.6, 111.9, 111.6, 
109.1, 107.5, 107.0, 97.1, 80.4, 78.5, 74.2, 71.2, 70.4, 63.3, 62.7, 55.9, 55.7, 43.6, 29.9, 29.9, 
14.3. HRESI-TOFMS m/z [M+H]+ 572.2120 (calcd for C29H34NO11+, 572.2126, 1.1 ppm error). 
HPLC purity: 98.3% (210 nm). 
(2S,3S,4R,5R,6S)-N-Cyclopentyl-6-(2-(3,4-dimethoxyphenyl)-5,7-dimethoxy-4-oxo-4H-
chromen-6-yl)-3,4,5-trihydroxytetrahydro-2H-pyran-2-carboxamide (16). Light yellow solid 
(86% yield). 1H NMR (DMSO-d6) δ 7.66 (d, J = 8.4 Hz, 1H), 7.53 (d, J = 2.1 Hz, 1H), 7.16 (s, 
1H), 7.12 (d, J = 8.4 Hz, 1H), 6.75 (d, J = 6.5 Hz, 1H), 4.64 (br d, J = 10.2 Hz, 1H), 3.95 (m, 
1H), 3.87 (s, 3H), 3.82 (s, 3H), 3.79 (m, 1H), 3.77 (s, 3H), 3.71 (s, 3H), 3.53 (m, 1H), 3.51 (m, 
1H), 3.21 (m, 1H), 1.79 – 1.40 (m, 8H). 13C NMR (DMSO-d6) δ 175.4, 167.1, 163.6, 161.4, 
160.3, 158.8, 152.1, 149.1, 123.0, 119.8, 112.1, 111.8, 109.2, 107.7, 107.1, 97.3, 80.2, 78.5, 74.2, 
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71.2, 68.6, 63.6, 62.8, 56.3, 55.9, 50.5, 32.1, 32.1, 23.6, 23.6. HRESI-TOFMS m/z [M+H]+ 
586.2291 (calcd for C30H36NO11+, 586.2283, -1.4 ppm error). HPLC purity: 96.6% (210 nm). 
(2S,3S,4R,5R,6S)-N-Cyclohexyl-6-(2-(3,4-dimethoxyphenyl)-5,7-dimethoxy-4-oxo-4H-
chromen-6-yl)-3,4,5-trihydroxytetrahydro-2H-pyran-2-carboxamide (17). Light yellow solid 
(88% yield). 1H NMR (DMSO-d6) δ 7.68 (d, J = 8.4 Hz, 1H), 7.55 (d, J = 2.1 Hz, 1H), 7.14 (s, 
1H), 7.12 (d, J = 8.4 Hz, 1H), 6.80 (d, J = 6.5 Hz, 1H), 4.65 (br d, J = 10.2 Hz, 1H), 4.04 (q, J = 
8.4 Hz, 1H), 3.88 (s, 3H), 3.84 (s, 3H), 3.79 (s, 3H), 3.74 (s, 3H), 3.58 (m, 1H), 3.51 (m, 1H), 
3.49 (m, 1H), 3.21 (m, 1H), 1.74 – 1.47 (m, 6H), 1.27 – 0.99 (m, 4H). 13C NMR (DMSO-d6) δ 
175.5, 167.2, 163.2, 161.3, 160.3, 158.8, 152.0, 149.1, 123.1, 119.8, 112.0, 111.4, 109.4, 107.2, 
107.0, 96.9, 80.5, 79.1, 74.1, 71.6, 70.6, 63.9, 62.7, 56.4, 56.0, 47.8, 32.6, 32.6, 29.1, 24.6, 24.6. 
HRESI-TOFMS m/z [M+H]+ 600.2446 (calcd for C31H38NO11+, 600.2439, -1.1 ppm error). 
HPLC purity: 98.6 % (210 nm). 
(2S,3S,4R,5R,6S)-N-(Cyclohexylmethyl)-6-(2-(3,4-dimethoxyphenyl)-5,7-dimethoxy-4-
oxo-4H-chromen-6-yl)-3,4,5-trihydroxytetrahydro-2H-pyran-2-carboxamide (18). Light 
yellow solid (88% yield). 1H NMR (DMSO-d6) δ 7.66 (d, J = 8.7 Hz, 1H), 7.54 (d, J = 2.0 Hz, 
1H), 7.13 (s, 1H), 7.11 (d, J = 8.7 Hz, 1H), 6.76 (d, J = 6.2 Hz, 1H), 4.66 (br d, J = 9.9 Hz, 1H), 
4.05 (q, J = 9.9 Hz, 1H), 3.87 (s, 3H), 3.83 (s, 3H), 3.78 (s, 3H), 3.73 (s, 3H), 3.61 (m, 1H), 3.48 
(m, 1H), 3.23 (m, 1H), 2.87 (m, 2H), 1.69 – 1.47 (m, 6H), 1.33 (m, 1H), 1.08 (m, 2H), 0.80 (m, 
2H). 13C NMR (DMSO-d6) δ 176.0, 167.0, 163.7, 160.8, 160.6, 158.9, 152.0, 149.3, 123.4, 
119.7, 112.0, 111.7, 109.3, 107.2, 107.1, 96.2, 80.3, 78.7, 74.7, 71.3, 69.9, 63.8, 63.1, 56.9, 56.2, 
45.1, 37.1, 30.6, 30.6, 26.3, 25.7, 25.7. HRESI-TOFMS m/z [M+H]+ 614.2597 (calcd for 
C32H40NO11+, 614.2596, -0.1 ppm error). HPLC purity: 98.3% (210 nm). 
 105 
 
 
(2S,3S,4R,5R,6S)-N-(Adamantan-1-yl)-6-(2-(3,4-dimethoxyphenyl)-5,7-dimethoxy-4-
oxo-4H-chromen-6-yl)-3,4,5-trihydroxytetrahydro-2H-pyran-2-carboxamide (19). Light 
yellow solid (81% yield). 1H NMR (DMSO-d6) δ 7.67 (d, J = 8.4 Hz, 1H), 7.54 (d, J = 2.1 Hz, 
1H), 7.13 (s, 1H), 7.12 (d, J = 8.4 Hz, 1H), 6.78 (d, J = 6.8 Hz, 1H), 4.65 (br d, J = 10.2 Hz, 1H), 
4.03 (m, 1H), 3.88 (s, 3H), 3.84 (s, 3H), 3.80 (s, 3H), 3.74 (s, 3H), 3.57 (m, 1H), 3.52 (m, 1H), 
3.49 (m, 1H), 1.96 (m, 3H), 1.88 – 1.57 (m, 12H). 13C NMR (DMSO-d6) δ 175.3, 167.2, 163.3, 
161.1, 160.2, 158.9, 152.1, 149.2, 123.2, 119.8, 112.1, 111.6, 109.5, 107.2, 107.0, 97.0, 80.7, 
79.2, 74.2, 71.7, 70.5, 63.9, 62.5, 56.4, 56.0, 51.2, 41.2, 41.2, 41.2, 36.1, 36.1, 36.1, 28.9, 28.9, 
28.9. HRESI-TOFMS m/z [M+H]+ 652.2764 (calcd for C35H42NO11+, 652.2752, -1.8 ppm error). 
HPLC purity: 97.7% (210 nm). 
(2S,3S,4R,5R,6S)-6-(2-(3,4-Dimethoxyphenyl)-5,7-dimethoxy-4-oxo-4H-chromen-6-yl)-
3,4,5-trihydroxy-N-phenyltetrahydro-2H-pyran-2-carboxamide (20). Light yellow solid 
(88% yield). 1H NMR (DMSO-d6) δ 7.66 (dd, J = 8.6, 2.2 Hz, 1H), 7.62 (dd, J = 8.2, 2.5 Hz, 
2H), 7.55 (d, J = 2.2 Hz, 1H), 7.28 (td, J = 8.1, 2.2 Hz, 2H), 7.16‒7.10 (m, 2H), 7.03 (t, J = 7.4 
Hz, 1H), 6.77 (d, J = 6.5 Hz, 1H), 4.75 (br d, J = 9.7 Hz, 1H), 4.12 (td, J = 9.7, 2.4 Hz, 1H), 3.94 
(s, 3H), 3.89 (s, 3H), 3.85 (s, 3H), 3.84 (m, 1H), 3.79 (s, 3H), 3.66 (m, 1H), 3.29 (m, 1H). 13C 
NMR (DMSO-d6) δ 175.4, 167.3, 163.4, 161.9, 160.3, 158.8, 151.8, 149.1, 138.8, 128.6, 128.6, 
123.4, 123.1, 119.5, 119.3, 119.3, 112.0, 111.8, 109.4, 107.1, 106.9, 97.1, 81.0, 78.6, 73.7, 71.2, 
69.6, 63.4, 62.7, 56.5, 56.0. HRESI-TOFMS m/z [M+H]+ 594.1986 (calcd for C31H32NO11+, 
594.1970, -2.8 ppm error). HPLC purity: 96.5% (210 nm). 
(2S,3S,4R,5R,6S)-6-(2-(3,4-Dimethoxyphenyl)-5,7-dimethoxy-4-oxo-4H-chromen-6-yl)-
3,4,5-trihydroxy-N-benzyltetrahydro-2H-pyran-2-carboxamide (21). Light yellow solid 
(92% yield). 1H NMR (500 MHz, DMSO-d6) δ 7.67 (d, J = 10.2 Hz, 1H), 7.54 (d, J = 2.1 Hz, 
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1H), 7.29 – 7.16 (m, 5H), 7.16 – 7.08 (m, 2H), 6.80 (d, J = 6.7 Hz, 1H), 4.68 (dd, J = 9.8, 6.7 Hz, 
1H), 4.27 (m, 2H), 4.10 (m, 1H), 3.87 (s, 3H), 3.83 (s, 3H), 3.79 (s, 3H), 3.75 (s, 3H), 3.71 (m, 
1H), 3.57 (m, 1H), 3.26 (m, 1H). 13C NMR (DMSO-d6) δ 175.6, 169.1, 163.6, 162.0, 160.3, 
158.9, 151.8, 149.1, 139.2, 128.2, 128.2, 127.3, 127.3, 126.7, 123.1, 119.6, 112.1, 111.7, 109.2, 
107.1, 107.0, 97.1, 80.2, 78.8, 73.7, 71.6, 71.0, 63.5, 62.8, 56.6, 56.0, 42.0. HRESI-TOFMS m/z 
[M+H]+ 608.2130 (calcd for C32H34NO11+, 608.2126, -0.5 ppm error). HPLC purity: 97.1% (210 
nm). 
(2S,3S,4R,5R,6S)-6-(2-(3,4-Dimethoxyphenyl)-5,7-dimethoxy-4-oxo-4H-chromen-6-yl)-
3,4,5-trihydroxy-N-(pyridin-4-yl)tetrahydro-2H-pyran-2-carboxamide (22). Light yellow 
solid (81% yield). 1H NMR (500 MHz, DMSO-d6) δ 8.40 (d, J = 5.0 Hz, 2H), 7.68 (d, J = 8.5 
Hz, 1H), 7.60 (d, J = 5.0 Hz, 2H), 7.55 (s, 1H), 7.15 (s, 1H), 7.12 (d, J = 8.5 Hz, 1H), 6.81 (d, J = 
6.9 Hz, 1H), 4.72 (br d, J = 9.7 Hz, 1H), 4.11 (td, J = 9.2, 4.1 Hz, 1H), 3.94 (m, 1H), 3.88 (s, 
3H), 3.84 (s, 3H), 3.83 (s, 3H), 3.76 (s, 3H), 3.62 (m, 1H), 3.29 (m, 1H). 13C NMR (DMSO-d6) δ 
175.6, 167.5, 163.3, 161.7, 160.2, 158.7, 152.0, 150.9, 150.9, 149.2, 145.3, 123.1, 119.9, 112.1, 
113.9, 113.9, 111.5, 109.8, 107.5, 106.8, 97.1, 81.2, 78.8, 74.4, 71.5, 69.8, 63.9, 63.0, 56.5, 56.1. 
HRESI-TOFMS m/z [M+H]+ 595.1921 (calcd for C30H31N2O11+, 595.1922, 0.1 ppm error). 
HPLC purity: 97.8% (210 nm). 
(2S,3S,4R,5R,6S)-6-(2-(3,4-Dimethoxyphenyl)-5,7-dimethoxy-4-oxo-4H-chromen-6-yl)-
3,4,5-trihydroxy-N-(thiazol-2-yl)tetrahydro-2H-pyran-2-carboxamide (23). Light yellow 
solid (80% yield). 1H NMR (DMSO-d6) δ 7.68 (d, J = 8.8 Hz, 1H), 7.56 (d, J = 2.0 Hz, 1H), 7.53 
(d, J = 1.7 Hz, 1H), 7.18 (d, J = 1.7 Hz, 1H), 7.17 (s, 1H), 7.12 (d, J = 8.8 Hz, 1H), 6.82 (d, J = 
6.8 Hz, 1H), 4.67 (br d, J = 10.5 Hz, 1H), 4.03 (m, 1H), 3.89 (s, 3H), 3.84 (s, 3H), 3.82 (s, 3H), 
3.76 (s, 3H), 3.60 (m, 1H), 3.55 (m, 1H), 3.23 (m, 1H). 13C NMR (DMSO-d6) δ 175.4, 168.5, 
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163.2, 162.3, 161.6, 160.5, 158.9, 151.9, 149.2, 137.2, 123.3, 119.8, 114.1, 111.9, 111.5, 109.5, 
107.3, 105.8, 97.3, 80.0, 79.2, 74.3, 72.1, 70.3, 63.7, 62.9, 56.2, 56.0. HRESI-TOFMS m/z 
[M+H]+ 601.1493 (calcd for C28H29N2O11S+, 601.1487, -1.1 ppm error). HPLC purity: 96.8% 
(210 nm). 
(2S,3S,4R,5R,6S)-6-(2-(3,4-Dimethoxyphenyl)-5,7-dimethoxy-4-oxo-4H-chromen-6-yl)-
3,4,5-trihydroxy-N-(4-fluorophenyl)tetrahydro-2H-pyran-2-carboxamide (24). Light yellow 
solid (88% yield). 1H NMR (DMSO-d6) δ 7.70 – 7.61 (m, 3H), 7.54 (d, J = 2.1 Hz, 1H), 7.18 – 
7.08 (m, 4H), 6.78 (d, J = 7.1 Hz, 1H), 4.72 (dd, J = 12.0, 9.7 Hz, 1H), 4.11 (q, J = 8.7 Hz, 1H), 
3.92 (s, 3H), 3.88 (s, 3H), 3.84 (s, 3H), 3.83 (m, 1H), 3.76 (s, 3H), 3.61 (m, 1H), 3.28 (m, 1H). 
13C NMR (DMSO-d6) δ 175.6, 167.4, 162.8, 160.4, 160.1, 158.6, 156.9, 150.7, 149.2, 136.5, 
121.2, 121.2, 123.5, 119.8, 115.5, 115.5, 113.5, 111.8, 109.3, 107.0, 105.7, 97.2, 81.2, 78.5, 74.7, 
71.7, 70.4, 63.7, 63.0, 56.1, 55.9. HRESI-TOFMS m/z [M+H]+ 612.1892 (calcd for 
C31H31FNO11+, 612.1876, -2.7 ppm error). HPLC purity: 97.1% (210 nm). 
(2S,3S,4R,5R,6S)-6-(2-(3,4-Dimethoxyphenyl)-5,7-dimethoxy-4-oxo-4H-chromen-6-yl)-
3,4,5-trihydroxy-N-(4-fluorobenzyl)tetrahydro-2H-pyran-2-carboxamide (25). Light yellow 
solid (89% yield). 1H NMR (500 MHz, DMSO-d6) δ 7.68 (d, J = 8.5 Hz, 1H), 7.55 (d, J = 2.1 
Hz, 1H), 7.27 (ddd, J = 8.1, 5.4, 2.2 Hz, 2H), 7.18 – 7.06 (m, 4H), 6.80 (d, J = 6.8 Hz, 1H), 4.67 
(t, J = 9.3 Hz, 1H), 4.24 (dd, J = 9.9, 9.0 Hz, 2H), 4.07 (m, 1H), 3.88 (s, 3H), 3.84 (s, 3H), 3.78 
(s, 3H), 3.74 (s, 3H), 3.69 (m, 1H), 3.54 (m, 1H), 3.24 (m, 1H). 13C NMR (DMSO-d6) δ 175.7, 
169.1, 163.5, 162.0, 161.2, 160.4, 159.0, 151.9, 149.1, 135.4, 129.3, 129.3, 126.5, 119.7, 115.1, 
115.1, 111.8, 111.3, 109.3, 107.1, 105.5, 97.2, 80.2, 78.8, 73.7, 71.9, 71.0, 63.6, 62.9, 56.6, 55.9, 
41.3. HRESI-TOFMS m/z [M+H]+ 626.2043 (calcd for C32H33FNO11+, 626.2032, -1.7 ppm 
error). HPLC purity: 97.4% (210 nm). 
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(2S,3S,4R,5R,6S)-6-(2-(3,4-Dimethoxyphenyl)-5,7-dimethoxy-4-oxo-4H-chromen-6-yl)-
3,4,5-trihydroxy-N-(2-fluoroethyl)tetrahydro-2H-pyran-2-carboxamide (26). Light yellow 
solid (84% yield). 1H NMR (DMSO-d6) δ 7.68 (d, J = 8.7 Hz, 1H), 7.56 (d, J = 2.1 Hz, 1H), 7.17 
(s, 1H), 7.12 (d, J = 8.7 Hz, 1H), 6.82 (d, J = 6.6 Hz, 1H), 4.67 (br d, J = 10.5 Hz, 1H), 4.45 (m, 
1H), 4.35 (m, 1H), 4.07 (t, J = 9.2 Hz, 1H), 3.89 (s, 3H), 3.85 (s, 3H), 3.80 (s, 3H), 3.75 (s, 3H), 
3.60 (m, 1H), 3.50 (m, 1H), 3.23 (m, 1H), 3.37 (m, 2H). 13C NMR (DMSO-d6) δ 175.1, 168.6, 
163.5, 161.6, 160.5, 158.9, 151.9, 149.2, 123.6, 119.7, 111.8, 111.4, 109.3, 107.2, 105.5, 97.3, 
81.7, 79.9, 79.4, 74.3, 72.3, 70.3, 63.5, 62.9, 56.1, 55.9, 39.1. HRESI-TOFMS m/z [M+H]+ 
564.1892 (calcd for C27H31FNO11+, 564.1876, -2.9 ppm error). HPLC purity: 97.5% (210 nm). 
(2S,3S,4R,5R,6S)-6-(2-(3,4-Dimethoxyphenyl)-5,7-dimethoxy-4-oxo-4H-chromen-6-yl)-
3,4,5-trihydroxy-N-(2,2,2-trifluoroethyl)tetrahydro-2H-pyran-2-carboxamide (27). Light 
yellow solid (85% yield). 1H NMR (DMSO-d6) δ 7.68 (dd, J = 8.5, 2.0 Hz, 1H), 7.56 (d, J = 2.0 
Hz, 1H), 7.17 (s, 1H), 7.12 (d, J = 8.5 Hz, 1H), 6.81 (d, J = 7.7 Hz, 1H), 4.68 (br d, J = 9.7 Hz, 
1H), 4.07 (q, J = 9.1 Hz, 1H), 3.89 (s, 3H), 3.85 (s, 3H), 3.78 (s, 3H), 3.75 (s, 3H), 3.69 (m, 1H), 
3.48 (m, 1H), 3.67 (m, 2H), 3.21 (m, 1H). 13C NMR (DMSO-d6) δ 174.5, 169.5, 163.4, 161.3, 
160.4, 158.9, 151.8, 149.1, 125.0, 123.4, 119.7, 112.1, 111.2, 109.4, 107.1, 105.4, 97.2, 80.4, 
78.5, 74.8, 71.6, 69.5, 63.6, 62.7, 56.3, 55.9, 41.6. HRESI-TOFMS m/z [M+H]+ 600.1700 (calcd 
for C27H29F3NO11+, 600.1687, -2.2 ppm error). HPLC purity: 96.8% (210 nm). 
(2S,3S,4R,5R,6S)-6-(2-(3,4-Dimethoxyphenyl)-5,7-dimethoxy-4-oxo-4H-chromen-6-yl)-
3,4,5-trihydroxy-N-(3-fluoropropyl)tetrahydro-2H-pyran-2-carboxamide (28). Light yellow 
solid (86% yield). 1H NMR (DMSO-d6) δ 7.68 (d, J = 8.7 Hz, 1H), 7.56 (d, J = 2.1 Hz, 1H), 7.17 
(s, 1H), 7.12 (d, J = 8.7 Hz, 1H), 6.82 (d, J = 6.4 Hz, 1H), 4.66 (br d, J = 10.6 Hz, 1H), 4.46 (m, 
1H), 4.37 (m, 1H), 4.07 (m, 1H), 3.89 (s, 3H), 3.85 (s, 3H), 3.80 (s, 3H), 3.74 (s, 3H), 3.59 (m, 
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1H), 3.50 (m, 1H), 3.22 (m, 1H), 3.12 (m, 2H), 1.83 – 1.68 (m, 2H). 13C NMR (DMSO-d6) δ 
175.1, 168.5, 163.4, 161.6, 160.6, 158.8, 151.9, 149.3, 123.7, 119.8, 111.9, 111.5, 109.6, 107.3, 
105.5, 97.3, 81.9, 80.2, 78.8, 74.2, 71.8, 70.6, 63.6, 62.8, 56.2, 55.8, 34.9, 30.0. HRESI-TOFMS 
m/z [M+H]+ 578.2041 (calcd for C28H33FNO11+, 578.2032, -1.6 ppm error). HPLC purity: 98.3% 
(210 nm). 
(2S,3S,4R,5R,6S)-6-(2-(3,4-Dimethoxyphenyl)-5,7-dimethoxy-4-oxo-4H-chromen-6-yl)-
3,4,5-trihydroxy-N-(3,3,3-trifluoropropyl)tetrahydro-2H-pyran-2-carboxamide (29). Light 
yellow solid (85% yield). 1H NMR (DMSO-d6) δ 7.68 (d, J = 8.4 Hz, 1H), 7.55 (d, J = 2.2 Hz, 
1H), 7.14 (s, 1H), 7.12 (d, J = 8.4 Hz, 1H), 6.81 (d, J = 5.5 Hz, 1H), 4.68 (br d, J = 10.0 Hz, 1H), 
4.07 (m, 1H), 3.89 (s, 3H), 3.85 (s, 3H), 3.80 (s, 3H), 3.74 (s, 3H), 3.61 (m, 1H), 3.49 (m, 1H), 
3.28 (m, 2H), 3.21 (m, 1H), 2.40 (m, 2H). 13C NMR (DMSO-d6) δ 174.6, 169.3, 163.4, 161.1, 
160.3, 158.7, 151.8, 149.1, 125.7, 123.1, 119.6, 111.7, 110.9, 109.2, 107.0, 105.2, 97.4, 79.6, 
78.3, 73.6, 71.6, 69.5, 63.4, 62.7, 56.0, 55.8, 32.8, 32.1. HRESI-TOFMS m/z [M+H]+ 614.1857 
(calcd for C28H31F3NO11+, 614.1844, -2.2 ppm error). HPLC purity: 97.2% (210 nm). 
(2S,3S,4R,5R,6S)-6-(2-(3,4-Dimethoxyphenyl)-5,7-dimethoxy-4-oxo-4H-chromen-6-yl)-
3,4,5-trihydroxy-N-((S)-1,1,1-trifluoropropan-2-yl)tetrahydro-2H-pyran-2-carboxamide 
(30). Light yellow solid (82% yield). 1H NMR (500 MHz, DMSO-d6) δ 7.67 (dd, J = 8.5, 2.1 Hz, 
1H), 7.55 (d, J = 2.1 Hz, 1H), 7.15 (br s, 1H), 7.12 (d, J = 8.5 Hz, 1H), 6.78 (d, J = 6.2 Hz, 1H), 
4.69 (d, J = 9.6 Hz, 1H), 4.55 (m, 1H), 4.07 (m, 1H), 3.89 (s, 3H), 3.85 (s, 3H), 3.79 (s, 3H), 3.76 
(s, 3H), 3.71 (m, 1H), 3.56 (m, 1H), 3.24 (m, 1H), 1.23 (d, J = 6.8 Hz, 3H). 13C NMR (125 MHz, 
DMSO-d6) δ 175.5, 168.8, 163.5, 161.7, 160.3, 158.6, 152.1, 149.1, 124.4, 123.1, 119.5, 111.8, 
111.3, 109.4, 107.7, 106.9, 96.2, 79.8, 78.3, 73.8, 71.3, 70.3, 62.9, 62.7, 55.9, 55.6, 45.1, 13.3. 
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HRESI-TOFMS m/z [M+H]+ 614.1843 (calcd for C28H31F3NO11+, 614.1844, 0.1 ppm error). 
HPLC purity: 98.1% (210 nm). 
(2S,3S,4R,5R,6S)-6-(2-(3,4-Dimethoxyphenyl)-5,7-dimethoxy-4-oxo-4H-chromen-6-yl)-
3,4,5-trihydroxy-N-((R)-1,1,1-trifluoropropan-2-yl)tetrahydro-2H-pyran-2-carboxamide 
(31). Light yellow solid (86% yield). 1H NMR (500 MHz, DMSO-d6) δ 7.66 (dd, J = 8.5, 2.0 Hz, 
1H), 7.55 (d, J = 2.0 Hz, 1H), 7.14 (br s, 1H), 7.12 (d, J = 8.5 Hz, 1H), 6.77 (d, J = 6.4 Hz, 1H), 
4.68 (d, J = 9.8 Hz, 1H), 4.54 (m, 1H), 4.06 (m, 1H), 3.88 (s, 3H), 3.84 (s, 3H), 3.79 (s, 3H), 3.75 
(s, 3H), 3.71 (m, 1H), 3.55 (m, 1H), 3.24 (m, 1H), 1.23 (d, J = 6.8 Hz, 3H). 13C NMR (125 MHz, 
DMSO-d6) δ 175.3, 168.6, 163.4, 161.5, 160.2, 158.5, 152.1, 149.0, 124.2, 123.0, 119.4, 111.6, 
111.1, 109.3, 107.6, 106.8, 96.4, 79.7, 78.5, 73.9, 71.2, 70.4, 63.1, 62.5, 55.7, 55.4, 45.1, 13.3. 
HRESI-TOFMS m/z [M+H]+ 614.1847 (calcd for C28H31F3NO11+, 614.1844, -0.5 ppm error). 
HPLC purity: 96.5% (210 nm). 
3.7. Kinase Luminescent Assay 
Kinase inhibition was assessed with the ADP-Glo Kinase Assay. For screening, 5 ng/μL of 
kinase was assayed in a reaction containing 50 ng/μL substrate, 40 mM Tris, pH 7.5, 20 mM 
MgCl2, 0.1 mg/mL bovine serum albumin, 50 μM dithiothreitol (DTT), 25 μM ATP, varying 
concentrations of test samples or 5% DMSO as vehicle. The reaction mixture was incubated for 1 
h at room temperature followed by the addition of the ADP-Glo reagents according to the 
manufacturer’s protocol. The kinase inhibitor staurosporine was used at 1 μM as a reference 
control. Each data point was collected in quadruplicate of two independent experiments. Inhibition 
was presented as the percentage of the kinase activity relative to control (5% DMSO vehicle). 
Inhibition curves were analyzed by four-parameter regression. 
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Promiscuous aggregations were assessed with the screening assay in the presence of 0%, 
0.001%, 0.01% and 0.05% (v/v) of Triton X-100. Luteolin was used as a reference control for 
promiscuous inhibition. All natural C-glycosylflavones and their new analogues were not 
promiscuous or pan-assay interference compounds as determined with a detergent-based assay.65, 
92 
To study the GSK-3β kinetics, a reaction solution contained 5 ng/μL kinase, 40 mM Tris, pH 
7.5, 20 mM MgCl2, 0.1 mg/mL BSA, 50 μM DTT, and varying concentrations of ATP or substrate 
GS2 (peptide YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE that is derived from human muscle 
glycogen synthase) versus test samples. The mixture was incubated for 5, 15, 30, and 60 min at 
room temperature followed by the addition of the ADP-Glo reagents according to the 
manufacturer’s protocol. The Dixon and Lineweaver−Burk representations are derived from the 
single and double reciprocal plotting of the enzyme kinetic data, respectively. 
3.8. Cell Culture 
Human neuroblastoma SH-SY5Y cell line (ATCC CRL-2266; Sigma-Aldrich, Saint Louis, 
MO) was cultured in DMEM/F12 (v/v 1:1) media supplemented with 2 mM glutamine, 10% heat-
inactivated fetal bovine serum (FBS) and 1% antibiotics including penicillin and streptomycin. 
After reaching 70-80% confluence, cells were then subcultured on poly-L-lysine plates with 10 
μM retinoic acid in a reduced serum media (1% FBS) to promote differentiation as described.85 
Differentiation was confirmed by the change to polygonal morphology and extension of long 
neurites. Cell cultures were incubated at 37 °C in a fully humidified atmosphere containing 5% 
CO2. 
 112 
 
 
3.9. Whole-Cell Lysate GSK-3β Assay 
The assay procedure was followed as described.65 SH-SY5Y cells were washed with 
phosphate buffered saline (PBS) and lysed with cell extraction buffer containing 10 mM Tris, pH 
7.4, 100 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM NaF, 20 mM Na4P2O7, 2 mM Na3VO4, 1% 
Triton X-100, 10% glycerol, 0.1% sodium dodecyl sulfate (SDS), 0.5% sodium deoxycholate, 1 
mM phenylmethanesulfonyl fluoride (PMSF) and a protease inhibitor cocktail. Lysate was diluted 
with kinase buffer (40 mM Tris, pH 7.5, 20 mM MgCl2, 50 μM DTT, 400 μM ATP) to afford a 
concentration of 5 μg/μL of total protein, and split into aliquots. Recombinant human GSK-3β was 
fortified into lysate aliquots to a final concentration of 0.25% (wt/wt) of total protein. A lysate 
aliquot fortified with heat-inactivated GSK-3β was used as a negative control. The fortified lysate 
aliquots were incubated with test sample or 5% DMSO vehicle at 37 °C for 2 h followed by ELISA 
analysis. The GSK-3β inhibitor TDZD-8 was used at 10 μM as a reference control. 
3.10. Western Blot Analysis 
SH-SY5Y cells were seeded at a density of 3 × 105 cells/mL in a 24-well plate in DMEM/F12 
media containing 1% FBS. Cells were pretreated with different concentrations of test samples or 
the 0.2% DMSO vehicle for 1 h followed by co-incubation with 10 μM Aβ42 for 72 h. The cultures 
were then washed with PBS and lysed with phosphate protein extraction buffer (20 mM Na4P2O7, 
pH 7.4, 115 mM NaCl) containing 1 mM PMSF and a protease inhibitor cocktail. Concentrations 
of the harvested proteins were determined by Bradford assay. Equal amounts of total proteins for 
each sample (10 μg per lane) were resolved by 10% SDS-PAGE and transferred onto PVDF 
membranes. The membranes were blocked with 5% BSA overnight and hybridized with primary 
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antibodies against Tau-5 (total tau), Tau pS199/pS202, Tau pS396, GSK-3β (total GSK-3β), GSK-
3β pS9 or β-actin (loading control) at room temperature for 2 h. After washes, the membranes were 
incubated with corresponding alkaline phosphatase-conjugated secondary antibodies at room 
temperature for 1 h, and the immunoreactive bands were detected by the BCIP/NBT reagent. 
Densitometric analysis was performed on three independent blots per experiment. 
3.11. Human Tau pS396 ELISA 
The quantitative determination of phosphorylated human tau at GSK-3β specific pS396 site 
was conducted by taking 50 μL diluted cell lysate and using a specific antibody against human tau 
[pS396] in a sandwich ELISA according to the manufacturer’s protocol. Tau phosphorylation was 
quantified by measuring the absorbance at 450 nm in a microtiter plate reader. The analysis was 
collected in quadruplicate of two independent experiments. 
3.12. Aβ42 Oligomer Preparation 
The toxic oligomers of Aβ42 were prepared as described.65 Briefly, lyophilized Aβ42 peptide 
was dissolved in hexafluoroisopropanol, dried under vacuum, and stored at -20 °C. Immediately 
prior to use, the peptide residue was reconstituted in DMEM/F12 media to make a stock solution 
at 0.1 mM and incubated at 4 °C for 24 h to form diffusible oligomers. Aβ42 oligomers at a final 
concentration of 10 μM were assayed for cell viability. 
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3.13. Anti-Aβ42 Neurotoxicity Assay 
SH-SY5Y cells were seeded at a density of 3 × 105 cells/mL in a 96-well plate in DMEM/F12 
media containing 10 μM retinoic acid and 1% FBS to induce postmitotic differentiation. Cells were 
incubated under regular culture conditions for attachment. After 24 h of plating, the cells were 
pretreated with different concentrations of test samples or the 0.2% DMSO as a vehicle control for 
1 h and then co-incubated with 10 μM Aβ42 for 72 h. After the experimental treatment, the cells 
were subject to a CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay according to 
the manufacturer’s instruction. Staurosporine at 1 μM was used as a reference control for 
cytotoxicity, while 10 μM TDZD-8 was used as a reference control for GSK-3β inhibition. Each 
data point was collected in triplicate of two independent experiments. Colorimetric intensity of 
nontreated control cells in the MTS assay was normalized as 100% cell viability and that of solvent 
blank without cell culture was normalized as 0% cell viability. 
Neuroprotection was presented as the percentage of the cell viability relative to control (100%) 
and 10 μM Aβ42 treatment (0%). Neuroprotection curve was analyzed by four-parameter 
regression. 
3.14. PAMPA Studies 
A 96-well filter plate with 0.45 μm polyvinylidene fluoride (PVDF) membrane was precoated 
with trilayer phospholipids. Then 300 μL of sample solutions (20 μM) in 5% DMSO-PBS at pH 
7.4 were added to the donor wells. The acceptor plate containing 200 μL 5% DMSO-PBS was then 
placed on top of the donor plate so that the artificial membrane was in contact with the solution 
below. The PAMPA system was covered with a lid and incubated for 5 h at room temperature. The 
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concentration of compound in the donor and acceptor wells was quantified by LC-ESI-QTOF-MS. 
Theophylline and atenolol known for their low permeability were used as negative controls, and 
desipramine known for its high permeability was used as a positive control. Samples were run in 
quadruplicate. Pe values and R% were calculated according to the manufacturer’s instruction. 
3.15. Molecular Docking Studies 
Compounds of interest were docked with AutoDock Vina 1.1.2133-134 using the X-ray 
crystallographic structures of GSK-3β (PDB codes 1PYX97 and 1H8F137). To streamline the 
docking process, the PDB crystallographic structures were treated without water molecules 
according to the published GSK-3β docking protocols,40, 94, 118, 134 although the explicit hydration 
effect of water molecules is known to affect the binding of small molecules to GSK-3β.139 Proteins 
were prepared by adding polar hydrogens and Gasteiger charges using AutoDockTools.134 The 
molecular model of ligands were drawn using ChemBioDraw Ultra 12.0 (PerkinElmer Inc.) and 
constructed in the ChemBio3D interface. Ligands were optimized for their energy and geometry 
using MMFF94 and AM1 force fields prior to docking as described.196 All bonds of ligands were 
treated as rotatable except for the aromatic, alkenyl, carbonyl bonds and rings. The dimensions of 
the grid map were 30 × 30 × 30 points with a grid-point spacing of 1 Å. Docking was proceeded 
with an exhaustiveness value of 500 and a maximum output of 100 structures. Details for the 
docking method validation was elaborated in Appendix 10. Re-docking experiments were 
conducted using the ligands ANP and HEPES for 1PYX and 1H8F, respectively. ANP showed a 
binding pose at the ATP site of GSK-3β (PDB code 1PYX) with a RMSD of 0.33 Å as compared 
to its original crystal structure. HEPES showed a binding pose at the substrate site of GSK-3β 
(PDB code 1H8F) with a RMSD of 0.62 Å as compared to its original crystal structure. 
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AutoDockTools134 was used to analyze the docking data of compounds of interest on molecular 
interactions including hydrogen bonds, hydrophobic contact, π-cation interactions, π-π interactions, 
and multipolar interactions. 
3.16. Homology Modeling 
The GSK-3α homology model was built with the SWISS-MODEL server.146 The full sequence 
of human GSK-3α (UniProt code P49840) was obtained from the Universal Protein Resource. The 
target sequence was searched against BLAST and HHblits databases for evolutionary related 
protein structures. A total of 4470 templates were found. For each identified template, the 
template’s quality was predicted from features of the target-template alignment. A template of the 
GSK-3β structure (PDB code 1PYX) showing the highest quality (sequence identity, 82.97%) in 
the template ranking was selected for model building. The model was built based on the target-
template alignment using ProMod3. Coordinates that are conserved between the target and the 
template were copied from the template to the model. Insertions and deletions were remodeled 
using a fragment library. Side chains were then rebuilt. Finally, the geometry and energy 
minimization of the resulting model was performed using the OpenMM molecular mechanics force 
field. The model quality assessment was performed based on the global and per-residue model 
quality using the QMEAN scoring function (see Appendix 14). 
3.17. SH-SY5Y Cell Culture with Aβ42 Challenge for Proteomics 
SH-SY5Y cells were seeded at a density of 3 × 105 cells/mL on poly-L-lysine plates in 
DMEM/F12 media containing 2 mM glutamine, 10 μM retinoic acid and 1% FBS to induce 
postmitotic differentiation. Cells were incubated under regular culture conditions for attachment. 
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After 24 h of plating, the cells were co-incubated with 1 μM Aβ42 for additional 72 h at 37 °C in a 
fully humidified atmosphere containing 5% CO2. 
3.18. Cell Lysis and Protein Extraction 
SH-SY5Y cells were washed with phosphate buffered saline (PBS) and lysed with cell 
extraction buffer containing 10 mM Tris, pH 7.4, 100 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1 
mM NaF, 20 mM Na4P2O7, 2 mM Na3VO4, 1% Triton X-100, 10% glycerol, 0.1% sodium dodecyl 
sulfate (SDS), 0.5% sodium deoxycholate, 1 mM phenylmethanesulfonyl fluoride (PMSF) and a 
protease inhibitor cocktail. Lysates were centrifuged for 15 min at 13,000 rpm and 4 °C. 
Supernatant was transferred to a clean tube. Lysis buffer of supernatant was exchanged to binding 
buffer (PBS, pH 7.4, with 1 mM PMSF and a protease inhibitor cocktail) using an Amicon Ultra-
4 mL 3K MWCO centrifugal filter device (Millipore, Burlington, MA). Concentrations of the 
harvested proteins were determined by Bradford assay. The protein sample was stored at -80 °C.  
3.19. C-Glycosylflavone Coupling with EAH Sepharose-4B Resins 
EAH Sepharose-4B resin contains a covalent linkage of 1,6-diaminohexane to agarose (4 % 
agarose, 45-165 μm, exclusion limit 20,000 kDa), which has reactive primary amine groups at the 
end of 11-atom spacer arms. EAH Sepharose-4B resins are used to couple ligands containing 
carboxyl groups with the carbodiimide coupling method. 
To a solution of the synthetic compound 6 (50 mg, 0.1 mmol) in acidic distilled water (4 mL, 
pH 4.5) was added with the EAH-4B matrix in a matrix-ligand solution ratio of 1:0.5. Excess of 
EDCI (1.9 g, 10 mmol) was added to the matrix suspension to a final concentration of 0.1 M at pH 
4.5-5.0. The mixture was rotated end-over-end for 48 h at 4 °C. After coupling, the product was 
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thoroughly washed in sequence with 0.1 M sodium acetate buffer pH 4.0 containing 0.5 M NaCl, 
0.1 M Tris-HCl buffer pH 8.5 containing 0.5 M NaCl, and distilled water pH 7.5. The product 
matrix was stored at 2-8 °C. 
3.20. C-Glycosylflavone-Probe Affinity Pulldown Assay 
A 1.5 × 10 cm chromatography column was packed with 2 ml of ligand-tag resin (binding 
capacity: 1 ml of the ligand-tag resin can bind 7-12 mg/ml of target proteins). The column was 
equilibrated with 12 ml of binding buffer (PBS, pH 7.4, with 1 mM PMSF and a protease inhibitor 
cocktail). 2 ml of protein sample (10 mg/mL of total protein) was added carefully to the column 
without disturbing the surface of the packing resins, and affinity chromatography was proceeded 
at 4 °C. For competitive affinity assay, 2 ml of protein sample (10 mg/mL of total protein) 
containing varied concentrations of free ligands was added to the column. To maximize binding 
capacity, the column was connected to a peristaltic pump to circulate the protein sample where 
eluates passed through the resin bed were reloaded to column. After 24 h, the resins were washed 
with 12 ml of binding buffer. 
The bound proteins were eluted by applying 12 mL of elution buffer (0.1 M glycine-HCl, pH 
2.5-3.0, 1 mM PMSF, and a protease inhibitor cocktail). The resulting eluate was collected and 
neutralized by adding 50 μL of neutralization buffer (1 M Tris-HCl, pH 8.5) per 1 mL of collected 
eluate. The resulting buffer was exchanged to 1 M triethylammonium bicarbonate (TEAB) buffer, 
pH 8.5, using an Amicon Ultra-4 mL 3K MWCO centrifugal filter device (Millipore, Burlington, 
MA). The eluate sample was concentrated to 250 μL and stored at -80 °C.  
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The column containing ligand-tag resins was regenerated by washing in sequence with 12 ml 
of distilled water, 12 ml of 0.1 M Tris-HCl (pH 8.5) containing 0.5 M NaCl, and 12 mL of binding 
buffer. The ligand-tag resins were stored at 2-8 °C in presence of 20% ethanol. 
3.21. SDS-PAGE Analysis 
The lysate eluates from affinity chromatography were resolved by 10-12% SDS-PAGE. A 
mixture of standard proteins (bovine thyroglobulin, IgA, IgG, GSK-3β, ovalbumin, myoglobin) 
was used to validate the binding specificity of the CFG-tag resins. Concentrations of the protein 
samples were determined by Bradford assay. Equal amounts of total proteins for each sample (10 
μg per lane) were resolved by SDS-PAGE with a MiniProtean apparatus (Bio-Rad, Hercules, CA). 
The gel was stained with Bio-Safe Coomassie Stain according to the Bio-Rad protocol. 
Densitometric analysis was performed in triplicate. 
3.22. Tryptic Digestion of Proteins 
For in-solution digest, 100 μg of each protein sample were transferred to new tubes and 
volume was adjusted to 80 μL with TEAB buffer, pH 8.5. Proteins were denatured and reduced 
using 0.05% v/v SDS and 5 mM tris(2-carboxyethyl)phosphine (TCEP) and incubated at 60 °C for 
1 h. Cysteine residues were alkylated with 10 mM methylmethanethiosulfate (MMTS) for 10 min 
at room temperature. Proteins were subjected to in-solution digestion by adding 5 μg of the mass 
spec grade Trypsin/Lys-C (protein:(Trypsin/Lys-C) ratio of 20:1) mix resuspended in TEAB 
buffer, pH 8.5, and incubated at 37 °C for 16 h. 
For in-gel digest, the target protein band was cut and chopped into pieces (about 1 mm3) and 
transferred to a microcentrifuge tube. The gel pieces were destained with 25 mM NH4HCO3 in 50% 
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acetonitrile and dried completely in a speed-vacuum at 45 °C. Proteins in gel were denatured and 
reduced with 10 mM DTT at 56 °C for 30 min. Cysteine residues were alkylated with 55 mM 
iodoacetamide (IAA) for 30 min in the dark at room temperature. The gel pieces were dehydrated 
with 100% acetonitrile at 37 °C until becoming an opaque-white color and shrink, then dried 
completely in a speed-vacuum. Proteins were subjected to in-gel digestion by adding 5 μg of the 
mass spec grade Trypsin/Lys-C (protein:(Trypsin/Lys-C) ratio of 20:1) mix resuspended in 25 mM 
NH4HCO3 buffer, pH 8.5, and incubated at 37 °C for 16 h. The digested peptides were extracted 
with 50% acetonitrile in 5% formic acid aqueous solution and transferred to a new tube. Sample 
was desalted with C18 ZipTip prior to LC-MS analysis. 
3.23. iTRAQ Labeling of the Tryptic Peptides 
Labeling was performed using iTRAQ Reagent-8plex kit (reporter ions 113, 114, 115, 116, 
117, 118, 119, and 121) according to the manufacturer’s protocol. iTRAQ reagents resuspended 
in 50 μL of isopropanol were reacted with the digested protein samples in TEAB buffer, pH 8.5, 
for 3 h at room temperature. The iTRAQ labels 113-114 were used on the control samples whose 
proteins were from the affinity chromatography with no-tag resins; labels 115-116 were used on 
the samples whose proteins were from the affinity chromatography with CGF-tag resins; labels 
117-118 were used on the samples whose proteins were from the low-dose competitive affinity 
chromatography (50 μM free ligand 13) with CGF-tag resins; and labels 119-121 were used on the 
samples whose proteins were from the high-dose competitive affinity chromatography (100 μM 
free ligand 13) with CGF-tag resins. After labeling, samples were pooled together in TEAB buffer. 
Samples were stored at -80 °C. Samples were desalted and cleaned up using C18 ZipTip prior to 
LC-MS proteomics analysis. 
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3.24. Nano-UPLC-ESI-MS/MS Analysis for Proteomics 
An nano-Advance UHPLC coupled to a maXis Impact QTOF mass spectrometer (Bruker, 
Billerica, MA) equipped with a CaptiveSpray source. The digested peptide mixtures were eluted 
on a ProntoSIL C18AQ column (0.1 × 150 mm, 3 μm, 200 Å pore size) with a linear gradient over 
80 min from 5 to 45% aqueous acetonitrile containing 0.1% formic acid, flow rate of 500 nL/min. 
Samples were measured in auto MS/MS mode, a mass range of m/z 50-2200 with a fixed cycle 
time of 3 s. Acquisition speed was 2 Hz in MS and 4 or 16 Hz in MS/MS mode depending on 
precursor intensity. Precursors were selected in the m/z 300-2200 range with charge states at 2-5 
(singly charge ions were excluded). Active exclusion was activated after 1 spectrum for 2 min. 
The collision energy was adjusted between 23–65 eV as a function of the m/z value. Data were 
collected in three technical replicates per sample. 
3.25. Protein Identification and Quantification 
Raw MS data were converted into peak list files in xml or mascot generic file (mgf) format 
using Daltonics DataAnalysis software 4.2 (Bruker, Billerica, MA). Peak lists were submitted to 
ProteinScape version 3.2 (Bruker, Billerica, MA) and searched against the SwissProt database with 
MASCOT 2.3 server (Matrix Science, London, UK). Search parameters were set as followed the 
Bruker’s proteomics application manual: the peptide and MS/MS tolerance were set to 10 ppm 
and 0.06 Da, respectively; trypsin was set as the cleaving enzyme and two missed cleavages were 
allowed; methylthio (C) and iTRAQ-8plex (K and N-term) were set as fixed modifications, and 
oxidation (M) and iTRAQ-8plex (Y) were set as variable modifications; the peptide decoy and 
percolator strategies were applied to evaluate the database search results; the significance value 
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was set at p < 0.05 for protein identification, and the false discovery rate (FDR) for peptide 
identification was set at 1%; proteins with a Mascot score ≥ 13 and peptides with a Mascot score 
≥ 13 were accepted. 
Quantification ratios were obtained using WARP-LC (Bruker, Billerica, MA). Combinations 
of iTRAQ ratios were calculated for the accepted proteins (114/113, 115/113, 116/113, 117/113, 
118/113, 119/113, 121/113, 115/114, 116/114, 117/114, 118/114, 119/114, and 121/114). The 
median of all ratios was calculated for each protein and a stringent 2.5-fold cutoff to avoid false 
positives was applied to differentiate between the specific and nonspecific binding proteins 
according to the described procedure.62 
3.26. Molecular Interaction Networks Analysis 
Molecular interaction networks and biological pathways were visualized, integrated, and 
analyzed with open source software platforms Cytoscape 3.6170 and STRING 10.5171.  
3.27. Statistical Analysis 
Data were presented as the mean ± SEM or ± SD. The data were analyzed by one-way 
ANOVA with Bonferroni’s multiple comparison test, Tukey’s multiple comparison posthoc test, 
as well as Student’s t test. The p values less than 0.05 were considered statistically significant. 
Analyses were performed using Excel and GraphPad Prism. 
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APPENDICES 
Appendix 1. Proposed fragmentations of (A) 1 and (B) 2 in tandem mass spectrometry (ESI-
CID-MS/MS) 
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Appendix 2. GSK3β specific inhibition of 1 that is insensitive to the detergent Triton X-100 
 
 
 
GSK3β was assayed in the presence of 224 μM 1 with increasing concentrations of Triton X-
100 (v/v 0%, 0.001%, 0.01% and 0.05%). Luteolin (IC50, 2 μM; assay concentration, 25 μM) and 
staurosporine (IC50, 2 nM; assay concentration, 1 μM) were used as reference controls for 
promiscuous aggregations. Data were means of quadruplicate of each of two independent 
experiments with ± SEM. 
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Appendix 3. CS fractions with GSK3β inhibition alleviate neurotoxicity induced by Aβ42 in SH-
SY5Y cells 
 
 
 
Cells were pretreated with 100 μg/mL of CS fractions or 0.2% DMSO vehicle for 1 h followed 
by 10 μM Aβ42 treatment and incubated for 72 h. Results were presented as the percentage of the 
cell viability relative to control. Data were means of triplicate of each of two independent 
experiments with ± SEM. ####p < 0.0001 relative to vehicle control; ****p < 0.0001 relative to the 
10 μM Aβ42 treatment. 
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Appendix 4. HPLC chromatogram of CS fractions 
 
 
 
(A) HPLC chromatogram of fraction CS-EA-F. Numbers 1 to 5 correspond to collection 
windows for subfractions CS-EA-F-1 through CS-EA-F-5. (B) HPLC chromatogram of fraction 
CS-EA-F-2 (1) after purification. (C) HPLC chromatogram of fraction CS-EA-F-3 (2) after 
purification. 
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Appendix 5. Mass spectrometry spectra of 1 
 
 
 
(A) MS1 spectrum. (B) CID-MS/MS spectrum 
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Appendix 6. Mass spectrometry spectra of 2 
 
 
 
(A) MS1 spectrum. (B) CID-MS/MS spectrum. 
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Appendix 7. 1H NMR spectrum of 1 (from fraction CS-EA-F-2, > 95% purity) in DMSO-d6 
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Appendix 8. 13C NMR spectrum of 1 (from fraction CS-EA-F-2, > 95% purity) in DMSO-d6 
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Appendix 9. 1H NMR spectrum of 2 (from fraction CS-EA-F-3, > 95% purity) in DMSO-d6 
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Appendix 10. Docking Method Validation by Re-docking and Cross-docking Experiments with 
Known GSK-3β Inhibitors 
 
We chose two X-ray crystallographic structures of GSK-3β (PDB codes 1PYX97 and 
1H8F137). The docking method was validated by re-docking and cross-docking experiments using 
both ATP-competitive and substrate-competitive inhibitors.  
Re-docking the native ligand ANP to 1PYX resulted in a binding pose at the ATP site of GSK-
3β with a RMSD of 0.33 Å as compared to its original crystal structure.97 Under the same 
parameters, docking with the known ATP-competitive inhibitors, staurosporine and luteolin, led to 
the binding to the ATP site of GSK-3β, of which the binding poses and positions are similar to the 
reported data.97, 197 The ligands HEPES, manzamine A and isoorientin are known GSK-3β 
inhibitors bound to the substrate site. Docking these ligands to 1PYX confirmed their binding to 
the substrate site, and the predicted poses are comparable to the reported data.65, 96, 137 Cross-
docking of the same ligands to the 1H8F demonstrated that ANP, staurosporine, and luteolin reside 
the ATP site of GSK-3β, whereas HEPES, manzamine A, and isoorientin are in the substrate site. 
Re-docking experiment using the native ligand HEPES of 1H8F resulted in a binding pose at the 
substrate site of GSK-3β with a RMSD of 0.62 Å as compared to its original crystal structure.137 
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Predicted docking poses of ANP (A), staurosporine (B), luteolin (C), HEPES (D), manzamine 
A (E), and isoorientin (F) in GSK-3β (PDB code 1PYX). Ligands in magenta color are original 
structures in X-ray crystallographic complex, ligands in green color are docking structures. 
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Predicted docking poses of ANP (A), staurosporine (B), luteolin (C), HEPES (D), manzamine 
A (E), and isoorientin (F) into GSK-3β (PDB code 1H8F). Ligands in magenta color are original 
structures in X-ray crystallographic complex, ligands in green color are docking structures. 
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Appendix 11. Inhibitions and Docking Scores of C-Glycosylflavones and Reference Inhibitors 
to GSK3β 
 
cmpd 
GSK3β 
inhibition 
Docking Score b: 
Affinity (-kcal/mol)  
 
cmpd 
GSK3β 
inhibition 
Docking Score b: 
Affinity (-kcal/mol) 
no. IC50 (μM) a 1PYX 1H8F  no. IC50 (μM) a 1PYX 1H8F 
1 184.9 ± 1.4 7.3 7.1  21 15.8 ± 1.2 8.4 8.4 
3 5153 ± 31 6.8 6.3  22 35.6 ± 1.3 8.1 8.4 
4 3.1 ± 1.3 8.3 8.2  23 35.1 ± 1.0 8.2 8.3 
5 239.2 ± 1.2 7.4 7.8  24 56.2 ± 1.2 8.5 8.6 
6 237.3 ± 1.4 7.3 7.6  25 21.7 ± 1.2 8.4 8.5 
7 135.0 ± 1.3 7.6 7.8  26 34.8 ± 1.0 7.8 7.9 
8 29.2 ± 1.1 7.7 7.9  27 19.3 ± 0.8 8.2 8.0 
9 5.4 ± 0.1 8.3 8.3  28 49.5 ± 1.2 7.3 7.7 
10 33.3 ± 1.1 7.9 7.9  29 17.2 ± 0.9 8.2 7.9 
11 31.1 ± 1.2 7.8 8.0  30 0.59 ± 0.04 9.1 8.9 
12 28.0 ± 1.1 8.0 7.8  31 2.3 ± 0.5 8.7 8.5 
13 9.4 ± 0.9 8.4 7.8  Staurosporine 0.0023 ± 0.0006 10.2 10.0 
14 25.8 ± 1.1 7.6 8.0  Manzamine A 10.2 c 9.0 8.9 
15 61.9 ± 1.2 7.4 8.1  ANP n/a 9.7 9.3 
16 13.1 ± 1.1 7.7 8.4  HEPES n/a 4.4 4.5 
17 9.0 ± 1.3 8.3 8.4      
18 26.0 ± 1.2 8.1 8.4      
19 33.5 ± 0.8 8.4 8.8      
20 19.7 ± 1.1 8.4 8.4      
a IC50 values were the mean of quadruplicate of each of two independent experiments. 
bDocking scores were binding affinities calculated by AutoDock Vina. c IC50 value from ref 198. 
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Linear plots of pIC50 (-LogIC50) versus calculated binding affinity (PDB codes 1PYX and 
1H8F) for GSK-3β inhibitors 
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Appendix 12. Predicted Docking Poses of Flavones with GSK-3β (PDB Code 1PYX) 
 
Docking poses of flavones 1 (A), 9 (B), 17 (C), 21 (D), 3 (E), and 4 (F) with GSK-3β (PDB 
code 1PYX). Surface representation of the ATP site of GSK-3β is shown in orange, the substrate 
site of GSK-3β is shown in green. Within the substrate site, surface features are shown with acidic 
residues in red, basic residues in blue, and hydrophobic residues in green. Mg2+ ions are shown as 
bright green spheres. The dotted lines represent interactions with Mg2+ ions and hydrogen bonds 
with side chain residues of GSK-3β. 
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Appendix 13. Summary of Molecular Interaction Distances of Compound 30 with GSK3β (PDB 
Code 1PYX) in Molecular Docking 
 
Interaction type Interaction residue Distance (Å) 
Hydrogen bonds Carbonyl O···HN (Phe67) 
Methoxy O···HN (Lys183) 
Glycone HO···HN (Leu88) 
Glycone HO···HN (Asn95) 
Glycone OH···O=C (Leu88) 
Glycone OH···O=C (Gln89) 
Glycone OH···O=C (Glu97) 
Glycone OH···O=C (Gly202) 
2.3 
3.1, 3.2 
3.4 
1.8, 2.6 
2.8 
3.2 
2.8 
2.5 
Hydrophobic interactions Isopropyl Me    (Phe67) 
Methoxy Me     (Val87) 
Isopropyl CF3   (Leu88) 
 
π-cation interaction Catechol B-ring···NH3+ (Lys183) 4.1 (angle 71.5°) 
Orthogonal multipolar interactions  Isopropyl F···C=O (Leu88) 
Isopropyl F···C=O (Gln89) 
Isopropyl F···C=O (Asp90) 
3.3 
3.6 
3.3, 3.8 
Fluorine polar interaction Isopropyl F···HN (Asp90) 2.6 
 
139 
 
139 
 
Appendix 14. GSK-3α Homology Modeling Method 
  
The SWISS-MODEL146 template library (SMTL version 2017-09-21, PDB release 2017-09-
15) was searched with BLAST and HHBlits for evolutionary related structures matching the target 
sequence GSK-3α (UniProt Code P49840). For each identified template, the template's quality has 
been predicted from features of the target-template alignment. The templates with the highest 
quality have then been selected for model building. Overall 4470 templates were found to match 
the target sequence. The top templates are: 
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The GSK-3α homology model was built based on the GSK-3β template PDB code 1PYX: 
Template Sequence 
identity 
Oligo-
state 
Found 
by 
Method Resolution Sequence 
similarity 
Range Coverage Description 
1pyx.1.A 82.97 homodimer BLAST X-ray 2.40 Å 0.55 98‒
449 
0.77 GSK-3β 
Built 
with 
Oligo-
State 
Ligands GMQE  QMEAN      
ProMod3 
Version 
1.0.2. 
monomer Mg2+ ion 0.72 -0.90      
 
Model Quality Estimation: 
The global and per-residue model quality has been assessed using the QMEAN scoring function. 
For improved performance, weights of the individual QMEAN terms have been trained 
specifically for SWISS-MODEL. 
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Appendix 15. Protein Sequence Alignment Between Human GSK-3α (UniProt Code P49840) 
and Human GSK-3β (PDB Code 1PYX) 
 
Identical residues are unpainted, nonidentical residues are yellow highlighted, unmatched 
residues are green highlighted; key residues comprised of ATP site are colored in red, key residues 
comprised of substrate site are colored in blue. It is obvious that the kinase catalytic domain 
comprised of both ATP and substrate pocket sequences (D121-H208 and C241-L270 in GSK-3α; 
D58-H145 and C178-L207 in GSK-3β) are conserved as high as 93% identical. Only nine amino 
acid residues are nonidentical in these regions between two isoforms. 
 
 
P49840_hGSK3A 
1PYX_hGSK3B 
MSGGGPSGGGPGGSGRARTSSFAEPGGGGGGGGGGPGGSASGPGGTGGGKASVGAMGGGV 
------------------------------------------------------------ 
60 
P49840_hGSK3A 
1PYX_hGSK3B 
GASSSGGGPGGSGGGGSGGPGAGTSFPPPGVKLGRDSGKVTTVVATLGQGPERSQEVAYT 
------------------------------VSRDKDGSKVTTVVATPGQGPDRPQEVSYT 
120 
57 
P49840_hGSK3A 
1PYX_hGSK3B 
DIKVIGNGSFGVVYQARLAETRELVAIKKVLQDKRFKNRELQIMRKLDHCNIVRLRYFFY 
DTKVIGNGSFGVVYQAKLCDSGELVAIKKVLQDKRFKNRELQIMRKLDHCNIVRLRYFFY 
180 
117 
P49840_hGSK3A 
1PYX_hGSK3B 
SSGEKKDELYLNLVLEYVPETVYRVARHFTKAKLTIPILYVKVYMYQLFRSLAYIHSQGV 
SSGEKKDEVYLNLVLDYVPETVYRVARHYSRAKQTLPVIYVKLYMYQLFRSLAYIHSFGI 
240 
177 
P49840_hGSK3A 
1PYX_hGSK3B 
CHRDIKPQNLLVDPDTAVLKLCDFGSAKQLVRGEPNVSYICSRYYRAPELIFGATDYTSS 
CHRDIKPQNLLLDPDTAVLKLCDFGSAKQLVRGEPNVSYICSRYYRAPELIFGATDYTSS 
300 
237 
P49840_hGSK3A 
1PYX_hGSK3B 
IDVWSAGCVLAELLLGQPIFPGDSGVDQLVEIIKVLGTPTREQIREMNPNYTEFKFPQIK 
IDVWSAGCVLAELLLGQPIFPGDSGVDQLVEIIKVLGTPTREQIREMNPNYTEFKFPQIK 
360 
297 
P49840_hGSK3A 
1PYX_hGSK3B 
AHPWTKVFKSRTPPEAIALCSSLLEYTPSSRLSPLEACAHSFFDELRCLGTQLPNNRPLP 
AHPWTKVFRPRTPPEAIALCSRLLEYTPTARLTPLEACAHSFFDELRDPNVKLPNGRDTP 
420 
357 
P49840_hGSK3A 
1PYX_hGSK3B 
PLFNFSAGELSIQPSLNAILIPPHLRSPAGTTTLTPSSQALTETPTSSDWQSTDATPTLT 
ALFNFTTQELSSNPPLATILIPPHARIQAAASTPTNATAA-------------------- 
480 
397 
P49840_hGSK3A 
1PYX_hGSK3B 
NSS 
--- 
483 
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Appendix 16. HPLC Analysis for Purity Determination of Compounds 5-31a 
 
The purity of compounds 5-31 was determined by analytical reverse phase Agilent HPLC with 
a diode array detector (Waters XSELECT CSH Fluoro-Phenyl column, 150 × 4.6 mm, 3.5 μm, 
isocratic elution with 35% aqueous acetonitrile containing 0.1% formic acid for over 20 min, 
detection at 210 nm, flow rate of 0.8 mL/min). All tested compounds were over 95% purity. 
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Appendix 17. In Vitro Kinase Selectivity Screening for Compound 30 
 
The Kinase Selectivity Profiling System includes kinase and substrate pairs. Percentage kinase 
activities upon treatment of compound 30 at 5 μM in a panel of human protein kinases were 
measured by the ADP-Glo Kinase Assay Kit according to the manufacturer’s protocol. The kinase 
inhibitor staurosporine was used at 1 μM as a reference control. Each data point was collected in 
quadruplicate of two independent experiments. 
Assay Kinase Substrate/Co-Factor Kinase Activity (%) 
ERK2 MBP 101.3 
GSK3α GSK3 Substrate 92.5 
GSK3β GSK3 Substrate 7.7 
JNK1 p38 Substrate 101.4 
JNK3 p38 Substrate 74.5 
p38α p38 Substrate 71.1 
p38β p38 Substrate 75.2 
p38δ p38 Substrate 71.2 
p38γ p38 Substrate 77.5 
CDK1/CyclinA2 Histone H1 Protein 55.1 
CDK2/CyclinE1 Histone H1 Protein 77.5 
CDK3/CyclinE1 Histone H1 Protein 70.4 
CDK5/p25 Histone H1 Protein 101.3 
CDK5/p35 Histone H1 Protein 95.5 
CDK6/CyclinD3 Histone H1 Protein 70.1 
CDK9/CyclinK PDKtide 98.7 
CLK3 MBP 88.5 
AKT1 AKT (PKB) Substrate 85.5 
p70S6Kβ RSK Substrate 74.3 
PDK1 PDKtide 62.3 
PKA Kemptide 94.5 
PKC Neurogranin Peptide Substrate 91.8 
PRKG1 RSK Substrate 71.5 
ROCK1 S6K Substrate 90.8 
RSK2 RSK Substrate 91.3 
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AMPK A1/B1/G1 SAMStide 97.6 
AMPK A1/B1/G2 SAMStide 108.1 
AMPK A2/B1/G1 SAMStide 84.7 
CAMK2α Autocamtide-2 75.9 
CAMK2γ Autocamtide-2 94.9 
CAMK4 Autocamtide-2 92.8 
DAPK1 MBP 77.2 
STK33 MBP 72.0 
Aurora A MBP 89.2 
Aurora B MBP 65.4 
CK2α1 Casein 105.0 
DNA-PK DNA-PK Peptide Substrate 103.4 
CK1α1 De-Phospho Casein 82.3 
CK1ε De-Phospho Casein 77.7 
CK1γ1 Casein 70.1 
VRK2 Casein 92.5 
 
 
 
149 
 
149 
 
Appendix 18. LC-MS Method for Determination of the PAMPA Permeability 
 
At the end of the incubation period, 10 μL sample from each donor and acceptor well was 
quantified by LC-ESI-QTOF-MS analysis under a positive mode and used a 7-point calibration 
with appropriate dilution of the samples. A sum of pseudo-molecular ions [M+H]+, [M+Na]+ and 
[M+K]+ for each target analyte was extracted from total ion chromatogram (TOC) for 
quantification. Samples were run in quadruplicate. 
 
Permeability of the compounds (Pe) were calculated using the following formula: 
Permeability (cm/s): Pe = {-ln[1‒CA(t)/Ceq]}/[A*(1/VD+1/VA)*t] 
where A = filter area (0.3 cm2), VD = donor well volume (0.3 mL), VA = acceptor well volume (0.2 
mL), t = incubation time (5 hours = 18000 seconds), CA(t) = compound concentration in acceptor 
well at time t, CD(t) = compound concentration in donor well at time t,  
Ceq = [CD(t)*VD+CA(t)*VA]/(VD+VA). 
 
Mass retention (R%) is calculated using the following formula: 
R% = {1‒[CD(t)*VD+CA(t)*VA]/(C0*VD)}*100 
where C0 is the initial compound concentration in donor well. 
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Appendix 19. Structures of the Reference Compounds 
 
 
 
 
 
 
 
 
 
 
Staurosporine
NN
H
N
O
O
NH
O
H
N
S
N
O
O
TDZD-8 Theophylline
N
H
N N O
N
O
Atenolol
O
NH2
O
OH
NH
Desipramine
N
HN
151 
 
151 
 
REFERENCES 
1. Querfurth, H. W.; LaFerla, F. M., Alzheimer's disease. N. Engl. J. Med. 2010, 362, 329-344. 
2. National Institutes of Health. https://www.nia.nih.gov/. 
3. Mangialasche, F.; Solomon, A.; Winblad, B.; Mecocci, P.; Kivipelto, M., Alzheimer's 
disease: Clinical trials and drug development. Lancet Neurol. 2010, 9, 702-716. 
4. Scheuner, D.; Eckman, C.; Jensen, M.; Song, X.; Citron, M.; Suzuki, N.; Bird, T. D.; Hardy, 
J.; Hutton, M.; Kukull, W.; Larson, E.; Levy-Lahad, L.; Viitanen, M.; Peskind, E.; Poorkaj, 
P.; Schellenberg, G.; Tanzi, R.; Wasco, W.; Lannfelt, L.; Selkoe, D.; Younkin, S., Secreted 
amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased 
in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. 
Nat. Med. 1996, 2, 864-870. 
5. Selkoe, D. J.; Hardy, J., The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO 
Mol. Med. 2016, 8, 595-608. 
6. Hong, M.; Zhukareva, V.; Vogelsberg-Ragaglia, V.; Wszolek, Z.; Reed, L.; Miller, B. I.; 
Geschwind, D. H.; Bird, T. D.; McKeel, D.; Goate, A.; Morris, J. C.; Wilhelmsen, K. C.; 
Schellenberg, G. D.; Trojanowski, J. Q.; Lee, V. M.-Y., Mutation-specific functional 
impairments in distinct tau isoforms of hereditary FTDP-17. Science 1998, 282, 1914-1917. 
7. Ballatore, C.; Lee, V. M. Y.; Trojanowski, J. Q., Tau-mediated neurodegeneration in 
Alzheimer's disease and related disorders. Nat. Rev. Neurosci. 2007, 8, 663-672. 
8. Corder, E. H.; Saunders, A. M.; Strittmatter, W. J.; Schmechel, D. E.; Gaskell, P. C.; Small, 
G. W.; Roses, A. D.; Haines, J. L.; Pericak-Vance, M. A., Gene dose of apolipoprotein E 
type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993, 261, 
921-923. 
9. Kim, J.; Basak, J. M.; Holtzman, D. M., The role of apolipoprotein E in Alzheimer's disease. 
Neuron 2009, 63, 287-303. 
10. Citron, M., Alzheimer's disease: Strategies for disease modification. Nat. Rev. Drug Discov. 
2010, 9, 387-398. 
11. Huang, Y.; Mucke, L., Alzheimer mechanisms and therapeutic strategies. Cell 2012, 148, 
1204-1222. 
152 
 
152 
 
12. Conde, C.; Caceres, A., Microtubule assembly, organization and dynamics in axons and 
dendrites. Nat. Rev. Neurosci. 2009, 10, 319-332. 
13. Goedert, M.; Spillantini, M. G.; Jakes, R.; Rutherford, D.; Crowther, R. A., Multiple 
isoforms of human microtubule-associated protein tau: Sequences and localization in 
neurofibrillary tangles of Alzheimer's disease. Neuron 1989, 3, 519-526. 
14. Himmler, A.; Drechsel, D.; Kirschner, M. W.; Martin, D. W., Tau consists of a set of proteins 
with repeated C-terminal microtubule-binding domains and variable N-terminal domains. 
Mol. Cell. Biol. 1989, 9, 1381-1388. 
15. Lee, V. M.-Y.; Goedert, M.; Trojanowski, J. Q., Neurodegenerative tauopathies. Annu. Rev. 
Neurosci. 2001, 24, 1121-1159. 
16. Brunden, K. R.; Trojanowski, J. Q.; Lee, V. M. Y., Advances in tau-focused drug discovery 
for Alzheimer's disease and related tauopathies. Nat. Rev. Drug Discov. 2009, 8, 783-793. 
17. Fitzpatrick, A. W. P.; Falcon, B.; He, S.; Murzin, A. G.; Murshudov, G.; Garringer, H. J.; 
Crowther, R. A.; Ghetti, B.; Goedert, M.; Scheres, S. H. W., Cryo-EM structures of tau 
filaments from Alzheimer’s disease. Nature 2017, 547, 185-190. 
18. Hoover, B. R.; Reed, M. N.; Su, J.; Penrod, R. D.; Kotilinek, L. A.; Grant, M. K.; Pitstick, 
R.; Carlson, G. A.; Lanier, L. M.; Yuan, L.-L.; Ashe, K. H.; Liao, D., Tau mislocalization to 
dendritic spines mediates synaptic dysfunction independently of neurodegeneration. Neuron 
2010, 68, 1067-1081. 
19. Morris, M.; Maeda, S.; Vossel, K.; Mucke, L., The many faces of tau. Neuron 2011, 70, 410-
426. 
20. Ittner, L. M.; Götz, J., Amyloid-β and tau - a toxic pas de deux in Alzheimer's disease. Nat. 
Rev. Neurosci. 2011, 12, 65-72. 
21. Bloom, G. S., Amyloid-β and tau: The trigger and bullet in Alzheimer disease pathogenesis. 
JAMA Neurology 2014, 71, 505-508. 
22. Holtzman, D. M.; Morris, J. C.; Goate, A. M., Alzheimer’s disease: The challenge of the 
second century. Sci. Transl. Med. 2011, 3, 77sr71. 
23. McDade, E.; Bateman, R. J., Stop Alzheimer’s before it starts. Nature 2017, 547, 153-155. 
24. Schneider, L. S.; Mangialasche, F.; Andreasen, N.; Feldman, H.; Giacobini, E.; Jones, R.; 
Mantua, V.; Mecocci, P.; Pani, L.; Winblad, B.; Kivipelto, M., Clinical trials and late-stage 
153 
 
153 
 
drug development for Alzheimer's disease: An appraisal from 1984 to 2014. J. Intern. Med. 
2014, 275, 251-283. 
25. Khanna, M. R.; Kovalevich, J.; Lee, V. M. Y.; Trojanowski, J. Q.; Brunden, K. R., 
Therapeutic strategies for the treatment of tauopathies: Hopes and challenges. Alzheimers 
Dement. 2016, 12, 1051-1065. 
26. Iqbal, K.; Liu, F.; Gong, C.-X., Tau and neurodegenerative disease: The story so far. Nat. 
Rev. Neurol. 2016, 12, 15-27. 
27. Reardon, S., Alzheimer antibody drugs show questionable potential. Nat. Rev. Drug Discov. 
2015, 14, 591-592. 
28. Honig, L. S.; Vellas, B.; Woodward, M.; Boada, M.; Bullock, R.; Borrie, M.; Hager, K.; 
Andreasen, N.; Scarpini, E.; Liu-Seifert, H.; Case, M.; Dean, R. A.; Hake, A.; Sundell, K.; 
Hoffmann, V. P.; Carlson, C.; Khanna, R.; Mintun, M.; DeMattos, R.; Selzler, K. J.; Siemers, 
E., Trial of solanezumab for mild dementia due to Alzheimer’s disease. N. Engl. J. Med. 
2018, 378, 321-330. 
29. Verma, A. K.; Pratap, R., The biological potential of flavones. Nat. Prod. Rep. 2010, 27, 
1571-1593. 
30. Singh, M.; Arseneault, M.; Sanderson, T.; Murthy, V.; Ramassamy, C., Challenges for 
research on polyphenols from foods in Alzheimer’s disease: Bioavailability, metabolism, 
and cellular and molecular mechanisms. J. Agric. Food Chem. 2008, 56, 4855-4873. 
31. Vauzour, D.; Vafeiadou, K.; Rodriguez-Mateos, A.; Rendeiro, C.; Spencer, J. E., The 
neuroprotective potential of flavonoids: A multiplicity of effects. Genes Nutr 2008, 3, 115-
126. 
32. Solanki, I.; Parihar, P.; Mansuri, M. L.; Parihar, M. S., Flavonoid-based therapies in the 
early management of neurodegenerative diseases. Adv. Nutr. 2015, 6, 64-72. 
33. Hwang, S.-L.; Shih, P.-H.; Yen, G.-C., Neuroprotective effects of citrus flavonoids. J. Agric. 
Food Chem. 2012, 60, 877-885. 
34. Anand, P.; Singh, B., Flavonoids as lead compounds modulating the enzyme targets in 
Alzheimer’s disease. Med. Chem. Res. 2013, 22, 3061-3075. 
35. Baptista, F. I.; Henriques, A. G.; Silva, A. M. S.; Wiltfang, J.; da Cruz e Silva, O. A. B., 
Flavonoids as therapeutic compounds targeting key proteins involved in Alzheimer’s 
disease. ACS Chem. Neurosci. 2014, 5, 83-92. 
154 
 
154 
 
36. Pietta, P.-G., Flavonoids as antioxidants. J. Nat. Prod. 2000, 63, 1035-1042. 
37. Heim, K. E.; Tagliaferro, A. R.; Bobilya, D. J., Flavonoid antioxidants: Chemistry, 
metabolism and structure-activity relationships. J. Nutr. Biochem. 2002, 13, 572-584. 
38. Xiao, J.; Capanoglu, E.; Jassbi, A. R.; Miron, A., Advance on the flavonoid C-glycosides 
and health benefits. Crit. Rev. Food Sci. Nutr. 2016, 56, S29-S45. 
39. Shapiro, G. I., Cyclin-dependent kinase pathways as targets for cancer treatment. J. Clin. 
Oncol. 2006, 24, 1770-1783. 
40. Nguyen, T. B.; Lozach, O.; Surpateanu, G.; Wang, Q.; Retailleau, P.; Iorga, B. I.; Meijer, L.; 
Guéritte, F., Synthesis, biological evaluation, and molecular modeling of natural and 
unnatural flavonoidal alkaloids, inhibitors of kinases. J. Med. Chem. 2012, 55, 2811-2819. 
41. Lies, B.; Martens, S.; Schmidt, S.; Boll, M.; Wenzel, U., Flavone potently stimulates an 
apical transporter for flavonoids in human intestinal Caco-2 cells. Mol. Nutr. Food Res. 
2012, 56, 1627-1635. 
42. Jesus, A. R.; Vila-Viçosa, D.; Machuqueiro, M.; Marques, A. P.; Dore, T. M.; Rauter, A. P., 
Targeting type 2 diabetes with C-glucosyl dihydrochalcones as selective sodium glucose co-
transporter 2 (SGLT2) inhibitors: Synthesis and biological evaluation. J. Med. Chem. 2017, 
60, 568-579. 
43. Li, Y.; Shi, Z.; Chen, L.; Zheng, S.; Li, S.; Xu, B.; Liu, Z.; Liu, J.; Deng, C.; Ye, F., Discovery 
of a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor 
(HSK0935) for the treatment of type 2 diabetes. J. Med. Chem. 2017, 60, 4173-4184. 
44. Clemons, P. A., Complex phenotypic assays in high-throughput screening. Curr. Opin. 
Chem. Biol. 2004, 8, 334-338. 
45. Prior, M.; Chiruta, C.; Currais, A.; Goldberg, J.; Ramsey, J.; Dargusch, R.; Maher, P. A.; 
Schubert, D., Back to the future with phenotypic screening. ACS Chem. Neurosci. 2014, 5, 
503-513. 
46. Mayr, L. M.; Bojanic, D., Novel trends in high-throughput screening. Curr. Opin. 
Pharmacol. 2009, 9, 580-588. 
47. Macarron, R.; Banks, M. N.; Bojanic, D.; Burns, D. J.; Cirovic, D. A.; Garyantes, T.; Green, 
D. V. S.; Hertzberg, R. P.; Janzen, W. P.; Paslay, J. W.; Schopfer, U.; Sittampalam, G. S., 
Impact of high-throughput screening in biomedical research. Nat. Rev. Drug Discov. 2011, 
10, 188-195. 
155 
 
155 
 
48. Williams, P.; Sorribas, A.; Liang, Z., New methods to explore marine resources for 
Alzheimer's therapeutics. Curr. Alzheimer Res. 2010, 7, 210-213. 
49. Rix, U.; Superti-Furga, G., Target profiling of small molecules by chemical proteomics. Nat. 
Chem. Biol. 2009, 5, 616-624. 
50. Schirle, M.; Bantscheff, M.; Kuster, B., Mass spectrometry-based proteomics in preclinical 
drug discovery. Chem. Biol. 2012, 19, 72-84. 
51. Sutton, C. W., The role of targeted chemical proteomics in pharmacology. Br. J. Pharmacol. 
2012, 166, 457-475. 
52. Yao, Z.; Petschnigg, J.; Ketteler, R.; Stagljar, I., Application guide for omics approaches to 
cell signaling. Nat. Chem. Biol. 2015, 11, 387-397. 
53. Wang, J.; Gao, L.; Lee, Y. M.; Kalesh, K. A.; Ong, Y. S.; Lim, J.; Jee, J.-E.; Sun, H.; Lee, S. 
S.; Hua, Z.-C.; Lin, Q., Target identification of natural and traditional medicines with 
quantitative chemical proteomics approaches. Pharmacol. Ther. 2016, 162, 10-22. 
54. Zhao, S.; Iyengar, R., Systems pharmacology: Network analysis to identify multiscale 
mechanisms of drug action. Annu. Rev. Pharmacol. Toxicol. 2012, 52, 505-521. 
55. Moulick, K.; Ahn, J. H.; Zong, H.; Rodina, A.; Cerchietti, L.; Gomes DaGama, E. M.; 
Caldas-Lopes, E.; Beebe, K.; Perna, F.; Hatzi, K.; Vu, L. P.; Zhao, X.; Zatorska, D.; Taldone, 
T.; Smith-Jones, P.; Alpaugh, M.; Gross, S. S.; Pillarsetty, N.; Ku, T.; Lewis, J. S.; Larson, 
S. M.; Levine, R.; Erdjument-Bromage, H.; Guzman, M. L.; Nimer, S. D.; Melnick, A.; 
Neckers, L.; Chiosis, G., Affinity-based proteomics reveal cancer-specific networks 
coordinated by Hsp90. Nat. Chem. Biol. 2011, 7, 818-826. 
56. Wright, M. H.; Sieber, S. A., Chemical proteomics approaches for identifying the cellular 
targets of natural products. Nat. Prod. Rep. 2016, 33, 681-708. 
57. Li, Q. X.; Casida, J. E., 1,3-Dithianes with acid functionalities: Potent inhibitors and 
candidate affinity probes for the GABA-gated chloride channel. Bioorg. Med. Chem. Lett. 
1993, 3, 2671-2674. 
58. Li, Q. X.; Casida, J. E., Structure-activity studies leading to potent chloride channel blockers: 
5e-tert-Butyl-2-[4-(substituted-ethynyl)phenyl]-1,3-dithianes. Bioorg. Med. Chem. 1994, 2, 
1423-1434. 
156 
 
156 
 
59. Li, Q. X.; Casida, J. E., Affinity probes for the GABA-gated chloride channel: Selection of 
5e-tert-butyl-2e-[4-(substituted-ethynyl)phenyl]-1,3-dithianes and optimization of linker 
moiety. Bioorg. Med. Chem. 1995, 3, 1667-1674. 
60. Li, Q. X.; Casida, J. E., Affinity probes for the GABA-gated chloride channel: 5e-tert-Butyl-
2e-[4-(substituted-ethynyl)phenyl]-1,3-dithianes with photoactivatable, fluorescent, biotin, 
agarose and protein substituents. Bioorg. Med. Chem. 1995, 3, 1675-1684. 
61. Ong, S.-E.; Blagoev, B.; Kratchmarova, I.; Kristensen, D. B.; Steen, H.; Pandey, A.; Mann, 
M., Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate 
approach to expression proteomics. Mol. Cell. Proteomics 2002, 1, 376-386. 
62. Unwin, R. D.; Griffiths, J. R.; Whetton, A. D., Simultaneous analysis of relative protein 
expression levels across multiple samples using iTRAQ isobaric tags with 2D nano LC-
MS/MS. Nat. Protoc. 2010, 5, 1574-1582. 
63. Hasanudin, K.; Hashim, P.; Mustafa, S., Corn silk (Stigma maydis) in healthcare: A 
phytochemical and pharmacological review. Molecules 2012, 17, 9697-9715. 
64. Casas, M. I.; Duarte, S. M.; Doseff, A. I.; Grotewold, E., Flavone-rich maize: An 
opportunity to improve the nutritional value of an important commodity crop. Front. Plant 
Sci. 2014, 5, 440. 
65. Liang, Z.; Zhang, B.; Su, W. W.; Williams, P. G.; Li, Q. X., C-Glycosylflavones alleviate 
tau phosphorylation and amyloid neurotoxicity through GSK3β inhibition. ACS Chem. 
Neurosci. 2016, 7, 912-923. 
66. Yuan, L.; Wang, J.; Xiao, H.; Xiao, C.; Wang, Y.; Liu, X., Isoorientin induces apoptosis 
through mitochondrial dysfunction and inhibition of PI3K/Akt signaling pathway in HepG2 
cancer cells. Toxicol. Appl. Pharmacol. 2012, 265, 83-92. 
67. Yuan, L.; Wu, Y.; Ren, X.; Liu, Q.; Wang, J.; Liu, X., Isoorientin attenuates 
lipopolysaccharide-induced pro-inflammatory responses through down-regulation of ROS-
related MAPK/NF-κB signaling pathway in BV-2 microglia. Mol. Cell. Biochem. 2014, 386, 
153-165. 
68. Yuan, L.; Han, X.; Li, W.; Ren, D.; Yang, X., Isoorientin prevents hyperlipidemia and liver 
injury by regulating lipid metabolism, antioxidant capability, and inflammatory cytokine 
release in high-fructose-fed mice. J. Agric. Food Chem. 2016, 64, 2682-2689. 
157 
 
157 
 
69. Song, Y.; Kim, H.-D.; Lee, M.-K.; Hong, I.-H.; Won, C.-K.; Bai, H.-W.; Lee, S. S.; Lee, S.; 
Chung, B. Y.; Cho, J.-H., Maysin and its flavonoid derivative from centipedegrass 
attenuates amyloid plaques by inducting humoral immune response with Th2 skewed 
cytokine response in the Tg (APPswe, PS1dE9) Alzheimer’s mouse model. PLoS ONE 2017, 
12, e0169509. 
70. Wang, C.; Zhang, T.; Liu, J.; Lu, S.; Zhang, C.; Wang, E.; Wang, Z.; Zhang, Y.; Liu, J., 
Subchronic toxicity study of corn silk with rats. J. Ethnopharmacol. 2011, 137, 36-43. 
71. Peng, K.-Z.; Zhang, S.-Y.; Zhou, H.-L., Toxicological evaluation of the flavonoid-rich 
extract from Maydis stigma: Subchronic toxicity and genotoxicity studies in mice. J. 
Ethnopharmacol. 2016, 192, 161-169. 
72. Anighoro, A.; Bajorath, J.; Rastelli, G., Polypharmacology: Challenges and opportunities in 
drug discovery. J. Med. Chem. 2014, 57, 7874-7887. 
73. Liang, Z.; Li, Q. X., Discovery of selective, substrate-competitive, and passive membrane 
permeable glycogen synthase kinase-3β inhibitors: Synthesis, biological evaluation, and 
molecular modeling of new C-glycosylflavones. ACS Chem. Neurosci. 2018, DOI: 
10.1021/acschemneuro.1028b00010. 
74. Hanger, D. P.; Anderton, B. H.; Noble, W., Tau phosphorylation: The therapeutic challenge 
for neurodegenerative disease. Trends Mol. Med. 2009, 15, 112-119. 
75. Mazanetz, M. P.; Fischer, P. M., Untangling tau hyperphosphorylation in drug design for 
neurodegenerative diseases. Nat. Rev. Drug Discov. 2007, 6, 464-479. 
76. Hooper, C.; Killick, R.; Lovestone, S., The GSK3 hypothesis of Alzheimer’s disease. J. 
Neurochem. 2008, 104, 1433-1439. 
77. Martin, L.; Latypova, X.; Wilson, C. M.; Magnaudeix, A.; Perrin, M.-L.; Yardin, C.; Terro, 
F., Tau protein kinases: Involvement in Alzheimer's disease. Ageing Res. Rev. 2013, 12, 289-
309. 
78. Pandey, M. K.; DeGrado, T. R., Glycogen synthase kinase-3 (GSK-3) ‒ targeted therapy 
and imaging. Theranostics 2016, 6, 571-593. 
79. Elliger, C. A.; Chan, B. G.; Waiss Jr, A. C.; Lundin, R. E.; Haddon, W. F., C-
Glycosylflavones from Zea mays that inhibit insect development. Phytochemistry 1980, 19, 
293-297. 
158 
 
158 
 
80. Wang, G.-Q.; Xu, T.; Bu, X.-M.; Liu, B.-Y., Anti-inflammation effects of corn silk in a rat 
model of carrageenin-induced pleurisy. Inflammation 2012, 35, 822-827. 
81. Liu, J.; Wang, C.; Wang, Z.; Zhang, C.; Lu, S.; Liu, J., The antioxidant and free-radical 
scavenging activities of extract and fractions from corn silk (Zea mays L.) and related 
flavone glycosides. Food Chem. 2011, 126, 261-269. 
82. Tian, J.; Chen, H.; Chen, S.; Xing, L.; Wang, Y.; Wang, J., Comparative studies on the 
constituents, antioxidant and anticancer activities of extracts from different varieties of corn 
silk. Food Funct. 2013, 4, 1526-1534. 
83. Ferrari, A.; Hoerndli, F.; Baechi, T.; Nitsch, R. M.; Götz, J., β-Amyloid induces paired 
helical filament-like tau filaments in tissue culture. J. Biol. Chem. 2003, 278, 40162-40168. 
84. Datki, Z.; Papp, R.; Zádori, D.; Soós, K.; Fülöp, L.; Juhász, A.; Laskay, G.; Hetényi, C.; 
Mihalik, E.; Zarándi, M.; Penke, B., In vitro model of neurotoxicity of Aβ 1–42 and 
neuroprotection by a pentapeptide: Irreversible events during the first hour. Neurobiol. Dis. 
2004, 17, 507-515. 
85. Agholme, L.; Lindström, T.; Kågedal, K.; Marcusson, J.; Hallbeck, M., An in vitro model 
for neuroscience: Differentiation of SH-SY5Y cells into cells with morphological and 
biochemical characteristics of mature neurons. J. Alzheimer's Dis. 2010, 20, 1069-1082. 
86. Zheng, X.; Xie, Z.; Zhu, Z.; Liu, Z.; Wang, Y.; Wei, L.; Yang, H.; Yang, H.; Liu, Y.; Bi, J., 
Methyllycaconitine alleviates amyloid-β peptides-induced cytotoxicity in SH-SY5Y cells. 
PLoS ONE 2014, 9, e111536. 
87. Gray, N. E.; Morré, J.; Kelley, J.; Maier, C. S.; Stevens, J. F.; Quinn, J. F.; Soumyanath, A., 
Caffeoylquinic acids in Centella asiatica protect against amyloid-β toxicity. J. Alzheimer's 
Dis. 2014, 40, 359-373. 
88. Kato, T.; Morita, Y., C-Glycosylflavones with acetyl substitution from Rumex acetosa L. 
Chem. Pharm. Bull. 1990, 38, 2277-2280. 
89. Snook, M. E.; Gueldner, R. C.; Widstrom, N. W.; Wiseman, B. R.; Himmelsbach, D. S.; 
Harwood, J. S.; Costello, C. E., Levels of maysin and maysin analogs in silks of maize 
germplasm. J. Agric. Food Chem. 1993, 41, 1481-1485. 
90. Abad-García, B.; Garmón-Lobato, S.; Berrueta, L. A.; Gallo, B.; Vicente, F., New features 
on the fragmentation and differentiation of C-glycosidic flavone isomers by positive 
159 
 
159 
 
electrospray ionization and triple quadrupole mass spectrometry. Rapid Commun. Mass 
Spectrom. 2008, 22, 1834-1842. 
91. Sassano, M. F.; Doak, A. K.; Roth, B. L.; Shoichet, B. K., Colloidal aggregation causes 
inhibition of G protein-coupled receptors. J. Med. Chem. 2013, 56, 2406-2414. 
92. Feng, B. Y.; Shoichet, B. K., A detergent-based assay for the detection of promiscuous 
inhibitors. Nat. Protoc. 2006, 1, 550-553. 
93. Hur, E.-M.; Zhou, F.-Q., GSK3 signalling in neural development. Nat. Rev. Neurosci. 2010, 
11, 539-551. 
94. Palomo, V.; Soteras, I.; Perez, D. I.; Perez, C.; Gil, C.; Campillo, N. E.; Martinez, A., 
Exploring the binding sites of glycogen synthase kinase 3. Identification and 
characterization of allosteric modulation cavities. J. Med. Chem. 2011, 54, 8461-8470. 
95. Eldar-Finkelman, H.; Martinez, A., GSK-3 inhibitors: Preclinical and clinical focus on CNS. 
Front. Mol. Neurosci. 2011, 4, 32. 
96. Peng, J.; Kudrimoti, S.; Prasanna, S.; Odde, S.; Doerksen, R. J.; Pennaka, H. K.; Choo, Y.-
M.; Rao, K. V.; Tekwani, B. L.; Madgula, V.; Khan, S. I.; Wang, B.; Mayer, A. M. S.; Jacob, 
M. R.; Tu, L. C.; Gertsch, J.; Hamann, M. T., Structure-activity relationship and mechanism 
of action studies of manzamine analogues for the control of neuroinflammation and cerebral 
infections. J. Med. Chem. 2010, 53, 61-76. 
97. Bertrand, J. A.; Thieffine, S.; Vulpetti, A.; Cristiani, C.; Valsasina, B.; Knapp, S.; Kalisz, H. 
M.; Flocco, M., Structural characterization of the GSK-3β active site using selective and 
non-selective ATP-mimetic inhibitors. J. Mol. Biol. 2003, 333, 393-407. 
98. Forlenza, O. V.; De-Paula, V. J. R.; Diniz, B. S. O., Neuroprotective effects of lithium: 
Implications for the treatment of Alzheimer’s disease and related neurodegenerative 
disorders. ACS Chem. Neurosci. 2014, 5, 443-450. 
99. Ilouz, R.; Kowalsman, N.; Eisenstein, M.; Eldar-Finkelman, H., Identification of novel 
glycogen synthase kinase-3β substrate-interacting residues suggests a common mechanism 
for substrate recognition. J. Biol. Chem. 2006, 281, 30621-30630. 
100. Busciglio, J.; Lorenzo, A.; Yeh, J.; Yankner, B. A., β-Amyloid fibrils induce tau 
phosphorylation and loss of microtubule binding. Neuron 1995, 14, 879-888. 
101. Takashima, A., GSK-3 is essential in the pathogenesis of Alzheimer's disease. J. Alzheimer's 
Dis. 2006, 9, 309-317. 
160 
 
160 
 
102. Ma, R.; Xiong, N.; Huang, C.; Tang, Q.; Hu, B.; Xiang, J.; Li, G., Erythropoietin protects 
PC12 cells from β-amyloid25–35-induced apoptosis via PI3K/Akt signaling pathway. 
Neuropharmacology 2009, 56, 1027-1034. 
103. Li, L.; Liu, Z.; Liu, J.; Tai, X.; Hu, X.; Liu, X.; Wu, Z.; Zhang, G.; Shi, M.; Zhao, G., 
Ginsenoside Rd attenuates beta-amyloid-induced tau phosphorylation by altering the 
functional balance of glycogen synthase kinase 3beta and protein phosphatase 2A. 
Neurobiol. Dis. 2013, 54, 320-328. 
104. Domínguez, J. M.; Fuertes, A.; Orozco, L.; del Monte-Millán, M.; Delgado, E.; Medina, M., 
Evidence for irreversible inhibition of glycogen synthase kinase-3β by tideglusib. J. Biol. 
Chem. 2012, 287, 893-904. 
105. Martinez, A.; Alonso, M.; Castro, A.; Dorronsoro, I.; Gelpí, J. L.; Luque, F. J.; Pérez, C.; 
Moreno, F. J., SAR and 3D-QSAR studies on thiadiazolidinone derivatives:  Exploration of 
structural requirements for glycogen synthase kinase 3 inhibitors. J. Med. Chem. 2005, 48, 
7103-7112. 
106. Yankner, B. A.; Duffy, L. K.; Kirschner, D. A., Neurotrophic and neurotoxic effects of 
amyloid β protein: Reversal by tachykinin neuropeptides. Science 1990, 250, 279-282. 
107. Arora, K.; Alfulaij, N.; Higa, J. K.; Panee, J.; Nichols, R. A., Impact of sustained exposure 
to β-amyloid on calcium homeostasis and neuronal integrity in model nerve cell system 
expressing α4β2 nicotinic acetylcholine receptors. J. Biol. Chem. 2013, 288, 11175-11190. 
108. Arora, K.; Cheng, J.; Nichols, R. A., Nicotinic acetylcholine receptors sensitize a MAPK-
linked toxicity pathway on prolonged exposure to β-amyloid. J. Biol. Chem. 2015, 290, 
21409-21420. 
109. McMullen, M. D.; Byrne, P. F.; Snook, M. E.; Wiseman, B. R.; Lee, E. A.; Widstrom, N. 
W.; Coe, E. H., Quantitative trait loci and metabolic pathways. Proc. Natl. Acad. Sci. U.S.A. 
1998, 95, 1996-2000. 
110. Williams, P.; Sorribas, A.; Howes, M.-J. R., Natural products as a source of Alzheimer's 
drug leads. Nat. Prod. Rep. 2011, 28, 48-77. 
111. Kan, A.; Orhan, I.; Coksari, G.; Sener, B., In-vitro neuroprotective properties of the Maydis 
stigma extracts from four corn varieties. Int. J. Food Sci. Nutr. 2012, 63, 1-4. 
161 
 
161 
 
112. Choi, D. J.; Kim, S.-L.; Choi, J. W.; Park, Y. I., Neuroprotective effects of corn silk maysin 
via inhibition of H2O2-induced apoptotic cell death in SK-N-MC cells. Life Sci. 2014, 109, 
57-64. 
113. Pacifico, S.; Scognamiglio, M.; D’Abrosca, B.; Piccolella, S.; Tsafantakis, N.; Gallicchio, 
M.; Ricci, A.; Fiorentino, A., Spectroscopic characterization and antiproliferative activity 
on HepG2 human hepatoblastoma cells of flavonoid C-glycosides from Petrorhagia velutina. 
J. Nat. Prod. 2010, 73, 1973-1978. 
114. Yang, S.; Liu, W.; Lu, S.; Tian, Y.-Z.; Wang, W.-Y.; Ling, T.-J.; Liu, R.-T., A novel 
multifunctional compound camellikaempferoside B decreases Aβ production, interferes 
with Aβ aggregation, and prohibits Aβ-mediated neurotoxicity and neuroinflammation. ACS 
Chem. Neurosci. 2016, 7, 505-518. 
115. Swinney, Z. T.; Haubrich, B. A.; Xia, S.; Ramesha, C.; Gomez, S. R.; Guyett, P.; Mensa-
Wilmot, K.; Swinney, D. C., A four-point screening method for assessing molecular 
mechanism of action (MMOA) identifies tideglusib as a time-dependent inhibitor of 
Trypanosoma brucei GSK3β. PLoS Negl. Trop. Dis. 2016, 10, e0004506. 
116. Huggins, D. J.; Sherman, W.; Tidor, B., Rational approaches to improving selectivity in drug 
design. J. Med. Chem. 2012, 55, 1424-1444. 
117. Palomo, V.; Perez, D. I.; Perez, C.; Morales-Garcia, J. A.; Soteras, I.; Alonso-Gil, S.; 
Encinas, A.; Castro, A.; Campillo, N. E.; Perez-Castillo, A.; Gil, C.; Martinez, A., 5-Imino-
1,2,4-thiadiazoles: First small molecules as substrate competitive inhibitors of glycogen 
synthase kinase 3. J. Med. Chem. 2012, 55, 1645-1661. 
118. Tapia-Rojas, C.; Schüller, A.; Lindsay, C. B.; Ureta, R. C.; Mejías-Reyes, C.; Hancke, J.; 
Melo, F.; Inestrosa, N. C., Andrographolide activates the canonical Wnt signalling pathway 
by a mechanism that implicates the non-ATP competitive inhibition of GSK-3β: 
Autoregulation of GSK-3β in vivo. Biochem. J. 2015, 466, 415-430. 
119. Licht-Murava, A.; Paz, R.; Vaks, L.; Avrahami, L.; Plotkin, B.; Eisenstein, M.; Eldar-
Finkelman, H., A unique type of GSK-3 inhibitor brings new opportunities to the clinic. Sci. 
Signal. 2016, 9, ra110. 
120. Rodrigues, T.; Reker, D.; Schneider, P.; Schneider, G., Counting on natural products for drug 
design. Nature Chem. 2016, 8, 531-541. 
162 
 
162 
 
121. Sciacca, M. F. M.; Romanucci, V.; Zarrelli, A.; Monaco, I.; Lolicato, F.; Spinella, N.; Galati, 
C.; Grasso, G.; D’Urso, L.; Romeo, M.; Diomede, L.; Salmona, M.; Bongiorno, C.; Di Fabio, 
G.; La Rosa, C.; Milardi, D., Inhibition of Aβ amyloid growth and toxicity by silybins: The 
crucial role of stereochemistry. ACS Chem. Neurosci. 2017, 8, 1767-1778. 
122. Walle, T., Methylation of dietary flavones greatly improves their hepatic metabolic stability 
and intestinal absorption. Mol. Pharm. 2007, 4, 826-832. 
123. Liang, Z.; Sorribas, A.; Sulzmaier, F. J.; Jiménez, J. I.; Wang, X.; Sauvage, T.; Yoshida, W. 
Y.; Wang, G.; Ramos, J. W.; Williams, P. G., Stictamides A‒C, MMP12 inhibitors containing 
4-amino-3-hydroxy-5-phenylpentanoic acid subunits. J. Org. Chem. 2011, 76, 3635-3643. 
124. Bobbitt, J. M.; Bartelson, A. L.; Bailey, W. F.; Hamlin, T. A.; Kelly, C. B., Oxoammonium 
salt oxidations of alcohols in the presence of pyridine bases. J. Org. Chem. 2014, 79, 1055-
1067. 
125. Baell, J. B., Feeling nature’s PAINS: Natural products, natural product drugs, and pan assay 
interference compounds (PAINS). J. Nat. Prod. 2016, 79, 616-628. 
126. Leeson, P. D.; Springthorpe, B., The influence of drug-like concepts on decision-making in 
medicinal chemistry. Nat. Rev. Drug Discov. 2007, 6, 881-890. 
127. Wager, T. T.; Hou, X.; Verhoest, P. R.; Villalobos, A., Central nervous system 
multiparameter optimization desirability: Application in drug discovery. ACS Chem. 
Neurosci. 2016, 7, 767-775. 
128. Freeman-Cook, K. D.; Hoffman, R. L.; Johnson, T. W., Lipophilic efficiency: The most 
important efficiency metric in medicinal chemistry. Future Med. Chem. 2013, 5, 113-115. 
129. Chou, J. T.; Jurs, P. C., Computer-assisted computation of partition coefficients from 
molecular structures using fragment constants. J. Chem. Inf. Comput. Sci. 1979, 19, 172-
178. 
130. Chen, X.; Murawski, A.; Patel, K.; Crespi, C. L.; Balimane, P. V., A novel design of artificial 
membrane for improving the PAMPA model. Pharm. Res. 2008, 25, 1511-1520. 
131. Courts, F. L.; Williamson, G., The occurrence, fate and biological activities of C-glycosyl 
flavonoids in the human diet. Crit. Rev. Food Sci. Nutr. 2015, 55, 1352-1367. 
132. Wang, Z.; Sun, H.; Yao, X.; Li, D.; Xu, L.; Li, Y.; Tian, S.; Hou, T., Comprehensive 
evaluation of ten docking programs on a diverse set of protein-ligand complexes: The 
163 
 
163 
 
prediction accuracy of sampling power and scoring power. Phys. Chem. Chem. Phys. 2016, 
18, 12964-12975. 
133. Trott, O.; Olson, A. J., AutoDock Vina: Improving the speed and accuracy of docking with 
a new scoring function, efficient optimization, and multithreading. J. Comput. Chem. 2010, 
31, 455-461. 
134. Forli, S.; Huey, R.; Pique, M. E.; Sanner, M. F.; Goodsell, D. S.; Olson, A. J., Computational 
protein-ligand docking and virtual drug screening with the AutoDock suite. Nat. Protoc. 
2016, 11, 905-919. 
135. Hassandarvish, P.; Rothan, H. A.; Rezaei, S.; Yusof, R.; Abubakar, S.; Zandi, K., In silico 
study on baicalein and baicalin as inhibitors of dengue virus replication. RSC Advances 
2016, 6, 31235-31247. 
136. Neri-Bazán, R. M.; García-Machorro, J.; Méndez-Luna, D.; Tolentino-López, L. E.; 
Martínez-Ramos, F.; Padilla-Martínez, I. I.; Aguilar-Faisal, L.; Soriano-Ursúa, M. A.; 
Trujillo-Ferrara, J. G.; Fragoso-Vázquez, M. J.; Barrón, B. L.; Correa-Basurto, J., Design, 
in silico studies, synthesis and in vitro evaluation of oseltamivir derivatives as inhibitors of 
neuraminidase from influenza A virus H1N1. Eur. J. Med. Chem. 2017, 128, 154-167. 
137. Dajani, R.; Fraser, E.; Roe, S. M.; Young, N.; Good, V.; Dale, T. C.; Pearl, L. H., Crystal 
structure of glycogen synthase kinase 3β: Structural basis for phosphate-primed substrate 
specificity and autoinhibition. Cell 2001, 105, 721-732. 
138. Gadakar, P. K.; Phukan, S.; Balaji, V. N., Pose prediction accuracy in docking studies and 
enrichment of actives in the active site of GSK-3β. J. Chem. Inf. Model. 2007, 47, 1446-
1459. 
139. Fu, G.; Sivaprakasam, P.; Dale, O. R.; Manly, S. P.; Cutler, S. J.; Doerksen, R. J., 
Pharmacophore modeling, ensemble docking, virtual screening, and biological evaluation 
on glycogen synthase kinase-3β. Mol. Inform. 2014, 33, 610-626. 
140. Müller, K.; Faeh, C.; Diederich, F., Fluorine in pharmaceuticals: Looking beyond intuition. 
Science 2007, 317, 1881-1886. 
141. Bissantz, C.; Kuhn, B.; Stahl, M., A medicinal chemist’s guide to molecular interactions. J. 
Med. Chem. 2010, 53, 5061-5084. 
164 
 
164 
 
142. Abreu, R. M. V.; Froufe, H. J. C.; Queiroz, M.-J. R. P.; Ferreira, I. C. F. R., Selective 
flexibility of side-chain residues improves VEGFR-2 docking score using AutoDock Vina. 
Chem. Biol. Drug Des. 2012, 79, 530-534. 
143. Gallivan, J. P.; Dougherty, D. A., Cation-π interactions in structural biology. Proc. Natl. 
Acad. Sci. U.S.A. 1999, 96, 9459-9464. 
144. Pellequer, J.-L.; Zhao, B.; Kao, H.-I.; Bell, C. W.; Li, K.; Li, Q. X.; Karu, A. E.; Roberts, V. 
A., Stabilization of bound polycyclic aromatic hydrocarbons by a π-cation interaction. J. 
Mol. Biol. 2000, 302, 691-699. 
145. Liang, Z.; Li, Q. X., π–Cation interactions in molecular recognition: Perspectives on 
pharmaceuticals and pesticides. J. Agric. Food Chem. 2018, 66, 3315-3323. 
146. Biasini, M.; Bienert, S.; Waterhouse, A.; Arnold, K.; Studer, G.; Schmidt, T.; Kiefer, F.; 
Cassarino, T. G.; Bertoni, M.; Bordoli, L.; Schwede, T., SWISS-MODEL: Modelling 
protein tertiary and quaternary structure using evolutionary information. Nucleic Acids Res. 
2014, 42, W252-W258. 
147. Beurel, E.; Grieco, S. F.; Jope, R. S., Glycogen synthase kinase-3 (GSK3): Regulation, 
actions, and diseases. Pharmacol. Ther. 2015, 148, 114-131. 
148. Xiong, L.; Zhu, X.-L.; Shen, Y.-Q.; Kandergama Wasala Mudiyanselage Wishwajith, W.; Li, 
K.; Yang, G.-F., Discovery of N-benzoxazol-5-yl-pyrazole-4-carboxamides as nanomolar 
SQR inhibitors. Eur. J. Med. Chem. 2015, 95, 424-434. 
149. Liang, S. H.; Chen, J. M.; Normandin, M. D.; Chang, J. S.; Chang, G. C.; Taylor, C. K.; 
Trapa, P.; Plummer, M. S.; Para, K. S.; Conn, E. L.; Lopresti-Morrow, L.; Lanyon, L. F.; 
Cook, J. M.; Richter, K. E. G.; Nolan, C. E.; Schachter, J. B.; Janat, F.; Che, Y.; 
Shanmugasundaram, V.; Lefker, B. A.; Enerson, B. E.; Livni, E.; Wang, L.; Guehl, N. J.; 
Patnaik, D.; Wagner, F. F.; Perlis, R.; Holson, E. B.; Haggarty, S. J.; El Fakhri, G.; 
Kurumbail, R. G.; Vasdev, N., Discovery of a highly selective glycogen synthase kinase-3 
inhibitor (PF-04802367) that modulates tau phosphorylation in the brain: Translation for 
PET neuroimaging. Angew. Chem., Int. Ed. 2016, 55, 9601-9605. 
150. Wei, J.; Jin, F.; Wu, Q.; Jiang, Y.; Gao, D.; Liu, H., Molecular interaction study of flavonoid 
derivative 3d with human serum albumin using multispectroscopic and molecular modeling 
approach. Talanta 2014, 126, 116-121. 
165 
 
165 
 
151. Wilcken, R.; Zimmermann, M. O.; Lange, A.; Joerger, A. C.; Boeckler, F. M., Principles 
and applications of halogen bonding in medicinal chemistry and chemical biology. J. Med. 
Chem. 2013, 56, 1363-1388. 
152. Pollock, J.; Borkin, D.; Lund, G.; Purohit, T.; Dyguda-Kazimierowicz, E.; Grembecka, J.; 
Cierpicki, T., Rational design of orthogonal multipolar interactions with fluorine in protein–
ligand complexes. J. Med. Chem. 2015, 58, 7465-7474. 
153. Ali, A.; Hoeflich, K. P.; Woodgett, J. R., Glycogen synthase kinase-3:  Properties, functions, 
and regulation. Chem. Rev. 2001, 101, 2527-2540. 
154. Wang, Q. M.; Park, I. K.; Fiol, C. J.; Roach, P. J.; DePaoli-Roach, A. A., Isoform differences 
in substrate recognition by glycogen synthase kinases 3.alpha. and 3.beta. in the 
phosphorylation of phosphatase inhibitor 2. Biochemistry 1994, 33, 143-147. 
155. Soutar, M. P. M.; Kim, W.-Y.; Williamson, R.; Peggie, M.; Hastie, C. J.; McLauchlan, H.; 
Snider, W. D.; Gordon-Weeks, P. R.; Sutherland, C., Evidence that glycogen synthase 
kinase-3 isoforms have distinct substrate preference in the brain. J. Neurochem. 2010, 115, 
974-983. 
156. Cavalli, A.; Bolognesi, M. L.; Minarini, A.; Rosini, M.; Tumiatti, V.; Recanatini, M.; 
Melchiorre, C., Multi-target-directed ligands to combat neurodegenerative diseases. J. Med. 
Chem. 2008, 51, 347-372. 
157. Chiruta, C.; Schubert, D.; Dargusch, R.; Maher, P., Chemical modification of the multitarget 
neuroprotective compound fisetin. J. Med. Chem. 2012, 55, 378-389. 
158. León, R.; Garcia, A. G.; Marco-Contelles, J., Recent advances in the multitarget-directed 
ligands approach for the treatment of Alzheimer's disease. Med. Res. Rev. 2013, 33, 139-
189. 
159. Hughes, R. E.; Nikolic, K.; Ramsay, R. R., One for all? Hitting multiple Alzheimer’s disease 
targets with one drug. Front. Neurosci. 2016, 10, 177. 
160. Hopkins, A. L., Network pharmacology: The next paradigm in drug discovery. Nat. Chem. 
Biol. 2008, 4, 682-690. 
161. Moya-Alvarado, G.; Gershoni-Emek, N.; Perlson, E.; Bronfman, F. C., Neurodegeneration 
and Alzheimer's disease (AD). What can proteomics tell us about the Alzheimer's brain? 
Mol. Cell. Proteomics 2016, 15, 409-425. 
166 
 
166 
 
162. Pan, S.; Zhang, H.; Wang, C.; Yao, S. C. L.; Yao, S. Q., Target identification of natural 
products and bioactive compounds using affinity-based probes. Nat. Prod. Rep. 2016, 33, 
612-620. 
163. Shamir, D. B.; Rosenqvist, N.; Rasool, S.; Pedersen, J. T.; Sigurdsson, E. M., Internalization 
of tau antibody and pathological tau protein detected with a flow cytometry multiplexing 
approach. Alzheimers Dement. 2016, 12, 1098-1107. 
164. Jahn, K.; Wieltsch, C.; Blumer, N.; Mehlich, M.; Pathak, H.; Khan, A. Q.; Hildebrandt, H.; 
Frieling, H., A cell culture model for investigation of synapse influenceability: epigenetics, 
expression and function of gene targets important for synapse formation and preservation 
in SH-SY5Y neuroblastoma cells differentiated by retinoic acid. J. Neural. Transm. 2017, 
124, 1341-1367. 
165. Uberti, D.; Rizzini, C.; Spano, P.; Memo, M., Characterization of tau proteins in human 
neuroblastoma SH-SY5Y cell line. Neurosci. Lett. 1997, 235, 149-153. 
166. Jämsä, A.; Hasslund, K.; Cowburn, R. F.; Bäckström, A.; Vasänge, M., The retinoic acid 
and brain-derived neurotrophic factor differentiated SH-SY5Y cell line as a model for 
Alzheimer’s disease-like tau phosphorylation. Biochem. Biophys. Res. Commun. 2004, 319, 
993-1000. 
167. Zheng, L.; Roberg, K.; Jerhammar, F.; Marcusson, J.; Terman, A., Autophagy of amyloid 
beta-protein in differentiated neuroblastoma cells exposed to oxidative stress. Neurosci. Lett. 
2006, 394, 184-189. 
168. Meng, P.; Yoshida, H.; Tanji, K.; Matsumiya, T.; Xing, F.; Hayakari, R.; Wang, L.; Tsuruga, 
K.; Tanaka, H.; Mimura, J.; Kosaka, K.; Itoh, K.; Takahashi, I.; Kawaguchi, S.; Imaizumi, 
T., Carnosic acid attenuates apoptosis induced by amyloid-β 1–42 or 1–43 in SH-SY5Y 
human neuroblastoma cells. Neurosci. Res. 2015, 94, 1-9. 
169. González-Sarrías, A.; Núñez-Sánchez, M. Á.; Tomás-Barberán, F. A.; Espín, J. C., 
Neuroprotective effects of bioavailable polyphenol-derived metabolites against oxidative 
stress-induced cytotoxicity in human neuroblastoma SH-SY5Y cells. J. Agric. Food Chem. 
2017, 65, 752-758. 
170. Shannon, P.; Markiel, A.; Ozier, O.; Baliga, N. S.; Wang, J. T.; Ramage, D.; Amin, N.; 
Schwikowski, B.; Ideker, T., Cytoscape: A software environment for integrated models of 
biomolecular interaction networks. Genome Res. 2003, 13, 2498-2504. 
167 
 
167 
 
171. Szklarczyk, D.; Morris, J. H.; Cook, H.; Kuhn, M.; Wyder, S.; Simonovic, M.; Santos, A.; 
Doncheva, N. T.; Roth, A.; Bork, P.; Jensen, L. J.; von Mering, C., The STRING database 
in 2017: Quality-controlled protein–protein association networks, made broadly accessible. 
Nucleic Acids Res. 2017, 45, D362-D368. 
172. Anderson, K. W.; Turko, I. V., Histone post-translational modifications in frontal cortex 
from human donors with Alzheimer’s disease. Clin. Proteomics 2015, 12, 26. 
173. Sanchez-Mut, J. V.; Gräff, J., Epigenetic alterations in Alzheimer’s disease. Front. Behav. 
Neurosci. 2015, 9, 347. 
174. Cacabelos, R.; Torrellas, C., Epigenetics of aging and Alzheimer’s disease: Implications for 
pharmacogenomics and drug response. Int. J. Mol. Sci. 2015, 16, 30483-30543. 
175. Chin, D.; Means, A. R., Calmodulin: A prototypical calcium sensor. Trends Cell Biol. 2000, 
10, 322-328. 
176. Berridge, M. J., Calcium signalling and Alzheimer’s disease. Neurochem. Res. 2010, 36, 
1149-1156. 
177. Fernández-Morales, J.-C.; Arranz-Tagarro, J.-A.; Calvo-Gallardo, E.; Maroto, M.; Padín, 
J.-F.; García, A. G., Stabilizers of neuronal and mitochondrial calcium cycling as a strategy 
for developing a medicine for Alzheimer's disease. ACS Chem. Neurosci. 2012, 3, 873-883. 
178. Tinari, N.; Kuwabara, I.; Huflejt, M. E.; Shen, P. F.; Iacobelli, S.; Liu, F. T., Glycoprotein 
90K/MAC-2BP interacts with galectin-1 and mediates galectin-1-induced cell aggregation. 
Int. J. Cancer 2001, 91, 167-172. 
179. Calafate, S.; Flavin, W.; Verstreken, P.; Moechars, D., Loss of Bin1 promotes the 
propagation of tau pathology. Cell Rep. 2016, 17, 931-940. 
180. Kim, H. J.; Kim, N. C.; Wang, Y.-D.; Scarborough, E. A.; Moore, J.; Diaz, Z.; MacLea, K. 
S.; Freibaum, B.; Li, S.; Molliex, A.; Kanagaraj, A. P.; Carter, R.; Boylan, K. B.; Wojtas, A. 
M.; Rademakers, R.; Pinkus, J. L.; Greenberg, S. A.; Trojanowski, J. Q.; Traynor, B. J.; 
Smith, B. N.; Topp, S.; Gkazi, A.-S.; Miller, J.; Shaw, C. E.; Kottlors, M.; Kirschner, J.; 
Pestronk, A.; Li, Y. R.; Ford, A. F.; Gitler, A. D.; Benatar, M.; King, O. D.; Kimonis, V. E.; 
Ross, E. D.; Weihl, C. C.; Shorter, J.; Taylor, J. P., Mutations in prion-like domains in 
hnRNPA2B1 and hnRNPA1 cause multisystem proteinopathy and ALS. Nature 2013, 495, 
467-473. 
168 
 
168 
 
181. Donev, R.; Newall, A.; Thome, J.; Sheer, D., A role for SC35 and hnRNPA1 in the 
determination of amyloid precursor protein isoforms. Mol. Psychiatry 2007, 12, 681-690. 
182. Berson, A.; Barbash, S.; Shaltiel, G.; Goll, Y.; Hanin, G.; Greenberg, D. S.; Ketzef, M.; 
Becker, A. J.; Friedman, A.; Soreq, H., Cholinergic-associated loss of hnRNP-A/B in 
Alzheimer's disease impairs cortical splicing and cognitive function in mice. EMBO Mol. 
Med. 2012, 4, 730-742. 
183. Conforti, F.; Rigano, D.; Menichini, F.; Loizzo, M. R.; Senatore, F., Protection against 
neurodegenerative diseases of Iris pseudopumila extracts and their constituents. Fitoterapia 
2009, 80, 62-67. 
184. Choi, J. S.; Islam, M. N.; Ali, M. Y.; Kim, Y. M.; Park, H. J.; Sohn, H. S.; Jung, H. A., The 
effects of C-glycosylation of luteolin on its antioxidant, anti-Alzheimer’s disease, anti-
diabetic, and anti-inflammatory activities. Arch. Pharm. Res. 2014, 37, 1354-1363. 
185. Lim, J.; Park, H.-S.; Choi, J.-K.; Lee, I.-S.; Choi, H., Isoorientin induces Nrf2 pathway-
driven antioxidant response through phosphatidylinositol 3-kinase signaling. Arch. Pharm. 
Res. 2007, 30, 1590-1598. 
186. Yuan, L.; Wei, S.; Wang, J.; Liu, X., Isoorientin induces apoptosis and autophagy 
simultaneously by reactive oxygen species (ROS)-related p53, PI3K/Akt, JNK, and p38 
signaling pathways in HepG2 cancer cells. J. Agric. Food Chem. 2014, 62, 5390-5400. 
187. Yuan, L.; Wang, J.; Wu, W.; Liu, Q.; Liu, X., Effect of isoorientin on intracellular 
antioxidant defence mechanisms in hepatoma and liver cell lines. Biomed. Pharmacother. 
2016, 81, 356-362. 
188. Lin, X.; Wei, J.; Chen, Y.; He, P.; Lin, J.; Tan, S.; Nie, J.; Lu, S.; He, M.; Lu, Z.; Huang, Q., 
Isoorientin from Gypsophila elegans induces apoptosis in liver cancer cells via 
mitochondrial-mediated pathway. J. Ethnopharmacol. 2016, 187, 187-194. 
189. Ye, T.; Su, J.; Huang, C.; Yu, D.; Dai, S.; Huang, X.; Chen, B.; Zhou, M., Isoorientin induces 
apoptosis, decreases invasiveness, and downregulates VEGF secretion by activating AMPK 
signaling in pancreatic cancer cells. Onco Targets Ther. 2016, 9, 7481-7492. 
190. Czemplik, M.; Mierziak, J.; Szopa, J.; Kulma, A., Flavonoid C-glucosides derived from 
Flax Straw extracts reduce human breast cancer cell growth in vitro and induce apoptosis. 
Front. Pharmacol. 2016, 7, 282. 
169 
 
169 
 
191. Lee, W.; Ku, S.-K.; Bae, J.-S., Vascular barrier protective effects of orientin and isoorientin 
in LPS-induced inflammation in vitro and in vivo. Vascul. Pharmacol. 2014, 62, 3-14. 
192. Wedler, J.; Daubitz, T.; Schlotterbeck, G.; Butterweck, V., In vitro anti-inflammatory and 
wound-healing potential of a Phyllostachys edulis leaf extract – identification of isoorientin 
as an active compound. Planta Med. 2014, 80, 1678-1684. 
193. Luan, G.; Wang, Y.; Wang, Z.; Zhou, W.; Hu, N.; Li, G.; Wang, H., Flavonoid glycosides 
from Fenugreek seeds regulate glycolipid metabolism by improving mitochondrial function 
in 3T3-L1 adipocytes in vitro. J. Agric. Food Chem. 2018, 66, 3169-3178. 
194. Alonso-Castro, A. J.; Zapata-Bustos, R.; Gómez-Espinoza, G.; Salazar-Olivo, L. A., 
Isoorientin reverts TNF-α-induced insulin resistance in adipocytes activating the insulin 
signaling pathway. Endocrinology 2012, 153, 5222-5230. 
195. Higa, J. K.; Liang, Z.; Williams, P. G.; Panee, J., Phyllostachys edulis compounds inhibit 
palmitic acid-induced monocyte chemoattractant protein 1 (MCP-1) production. PLoS ONE 
2012, 7, e45082. 
196. Liang, Z.; Sulzmaier, F. J.; Yoshida, W. Y.; Kelly, M.; Ramos, J. W.; Williams, P. G., 
Neopetrocyclamines A and B, polycyclic diamine alkaloids from the sponge Neopetrosia cf 
exigua. J. Nat. Prod. 2015, 78, 543-547. 
197. Johnson, J. L.; Rupasinghe, S. G.; Stefani, F.; Schuler, M. A.; Gonzalez de Mejia, E., Citrus 
flavonoids luteolin, apigenin, and quercetin inhibit glycogen synthase kinase-3β enzymatic 
activity by lowering the interaction energy within the binding cavity. J. Med. Food 2011, 
14, 325-333. 
198. Hamann, M.; Alonso, D.; Martín-Aparicio, E.; Fuertes, A.; Pérez-Puerto, M. J.; Castro, A.; 
Morales, S.; Navarro, M. L.; del Monte-Millán, M.; Medina, M.; Pennaka, H.; Balaiah, A.; 
Peng, J.; Cook, J.; Wahyuono, S.; Martínez, A., Glycogen synthase kinase-3 (GSK-3) 
inhibitory activity and structure–activity relationship (SAR) studies of the manzamine 
alkaloids. Potential for Alzheimer’s disease. J. Nat. Prod. 2007, 70, 1397-1405. 
 
